{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For United Health Group, in 2022 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |   |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  |  |  |  |  |  |  | \nDelaware |  | 41-1321939\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)\nUnitedHealth Group Center |  | 55343\n9900 Bren Road East | \nMinnetonka, | Minnesota | \n(Address of principal executive offices) |  | (Zip Code)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered\nCommon Stock, $.01 par value |  | UNH |  | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 |  | Accelerated\u00a0filer | \u2610 |  | Non-accelerated filer | \u2610\nSmaller\u00a0reporting\u00a0company | \u2610 |  |  |  |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page\n |  |  |  | \nPart I. Financial\u00a0Information | \nItem\u00a01. | Financial Statements (unaudited) | 1\n |  | Condensed Consolidated Balance Sheets as of March 31, 2022and December 31, 2021 | 1\n |  | Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2022and 2021 | 2\n |  | Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2022and 2021 | 3\n |  | Condensed Consolidated Statements of Changes in Equity for the Three Months Ended March 31, 2022and 2021 | 4\n |  | Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2022and 2021 | 5\n |  | Notes to the Condensed Consolidated Financial Statements | 6\n |  | 1. | Basis of Presentation | 6\n |  | 2. | Investments | 7\n |  | 3. | Fair Value | 9\n |  | 4. | Medical Costs Payable | 10\n |  | 5. | Commitments and Contingencies | 10\n |  | 6. | Segment Financial Information | 12\nItem\u00a02. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 13\nItem\u00a03. | Quantitative and Qualitative Disclosures About Market Risk | 20\nItem\u00a04. | Controls and Procedures | 21\nPart\u00a0II. Other Information | \nItem\u00a01. | Legal Proceedings | 21\nItem\u00a01A. | Risk Factors | 21\nItem\u00a02. | Unregistered Sales of Equity Securities and Use of Proceeds | 21\nItem\u00a06. | Exhibits | 22\nSignatures | 23  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except per share data) |  | March 31,2022 |  | December 31,2021\nAssets |  |  |  | \nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 25,482 |  |  | $ | 21,375 | \nShort-term investments |  | 2,914 |  |  | 2,532 | \nAccounts receivable, net |  | 18,871 |  |  | 14,216 | \nOther current receivables, net |  | 11,994 |  |  | 13,866 | \nAssets under management |  | 4,155 |  |  | 4,449 | \nPrepaid expenses and other current assets |  | 5,613 |  |  | 5,320 | \nTotal current assets |  | 69,029 |  |  | 61,758 | \nLong-term investments |  | 42,353 |  |  | 43,114 | \nProperty, equipment and capitalized software, net |  | 9,183 |  |  | 8,969 | \nGoodwill |  | 77,548 |  |  | 75,795 | \nOther intangible assets, net |  | 9,918 |  |  | 10,044 | \nOther assets |  | 13,207 |  |  | 12,526 | \nTotal assets |  | $ | 221,238 |  |  | $ | 212,206 | \nLiabilities, redeemable noncontrolling interests and equity |  |  |  | \nCurrent liabilities: |  |  |  | \nMedical costs payable |  | $ | 28,676 |  |  | $ | 24,483 | \nAccounts payable and accrued liabilities |  | 25,058 |  |  | 24,643 | \nShort-term borrowings and current maturities of long-term debt |  | 6,697 |  |  | 3,620 | \nUnearned revenues |  | 2,675 |  |  | 2,571 | \nOther current liabilities |  | 25,064 |  |  | 22,975 | \nTotal current liabilities |  | 88,170 |  |  | 78,292 | \nLong-term debt, less current maturities |  | 40,796 |  |  | 42,383 | \nDeferred income taxes |  | 2,954 |  |  | 3,265 | \nOther liabilities |  | 11,671 |  |  | 11,787 | \nTotal liabilities |  | 143,591 |  |  | 135,727 | \nCommitments and contingencies (Note 5) |  |  |  | \nRedeemable noncontrolling interests |  | 1,519 |  |  | 1,434 | \nEquity: |  |  |  | \nPreferred stock, $0.001par value -10shares authorized;noshares issued or outstanding |  | \u2014 |  |  | \u2014 | \nCommon stock, $0.01par value -3,000shares authorized;939and941issued and outstanding |  | 10 |  |  | 10 | \nRetained earnings |  | 78,782 |  |  | 77,134 | \nAccumulated other comprehensive loss |  | (6,026) |  |  | (5,384) | \nNonredeemable noncontrolling interests |  | 3,362 |  |  | 3,285 | \nTotal equity |  | 76,128 |  |  | 75,045 | \nTotal liabilities, redeemable noncontrolling interests and equity |  | $ | 221,238 |  |  | $ | 212,206 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31,\n(in millions, except per share data) |  | 2022 |  | 2021\nRevenues: |  |  |  | \nPremiums |  | $ | 64,070 |  |  | $ | 55,486 | \nProducts |  | 9,340 |  |  | 8,340 | \nServices |  | 6,372 |  |  | 5,918 | \nInvestment and other income |  | 367 |  |  | 452 | \nTotal revenues |  | 80,149 |  |  | 70,196 | \nOperating costs: |  |  |  | \nMedical costs |  | 52,523 |  |  | 44,904 | \nOperating costs |  | 11,401 |  |  | 10,223 | \nCost of products sold |  | 8,487 |  |  | 7,572 | \nDepreciation and amortization |  | 788 |  |  | 758 | \nTotal operating costs |  | 73,199 |  |  | 63,457 | \nEarnings from operations |  | 6,950 |  |  | 6,739 | \nInterest expense |  | (433) |  |  | (397) | \nEarnings before income taxes |  | 6,517 |  |  | 6,342 | \nProvision for income taxes |  | (1,369) |  |  | (1,364) | \nNet earnings |  | 5,148 |  |  | 4,978 | \nEarnings attributable to noncontrolling interests |  | (121) |  |  | (116) | \nNet earnings attributable to UnitedHealth Group common shareholders |  | $ | 5,027 |  |  | $ | 4,862 | \nEarnings per share attributable to UnitedHealth Group common shareholders: |  |  |  | \nBasic |  | $ | 5.34 |  |  | $ | 5.14 | \nDiluted |  | $ | 5.27 |  |  | $ | 5.08 | \nBasic weighted-average number of common shares outstanding |  | 941 |  |  | 945 | \nDilutive effect of common share equivalents |  | 13 |  |  | 12 | \nDiluted weighted-average number of common shares outstanding |  | 954 |  |  | 957 | \nAnti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents |  | 2 |  |  | 3 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31,\n(in millions) |  | 2022 |  | 2021\nNet earnings |  | $ | 5,148 |  |  | $ | 4,978 | \nOther comprehensive loss: |  |  |  | \nGross unrealized losses on investment securities during the period |  | (2,023) |  |  | (764) | \nIncome tax effect |  | 465 |  |  | 174 | \nTotal unrealized losses, net of tax |  | (1,558) |  |  | (590) | \nGross reclassification adjustment for net realized gains included in net earnings |  | (3) |  |  | (7) | \nIncome tax effect |  | 1 |  |  | 2 | \nTotal reclassification adjustment, net of tax |  | (2) |  |  | (5) | \nTotal foreign currency translation gains (losses) |  | 918 |  |  | (417) | \nOther comprehensive loss |  | (642) |  |  | (1,012) | \nComprehensive income |  | 4,506 |  |  | 3,966 | \nComprehensive income attributable to noncontrolling interests |  | (121) |  |  | (116) | \nComprehensive income attributable to UnitedHealth Group common shareholders |  | $ | 4,385 |  |  | $ | 3,850 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Common Stock |  | Additional Paid-In Capital |  | Retained Earnings |  | Accumulated Other ComprehensiveIncome (Loss) |  | Nonredeemable Noncontrolling Interests |  | TotalEquity\nThree months ended March 31,(in millions) |  | Shares |  | Amount |  |  |  | Net Unrealized Gains (losses) on Investments |  | Foreign Currency Translation (Losses) Gains |  | \nBalance at January 1, 2022 |  | 941 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 77,134 |  |  | $ | 423 |  |  | $ | (5,807) |  |  | $ | 3,285 |  |  | $ | 75,045 | \nNet earnings |  |  |  |  |  |  |  | 5,027 |  |  |  |  |  |  | 88 |  |  | 5,115 | \nOther comprehensive (loss) income |  |  |  |  |  |  |  |  |  | (1,560) |  |  | 918 |  |  |  |  | (642) | \nIssuances of common stock, and related tax effects |  | 3 |  |  | \u2014 |  |  | 333 |  |  |  |  |  |  |  |  |  |  | 333 | \nShare-based compensation |  |  |  |  |  | 282 |  |  |  |  |  |  |  |  |  |  | 282 | \nCommon share repurchases |  | (5) |  |  | \u2014 |  |  | (484) |  |  | (2,016) |  |  |  |  |  |  |  |  | (2,500) | \nCash dividends paid on common shares ($1.45per share) |  |  |  |  |  |  |  | (1,363) |  |  |  |  |  |  |  |  | (1,363) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | (131) |  |  |  |  |  |  |  |  |  |  | (131) | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 91 |  |  | 91 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (102) |  |  | (102) | \nBalance at March 31, 2022 |  | 939 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 78,782 |  |  | $ | (1,137) |  |  | $ | (4,889) |  |  | $ | 3,362 |  |  | $ | 76,128 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at January 1, 2021 |  | 946 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 69,295 |  |  | $ | 1,336 |  |  | $ | (5,150) |  |  | $ | 2,837 |  |  | $ | 68,328 | \nNet earnings |  |  |  |  |  |  |  | 4,862 |  |  |  |  |  |  | 80 |  |  | 4,942 | \nOther comprehensive loss |  |  |  |  |  |  |  |  |  | (595) |  |  | (417) |  |  |  |  | (1,012) | \nIssuances of common stock, and related tax effects |  | 3 |  |  | \u2014 |  |  | 256 |  |  |  |  |  |  |  |  |  |  | 256 | \nShare-based compensation |  |  |  |  |  | 242 |  |  |  |  |  |  |  |  |  |  | 242 | \nCommon share repurchases |  | (5) |  |  | \u2014 |  |  | \u2014 |  |  | (1,650) |  |  |  |  |  |  |  |  | (1,650) | \nCash dividends paid on common shares ($1.25per share) |  |  |  |  |  |  |  | (1,181) |  |  |  |  |  |  |  |  | (1,181) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | (498) |  |  | (106) |  |  |  |  |  |  |  |  | (604) | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 66 |  |  | 66 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (74) |  |  | (74) | \nBalance at March 31, 2021 |  | 944 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 71,220 |  |  | $ | 741 |  |  | $ | (5,567) |  |  | $ | 2,909 |  |  | $ | 69,313 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31,\n(in millions) |  | 2022 |  | 2021\nOperating activities |  |  |  | \nNet earnings |  | $ | 5,148 |  |  | $ | 4,978 | \nNoncash items: |  |  |  | \nDepreciation and amortization |  | 788 |  |  | 758 | \nDeferred income taxes |  | 161 |  |  | 341 | \nShare-based compensation |  | 299 |  |  | 256 | \nOther, net |  | 17 |  |  | (55) | \nNet change in other operating items, net of effects from acquisitions and changes in AARP balances: |  |  |  | \nAccounts receivable |  | (4,521) |  |  | (2,895) | \nOther assets |  | (1,089) |  |  | (955) | \nMedical costs payable |  | 3,849 |  |  | 2,968 | \nAccounts payable and other liabilities |  | 589 |  |  | 870 | \nUnearned revenues |  | 78 |  |  | (261) | \nCash flows from operating activities |  | 5,319 |  |  | 6,005 | \nInvesting activities |  |  |  | \nPurchases of investments |  | (4,982) |  |  | (4,612) | \nSales of investments |  | 1,591 |  |  | 643 | \nMaturities of investments |  | 1,759 |  |  | 2,255 | \nCash paid for acquisitions, net of cash assumed |  | (1,231) |  |  | (1,193) | \nPurchases of property, equipment and capitalized software |  | (555) |  |  | (568) | \nOther, net |  | (255) |  |  | (232) | \nCash flows used for investing activities |  | (3,673) |  |  | (3,707) | \nFinancing activities |  |  |  | \nCommon share repurchases |  | (2,500) |  |  | (1,650) | \nCash dividends paid |  | (1,363) |  |  | (1,181) | \nProceeds from common stock issuances |  | 551 |  |  | 436 | \nRepayments of long-term debt |  | (1,100) |  |  | (1,150) | \nProceeds from short-term borrowings, net |  | 3,148 |  |  | 4,057 | \nCustomer funds administered |  | 5,120 |  |  | 2,131 | \nOther, net |  | (1,552) |  |  | (1,856) | \nCash flows from financing activities |  | 2,304 |  |  | 787 | \nEffect of exchange rate changes on cash and cash equivalents |  | 157 |  |  | (51) | \nIncrease in cash and cash equivalents |  | 4,107 |  |  | 3,034 | \nCash and cash equivalents, beginning of period |  | 21,375 |  |  | 16,921 | \nCash and cash equivalents, end of period |  | $ | 25,482 |  |  | $ | 19,955 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | AmortizedCost |  | GrossUnrealizedGains |  | GrossUnrealizedLosses |  | FairValue\nMarch 31, 2022 |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 3,507 |  |  | $ | 4 |  |  | $ | (140) |  |  | $ | 3,371 | \nState and municipal obligations |  | 7,022 |  |  | 57 |  |  | (224) |  |  | 6,855 | \nCorporate obligations |  | 21,669 |  |  | 55 |  |  | (811) |  |  | 20,913 | \nU.S. agency mortgage-backed securities |  | 6,210 |  |  | 7 |  |  | (316) |  |  | 5,901 | \nNon-U.S. agency mortgage-backed securities |  | 2,913 |  |  | 2 |  |  | (112) |  |  | 2,803 | \nTotal debt securities - available-for-sale |  | 41,321 |  |  | 125 |  |  | (1,603) |  |  | 39,843 | \nDebt securities - held-to-maturity: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 510 |  |  | 1 |  |  | (9) |  |  | 502 | \nState and municipal obligations |  | 29 |  |  | \u2014 |  |  | \u2014 |  |  | 29 | \nCorporate obligations |  | 87 |  |  | \u2014 |  |  | \u2014 |  |  | 87 | \nTotal debt securities - held-to-maturity |  | 626 |  |  | 1 |  |  | (9) |  |  | 618 | \nTotal debt securities |  | $ | 41,947 |  |  | $ | 126 |  |  | $ | (1,612) |  |  | $ | 40,461 | \nDecember 31, 2021 |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 3,206 |  |  | $ | 23 |  |  | $ | (31) |  |  | $ | 3,198 | \nState and municipal obligations |  | 6,829 |  |  | 297 |  |  | (20) |  |  | 7,106 | \nCorporate obligations |  | 20,947 |  |  | 372 |  |  | (145) |  |  | 21,174 | \nU.S. agency mortgage-backed securities |  | 5,868 |  |  | 88 |  |  | (55) |  |  | 5,901 | \nNon-U.S. agency mortgage-backed securities |  | 2,819 |  |  | 42 |  |  | (23) |  |  | 2,838 | \nTotal debt securities - available-for-sale |  | 39,669 |  |  | 822 |  |  | (274) |  |  | 40,217 | \nDebt securities - held-to-maturity: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 511 |  |  | 2 |  |  | (2) |  |  | 511 | \nState and municipal obligations |  | 30 |  |  | 2 |  |  | \u2014 |  |  | 32 | \nCorporate obligations |  | 100 |  |  | \u2014 |  |  | \u2014 |  |  | 100 | \nTotal debt securities - held-to-maturity |  | 641 |  |  | 4 |  |  | (2) |  |  | 643 | \nTotal debt securities |  | $ | 40,310 |  |  | $ | 826 |  |  | $ | (276) |  |  | $ | 40,860 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Available-for-Sale |  | Held-to-Maturity\n(in millions) |  | AmortizedCost |  | FairValue |  | AmortizedCost |  | FairValue\nDue in one year or less |  | $ | 2,987 |  |  | $ | 2,986 |  |  | $ | 217 |  |  | $ | 217 | \nDue after one year through five years |  | 12,900 |  |  | 12,608 |  |  | 355 |  |  | 347 | \nDue after five years through ten years |  | 12,055 |  |  | 11,461 |  |  | 29 |  |  | 29 | \nDue after ten years |  | 4,256 |  |  | 4,084 |  |  | 25 |  |  | 25 | \nU.S. agency mortgage-backed securities |  | 6,210 |  |  | 5,901 |  |  | \u2014 |  |  | \u2014 | \nNon-U.S. agency mortgage-backed securities |  | 2,913 |  |  | 2,803 |  |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 41,321 |  |  | $ | 39,843 |  |  | $ | 626 |  |  | $ | 618 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Less Than 12 Months |  | 12 Months or Greater |  | Total\n(in millions) |  | FairValue |  | GrossUnrealizedLosses |  | FairValue |  | GrossUnrealizedLosses |  | FairValue |  | GrossUnrealizedLosses\nMarch 31, 2022 |  |  |  |  |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 2,485 |  |  | $ | (96) |  |  | $ | 451 |  |  | $ | (44) |  |  | $ | 2,936 |  |  | $ | (140) | \nState and municipal obligations |  | 3,568 |  |  | (204) |  |  | 218 |  |  | (20) |  |  | 3,786 |  |  | (224) | \nCorporate obligations |  | 14,237 |  |  | (603) |  |  | 2,049 |  |  | (208) |  |  | 16,286 |  |  | (811) | \nU.S. agency mortgage-backed securities |  | 4,192 |  |  | (201) |  |  | 1,225 |  |  | (115) |  |  | 5,417 |  |  | (316) | \nNon-U.S. agency mortgage-backed securities |  | 2,097 |  |  | (78) |  |  | 348 |  |  | (34) |  |  | 2,445 |  |  | (112) | \nTotal debt securities - available-for-sale |  | $ | 26,579 |  |  | $ | (1,182) |  |  | $ | 4,291 |  |  | $ | (421) |  |  | $ | 30,870 |  |  | $ | (1,603) | \nDecember 31, 2021 |  |  |  |  |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 1,976 |  |  | $ | (18) |  |  | $ | 249 |  |  | $ | (13) |  |  | $ | 2,225 |  |  | $ | (31) | \nState and municipal obligations |  | 1,386 |  |  | (19) |  |  | 31 |  |  | (1) |  |  | $ | 1,417 |  |  | $ | (20) | \nCorporate obligations |  | 9,357 |  |  | (130) |  |  | 376 |  |  | (15) |  |  | $ | 9,733 |  |  | $ | (145) | \nU.S. agency mortgage-backed securities |  | 3,078 |  |  | (52) |  |  | 116 |  |  | (3) |  |  | $ | 3,194 |  |  | $ | (55) | \nNon-U.S. agency mortgage-backed securities |  | 1,321 |  |  | (18) |  |  | 114 |  |  | (5) |  |  | $ | 1,435 |  |  | $ | (23) | \nTotal debt securities - available-for-sale |  | $ | 17,118 |  |  | $ | (237) |  |  | $ | 886 |  |  | $ | (37) |  |  | $ | 18,004 |  |  | $ | (274) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | OtherObservableInputs(Level 2) |  | UnobservableInputs(Level 3) |  | TotalFair and CarryingValue\nMarch 31, 2022 |  |  |  |  |  |  |  | \nCash and cash equivalents |  | $ | 25,382 |  |  | $ | 100 |  |  | $ | \u2014 |  |  | $ | 25,482 | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 3,214 |  |  | 157 |  |  | \u2014 |  |  | 3,371 | \nState and municipal obligations |  | \u2014 |  |  | 6,855 |  |  | \u2014 |  |  | 6,855 | \nCorporate obligations |  | 36 |  |  | 20,670 |  |  | 207 |  |  | 20,913 | \nU.S. agency mortgage-backed securities |  | \u2014 |  |  | 5,901 |  |  | \u2014 |  |  | 5,901 | \nNon-U.S. agency mortgage-backed securities |  | \u2014 |  |  | 2,803 |  |  | \u2014 |  |  | 2,803 | \nTotal debt securities - available-for-sale |  | 3,250 |  |  | 36,386 |  |  | 207 |  |  | 39,843 | \nEquity securities |  | 2,036 |  |  | 20 |  |  | 68 |  |  | 2,124 | \nAssets under management |  | 1,727 |  |  | 2,333 |  |  | 95 |  |  | 4,155 | \nTotal assets at fair value |  | $ | 32,395 |  |  | $ | 38,839 |  |  | $ | 370 |  |  | $ | 71,604 | \nPercentage of total assets at fair value |  | 45 | % |  | 54 | % |  | 1 | % |  | 100 | %\nDecember 31, 2021 |  |  |  |  |  |  |  | \nCash and cash equivalents |  | $ | 21,359 |  |  | $ | 16 |  |  | $ | \u2014 |  |  | $ | 21,375 | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 3,017 |  |  | 181 |  |  | \u2014 |  |  | 3,198 | \nState and municipal obligations |  | \u2014 |  |  | 7,106 |  |  | \u2014 |  |  | 7,106 | \nCorporate obligations |  | 40 |  |  | 20,916 |  |  | 218 |  |  | 21,174 | \nU.S. agency mortgage-backed securities |  | \u2014 |  |  | 5,901 |  |  | \u2014 |  |  | 5,901 | \nNon-U.S. agency mortgage-backed securities |  | \u2014 |  |  | 2,838 |  |  | \u2014 |  |  | 2,838 | \nTotal debt securities - available-for-sale |  | 3,057 |  |  | 36,942 |  |  | 218 |  |  | 40,217 | \nEquity securities |  | 2,090 |  |  | 23 |  |  | 64 |  |  | 2,177 | \nAssets under management |  | 1,972 |  |  | 2,376 |  |  | 101 |  |  | 4,449 | \nTotal assets at fair value |  | $ | 28,478 |  |  | $ | 39,357 |  |  | $ | 383 |  |  | $ | 68,218 | \nPercentage of total assets at fair value |  | 42 | % |  | 57 | % |  | 1 | % |  | 100 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | OtherObservableInputs(Level 2) |  | UnobservableInputs(Level 3) |  | TotalFairValue |  | Total Carrying Value\nMarch 31, 2022 |  |  |  |  |  |  |  |  |  | \nDebt securities - held-to-maturity |  | $ | 525 |  |  | $ | 86 |  |  | $ | 7 |  |  | $ | 618 |  |  | $ | 626 | \nLong-term debt and other financing obligations |  | $ | \u2014 |  |  | $ | 46,686 |  |  | $ | \u2014 |  |  | $ | 46,686 |  |  | $ | 43,344 | \nDecember 31, 2021 |  |  |  |  |  |  |  |  |  | \nDebt securities - held-to-maturity |  | $ | 534 |  |  | $ | 102 |  |  | $ | 7 |  |  | $ | 643 |  |  | $ | 641 | \nLong-term debt and other financing obligations |  | $ | \u2014 |  |  | $ | 52,583 |  |  | $ | \u2014 |  |  | $ | 52,583 |  |  | $ | 46,003 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | 2022 |  | 2021\nMedical costs payable, beginning of period |  | $ | 24,483 |  |  | $ | 21,872 | \nAcquisitions |  | 8 |  |  | 12 | \nReported medical costs: |  |  |  | \nCurrent year |  | 52,813 |  |  | 45,914 | \nPrior years |  | (290) |  |  | (1,010) | \nTotal reported medical costs |  | 52,523 |  |  | 44,904 | \nMedical payments: |  |  |  | \nPayments for current year |  | (29,589) |  |  | (25,960) | \nPayments for prior years |  | (18,749) |  |  | (15,995) | \nTotal medical payments |  | (48,338) |  |  | (41,955) | \nMedical costs payable, end of period |  | $ | 28,676 |  |  | $ | 24,833 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Optum |  |  |  | \n(in millions) |  | UnitedHealthcare |  | Optum Health |  | Optum Insight |  | Optum Rx |  | Optum Eliminations |  | Optum |  | Corporate\u00a0andEliminations |  | Consolidated\nThree Months Ended March 31, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 59,937 |  |  | $ | 4,133 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 4,133 |  |  | $ | \u2014 |  |  | $ | 64,070 | \nProducts |  | \u2014 |  |  | 6 |  |  | 40 |  |  | 9,294 |  |  | \u2014 |  |  | 9,340 |  |  | \u2014 |  |  | 9,340 | \nServices |  | 2,515 |  |  | 2,558 |  |  | 974 |  |  | 325 |  |  | \u2014 |  |  | 3,857 |  |  | \u2014 |  |  | 6,372 | \nTotal revenues - unaffiliated customers |  | 62,452 |  |  | 6,697 |  |  | 1,014 |  |  | 9,619 |  |  | \u2014 |  |  | 17,330 |  |  | \u2014 |  |  | 79,782 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 9,829 |  |  | 2,138 |  |  | 14,291 |  |  | (553) |  |  | 25,705 |  |  | (25,705) |  |  | \u2014 | \nInvestment and other income |  | 143 |  |  | 156 |  |  | 67 |  |  | 1 |  |  | \u2014 |  |  | 224 |  |  | \u2014 |  |  | 367 | \nTotal revenues |  | $ | 62,595 |  |  | $ | 16,682 |  |  | $ | 3,219 |  |  | $ | 23,911 |  |  | $ | (553) |  |  | $ | 43,259 |  |  | $ | (25,705) |  |  | $ | 80,149 | \nEarnings from operations |  | $ | 3,798 |  |  | $ | 1,366 |  |  | $ | 847 |  |  | $ | 939 |  |  | $ | \u2014 |  |  | $ | 3,152 |  |  | $ | \u2014 |  |  | $ | 6,950 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (433) |  |  | (433) | \nEarnings before income taxes |  | $ | 3,798 |  |  | $ | 1,366 |  |  | $ | 847 |  |  | $ | 939 |  |  | $ | \u2014 |  |  | $ | 3,152 |  |  | $ | (433) |  |  | $ | 6,517 | \nThree Months Ended March 31, 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 52,558 |  |  | $ | 2,928 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 2,928 |  |  | $ | \u2014 |  |  | $ | 55,486 | \nProducts |  | \u2014 |  |  | 8 |  |  | 37 |  |  | 8,295 |  |  | \u2014 |  |  | 8,340 |  |  | \u2014 |  |  | 8,340 | \nServices |  | 2,350 |  |  | 2,336 |  |  | 961 |  |  | 271 |  |  | \u2014 |  |  | 3,568 |  |  | \u2014 |  |  | 5,918 | \nTotal revenues - unaffiliated customers |  | 54,908 |  |  | 5,272 |  |  | 998 |  |  | 8,566 |  |  | \u2014 |  |  | 14,836 |  |  | \u2014 |  |  | 69,744 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 6,952 |  |  | 1,821 |  |  | 13,004 |  |  | (475) |  |  | 21,302 |  |  | (21,302) |  |  | \u2014 | \nInvestment and other income |  | 206 |  |  | 179 |  |  | 33 |  |  | 34 |  |  | \u2014 |  |  | 246 |  |  | \u2014 |  |  | 452 | \nTotal revenues |  | $ | 55,114 |  |  | $ | 12,403 |  |  | $ | 2,852 |  |  | $ | 21,604 |  |  | $ | (475) |  |  | $ | 36,384 |  |  | $ | (21,302) |  |  | $ | 70,196 | \nEarnings from operations |  | $ | 4,108 |  |  | $ | 962 |  |  | $ | 779 |  |  | $ | 890 |  |  | $ | \u2014 |  |  | $ | 2,631 |  |  | $ | \u2014 |  |  | $ | 6,739 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (397) |  |  | (397) | \nEarnings before income taxes |  | $ | 4,108 |  |  | $ | 962 |  |  | $ | 779 |  |  | $ | 890 |  |  | $ | \u2014 |  |  | $ | 2,631 |  |  | $ | (397) |  |  | $ | 6,342 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except percentages and per share data) |  | Three Months Ended March 31, |  | Increase/(Decrease)\n | 2022 |  | 2021 |  | 2022 vs. 2021\nRevenues: |  |  |  |  |  |  |  | \nPremiums |  | $ | 64,070 |  |  | $ | 55,486 |  |  | $ | 8,584 |  |  | 15 | %\nProducts |  | 9,340 |  |  | 8,340 |  |  | 1,000 |  |  | 12 | \nServices |  | 6,372 |  |  | 5,918 |  |  | 454 |  |  | 8 | \nInvestment and other income |  | 367 |  |  | 452 |  |  | (85) |  |  | (19) | \nTotal revenues |  | 80,149 |  |  | 70,196 |  |  | 9,953 |  |  | 14 | \nOperating costs: |  |  |  |  |  |  |  | \nMedical costs |  | 52,523 |  |  | 44,904 |  |  | 7,619 |  |  | 17 | \nOperating costs |  | 11,401 |  |  | 10,223 |  |  | 1,178 |  |  | 12 | \nCost of products sold |  | 8,487 |  |  | 7,572 |  |  | 915 |  |  | 12 | \nDepreciation and amortization |  | 788 |  |  | 758 |  |  | 30 |  |  | 4 | \nTotal operating costs |  | 73,199 |  |  | 63,457 |  |  | 9,742 |  |  | 15 | \nEarnings from operations |  | 6,950 |  |  | 6,739 |  |  | 211 |  |  | 3 | \nInterest expense |  | (433) |  |  | (397) |  |  | (36) |  |  | 9 | \nEarnings before income taxes |  | 6,517 |  |  | 6,342 |  |  | 175 |  |  | 3 | \nProvision for income taxes |  | (1,369) |  |  | (1,364) |  |  | (5) |  |  | \u2014 | \nNet earnings |  | 5,148 |  |  | 4,978 |  |  | 170 |  |  | 3 | \nEarnings attributable to noncontrolling interests |  | (121) |  |  | (116) |  |  | (5) |  |  | 4 | \nNet earnings attributable to UnitedHealth Group common shareholders |  | $ | 5,027 |  |  | $ | 4,862 |  |  | $ | 165 |  |  | 3 | %\nDiluted earnings per share attributable to UnitedHealth Group common shareholders |  | $ | 5.27 |  |  | $ | 5.08 |  |  | $ | 0.19 |  |  | 4 | %\nMedical care ratio (a) |  | 82.0 | % |  | 80.9 | % |  | 1.1 | % |  | \nOperating cost ratio |  | 14.2 |  |  | 14.6 |  |  | (0.4) |  |  | \nOperating margin |  | 8.7 |  |  | 9.6 |  |  | (0.9) |  |  | \nTax rate |  | 21.0 |  |  | 21.5 |  |  | (0.5) |  |  | \nNet earnings margin (b) |  | 6.3 |  |  | 6.9 |  |  | (0.6) |  |  | \nReturn on equity (c) |  | 27.8 | % |  | 29.5 | % |  | (1.7) | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, |  | Increase/(Decrease)\n(in millions, except percentages) |  | 2022 |  | 2021 |  | 2022 vs. 2021\nRevenues |  |  |  |  |  |  |  | \nUnitedHealthcare |  | $ | 62,595 |  |  | $ | 55,114 |  |  | $ | 7,481 |  |  | 14 | %\nOptum Health |  | 16,682 |  |  | 12,403 |  |  | 4,279 |  |  | 34 | \nOptum Insight |  | 3,219 |  |  | 2,852 |  |  | 367 |  |  | 13 | \nOptum Rx |  | 23,911 |  |  | 21,604 |  |  | 2,307 |  |  | 11 | \nOptum eliminations |  | (553) |  |  | (475) |  |  | (78) |  |  | 16 | \nOptum |  | 43,259 |  |  | 36,384 |  |  | 6,875 |  |  | 19 | \nEliminations |  | (25,705) |  |  | (21,302) |  |  | (4,403) |  |  | 21 | \nConsolidated revenues |  | $ | 80,149 |  |  | $ | 70,196 |  |  | $ | 9,953 |  |  | 14 | %\nEarnings from operations |  |  |  |  |  |  |  | \nUnitedHealthcare |  | $ | 3,798 |  |  | $ | 4,108 |  |  | $ | (310) |  |  | (8) | %\nOptum Health |  | 1,366 |  |  | 962 |  |  | 404 |  |  | 42 | \nOptum Insight |  | 847 |  |  | 779 |  |  | 68 |  |  | 9 | \nOptum Rx |  | 939 |  |  | 890 |  |  | 49 |  |  | 6 | \nOptum |  | 3,152 |  |  | 2,631 |  |  | 521 |  |  | 20 | \nConsolidated earnings from operations |  | $ | 6,950 |  |  | $ | 6,739 |  |  | $ | 211 |  |  | 3 | %\nOperating margin |  |  |  |  |  |  |  | \nUnitedHealthcare |  | 6.1 | % |  | 7.5 | % |  | (1.4) | % |  | \nOptum Health |  | 8.2 |  |  | 7.8 |  |  | 0.4 |  |  | \nOptum Insight |  | 26.3 |  |  | 27.3 |  |  | (1.0) |  |  | \nOptum Rx |  | 3.9 |  |  | 4.1 |  |  | (0.2) |  |  | \nOptum |  | 7.3 |  |  | 7.2 |  |  | 0.1 |  |  | \nConsolidated operating margin |  | 8.7 | % |  | 9.6 | % |  | (0.9) | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, |  | Increase/(Decrease)\n(in millions, except percentages) |  | 2022 |  | 2021 |  | 2022 vs. 2021\nUnitedHealthcare Employer & Individual - Domestic |  | $ | 15,822 |  |  | $ | 14,632 |  |  | $ | 1,190 |  |  | 8 | %\nUnitedHealthcare Employer & Individual - Global (a) |  | 2,133 |  |  | 2,035 |  |  | 98 |  |  | 5 | %\nUnitedHealthcare Employer & Individual - Total (a) |  | 17,955 |  |  | 16,667 |  |  | 1,288 |  |  | 8 | %\nUnitedHealthcare Medicare & Retirement |  | 29,100 |  |  | 25,474 |  |  | 3,626 |  |  | 14 | \nUnitedHealthcare Community & State |  | 15,540 |  |  | 12,973 |  |  | 2,567 |  |  | 20 | \nTotal UnitedHealthcare revenues |  | $ | 62,595 |  |  | $ | 55,114 |  |  | $ | 7,481 |  |  | 14 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31, |  | Increase/(Decrease)\n(in thousands, except percentages) |  | 2022 |  | 2021 |  | 2022 vs. 2021\nCommercial - domestic: |  |  |  |  |  |  |  | \nRisk-based |  | 7,950 |  |  | 7,860 |  |  | 90 |  |  | 1 | %\nFee-based |  | 18,460 |  |  | 18,455 |  |  | 5 |  |  | \u2014 | \nTotal commercial - domestic |  | 26,410 |  |  | 26,315 |  |  | 95 |  |  | \u2014 | \nMedicare Advantage |  | 6,890 |  |  | 6,335 |  |  | 555 |  |  | 9 | \nMedicaid |  | 7,810 |  |  | 6,975 |  |  | 835 |  |  | 12 | \nMedicare Supplement (Standardized) |  | 4,355 |  |  | 4,390 |  |  | (35) |  |  | (1) | \nTotal community and senior |  | 19,055 |  |  | 17,700 |  |  | 1,355 |  |  | 8 | \nTotal UnitedHealthcare - domestic medical |  | 45,465 |  |  | 44,015 |  |  | 1,450 |  |  | 3 | \nCommercial - global |  | 5,500 |  |  | 5,460 |  |  | 40 |  |  | 1 | \nTotal UnitedHealthcare - medical |  | 50,965 |  |  | 49,475 |  |  | 1,490 |  |  | 3 | %\nSupplemental Data: |  |  |  |  |  |  |  | \nMedicare Part D stand-alone |  | 3,360 |  |  | 3,795 |  |  | (435) |  |  | (11) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, |  | Increase/(Decrease)\n(in millions) |  | 2022 |  | 2021 |  | 2022 vs. 2021\nSources of cash: |  |  |  |  |  | \nCash provided by operating activities |  | $ | 5,319 |  |  | $ | 6,005 |  |  | $ | (686) | \nIssuances of short-term borrowings and long-term debt, net of repayments |  | 2,048 |  |  | 2,907 |  |  | (859) | \nProceeds from common stock issuances |  | 551 |  |  | 436 |  |  | 115 | \nCustomer funds administered |  | 5,120 |  |  | 2,131 |  |  | 2,989 | \nTotal sources of cash |  | 13,038 |  |  | 11,479 |  |  | \nUses of cash: |  |  |  |  |  | \nCommon stock repurchases |  | (2,500) |  |  | (1,650) |  |  | (850) | \nCash paid for acquisitions, net of cash assumed |  | (1,231) |  |  | (1,193) |  |  | (38) | \nPurchases of investments, net of sales and maturities |  | (1,632) |  |  | (1,714) |  |  | 82 | \nPurchases of property, equipment and capitalized software |  | (555) |  |  | (568) |  |  | 13 | \nCash dividends paid |  | (1,363) |  |  | (1,181) |  |  | (182) | \nOther |  | (1,807) |  |  | (2,088) |  |  | 281 | \nTotal uses of cash |  | (9,088) |  |  | (8,394) |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | 157 |  |  | (51) |  |  | 208 | \nNet increase in cash and cash equivalents |  | $ | 4,107 |  |  | $ | 3,034 |  |  | $ | 1,073 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Moody\u2019s |  | S&P Global |  | Fitch |  | A.M. Best\n | Ratings |  | Outlook |  | Ratings |  | Outlook |  | Ratings |  | Outlook |  | Ratings |  | Outlook\nSenior unsecured debt | A3 |  | Stable |  | A+ |  | Stable |  | A |  | Stable |  | A |  | Stable\nCommercial paper | P-2 |  | n/a |  | A-1 |  | n/a |  | F1 |  | n/a |  | AMB-1+ |  | n/a  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31, 2022\nIncrease (Decrease) in Market Interest Rate |  | InvestmentIncome\u00a0PerAnnum |  | InterestExpense\u00a0PerAnnum |  | Fair\u00a0Value\u00a0ofFinancial Assets |  | Fair\u00a0Value\u00a0ofFinancial Liabilities\n2 % |  | $ | 578 |  |  | $ | 202 |  |  | $ | (3,090) |  |  | $ | (7,429) | \n1 |  | 289 |  |  | 101 |  |  | (1,586) |  |  | (4,041) | \n(1) |  | (92) |  |  | (46) |  |  | 1,650 |  |  | 4,857 | \n(2) |  | (92) |  |  | (46) |  |  | 3,280 |  |  | 10,710 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFor the Month Ended |  | Total Number of Shares Purchased |  | Average Price Paid Per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number of Shares That May Yet Be Purchased Under The Plans or Programs\n |  | (in millions) |  |  |  | (in millions) |  | (in millions)\nJanuary 31, 2022 |  | 1 |  | $ | 472.20 |  |  | 1 |  | 44\nFebruary 28, 2022 |  | 1 |  | 474.86 |  |  | 1 |  | 43\nMarch 31, 2022 |  | 3 |  | 494.10 |  |  | 3 |  | 40\nTotal |  | 5 |  | $ | 485.12 |  |  | 5 |  |   |  |  |  |  |  |  |  | \n3.1 |  | Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company\u2019s Registration Statement on Form 8-A/A filed on July 1, 2015)\n3.2 |  | Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by reference to Exhibit 3.2 to UnitedHealth Group Incorporated\u2019s Current Report on Form 8-K filed on February 26, 2021)\n4.1 |  | Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company\u2019s Registration Statement on Form S-3/A, SEC File Number 333-66013, filed on January 11, 1999)\n4.2 |  | Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998, between UnitedHealth Group Incorporated and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2001)\n4.3 |  | Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant to the Senior Indenture, dated as of November 15, 1998, amended November 6, 2000, among UnitedHealth Group Incorporated, The Bank of New York and Wilmington Trust Company (incorporated by reference to Exhibit 4.3 to the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended June\u00a030, 2007)\n4.4 |  | Indenture, dated as of February\u00a04,\u00a02008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company\u2019s Registration Statement on Form S-3, SEC File Number 333-149031, filed on February\u00a04, 2008)\n31.1 |  | Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\n32.1 |  | Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\n101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n101.SCH |  | Inline XBRL Taxonomy Extension Schema Document.\n101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document.\n101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document.\n101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document.\n101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document.\n104 |  |  | Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).  |  |  |  |  |  |  |  | \n* |  | Pursuant to Item\u00a0601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n/s/    ANDREWP. WITTY |  | Chief Executive Officer(principal executive officer) | Dated: | May 4, 2022\nAndrew P. Witty |  |  | \n |  | \n/s/    JOHNF. REX |  | Executive Vice President andChief\u00a0Financial\u00a0Officer(principal financial officer) | Dated: | May 4, 2022\nJohn F. Rex |  |  | \n |  | \n/s/THOMASE. ROOS |  | Senior Vice President andChief Accounting Officer(principal accounting officer) | Dated: | May 4, 2022\nThomas E. Roos |  |  | "}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For United Health Group, in 2022 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |   |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  |  |  |  |  |  |  | \nDelaware |  | 41-1321939\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)\nUnitedHealth Group Center |  | 55343\n9900 Bren Road East | \nMinnetonka, | Minnesota | \n(Address of principal executive offices) |  | (Zip Code)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered\nCommon Stock, $.01 par value |  | UNH |  | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 |  | Accelerated\u00a0filer | \u2610 |  | Non-accelerated filer | \u2610\nSmaller\u00a0reporting\u00a0company | \u2610 |  |  |  |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page\n |  |  |  | \nPart I. Financial\u00a0Information | \nItem\u00a01. | Financial Statements (unaudited) | 1\n |  | Condensed Consolidated Balance Sheets as ofJune30, 2022and December 31, 2021 | 1\n |  | Condensed Consolidated Statements of Operations for the Three andSixMonths EndedJune30, 2022and 2021 | 2\n |  | Condensed Consolidated Statements of Comprehensive Income for the Three andSixMonths EndedJune30, 2022and 2021 | 3\n |  | Condensed Consolidated Statements of Changes in Equity for the Three andSixMonths EndedJune30, 2022and 2021 | 4\n |  | Condensed Consolidated Statements of Cash Flows for theSixMonths EndedJune30, 2022and 2021 | 6\n |  | Notes to the Condensed Consolidated Financial Statements | 7\n |  | 1. | Basis of Presentation | 7\n |  | 2. | Investments | 8\n |  | 3. | Fair Value | 10\n |  | 4. | Medical Costs Payable | 11\n |  | 5. | Short-Term Borrowings and Long-Term Debt | 11\n |  | 6. | Dividends | 12\n |  | 7. | Commitments and Contingencies | 12\n |  | 8. | Business Combinations | 13\n |  | 9. | Segment Financial Information | 13\nItem\u00a02. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 16\nItem\u00a03. | Quantitative and Qualitative Disclosures About Market Risk | 23\nItem\u00a04. | Controls and Procedures | 24\nPart\u00a0II. Other Information | \nItem\u00a01. | Legal Proceedings | 24\nItem\u00a01A. | Risk Factors | 24\nItem\u00a02. | Unregistered Sales of Equity Securities and Use of Proceeds | 25\nItem\u00a06. | Exhibits | 26\nSignatures | 27  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except per share data) |  | June 30,2022 |  | December 31,2021\nAssets |  |  |  | \nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 24,612 |  |  | $ | 21,375 | \nShort-term investments |  | 3,352 |  |  | 2,532 | \nAccounts receivable, net |  | 18,718 |  |  | 14,216 | \nOther current receivables, net |  | 12,439 |  |  | 13,866 | \nAssets under management |  | 4,017 |  |  | 4,449 | \nPrepaid expenses and other current assets |  | 5,218 |  |  | 5,320 | \nTotal current assets |  | 68,356 |  |  | 61,758 | \nLong-term investments |  | 42,427 |  |  | 43,114 | \nProperty, equipment and capitalized software, net |  | 9,421 |  |  | 8,969 | \nGoodwill |  | 84,159 |  |  | 75,795 | \nOther intangible assets, net |  | 11,285 |  |  | 10,044 | \nOther assets |  | 14,524 |  |  | 12,526 | \nTotal assets |  | $ | 230,172 |  |  | $ | 212,206 | \nLiabilities, redeemable noncontrolling interests and equity |  |  |  | \nCurrent liabilities: |  |  |  | \nMedical costs payable |  | $ | 28,978 |  |  | $ | 24,483 | \nAccounts payable and accrued liabilities |  | 25,145 |  |  | 24,643 | \nShort-term borrowings and current maturities of long-term debt |  | 5,592 |  |  | 3,620 | \nUnearned revenues |  | 2,212 |  |  | 2,571 | \nOther current liabilities |  | 26,771 |  |  | 22,975 | \nTotal current liabilities |  | 88,698 |  |  | 78,292 | \nLong-term debt, less current maturities |  | 45,799 |  |  | 42,383 | \nDeferred income taxes |  | 2,581 |  |  | 3,265 | \nOther liabilities |  | 11,967 |  |  | 11,787 | \nTotal liabilities |  | 149,045 |  |  | 135,727 | \nCommitments and contingencies (Note 7) |  |  |  | \nRedeemable noncontrolling interests |  | 4,922 |  |  | 1,434 | \nEquity: |  |  |  | \nPreferred stock, $0.001par value -10shares authorized;noshares issued or outstanding |  | \u2014 |  |  | \u2014 | \nCommon stock, $0.01par value -3,000shares authorized;935and941issued and outstanding |  | 10 |  |  | 10 | \nRetained earnings |  | 80,540 |  |  | 77,134 | \nAccumulated other comprehensive loss |  | (7,730) |  |  | (5,384) | \nNonredeemable noncontrolling interests |  | 3,385 |  |  | 3,285 | \nTotal equity |  | 76,205 |  |  | 75,045 | \nTotal liabilities, redeemable noncontrolling interests and equity |  | $ | 230,172 |  |  | $ | 212,206 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n(in millions, except per share data) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nRevenues: |  |  |  |  |  |  |  | \nPremiums |  | $ | 63,896 |  |  | $ | 56,233 |  |  | $ | 127,966 |  |  | $ | 111,719 | \nProducts |  | 9,496 |  |  | 8,433 |  |  | 18,836 |  |  | 16,773 | \nServices |  | 6,645 |  |  | 6,099 |  |  | 13,017 |  |  | 12,017 | \nInvestment and other income |  | 295 |  |  | 556 |  |  | 662 |  |  | 1,008 | \nTotal revenues |  | 80,332 |  |  | 71,321 |  |  | 160,481 |  |  | 141,517 | \nOperating costs: |  |  |  |  |  |  |  | \nMedical costs |  | 52,093 |  |  | 46,546 |  |  | 104,616 |  |  | 91,450 | \nOperating costs |  | 11,709 |  |  | 10,359 |  |  | 23,110 |  |  | 20,582 | \nCost of products sold |  | 8,596 |  |  | 7,660 |  |  | 17,083 |  |  | 15,232 | \nDepreciation and amortization |  | 802 |  |  | 778 |  |  | 1,590 |  |  | 1,536 | \nTotal operating costs |  | 73,200 |  |  | 65,343 |  |  | 146,399 |  |  | 128,800 | \nEarnings from operations |  | 7,132 |  |  | 5,978 |  |  | 14,082 |  |  | 12,717 | \nInterest expense |  | (467) |  |  | (410) |  |  | (900) |  |  | (807) | \nEarnings before income taxes |  | 6,665 |  |  | 5,568 |  |  | 13,182 |  |  | 11,910 | \nProvision for income taxes |  | (1,466) |  |  | (1,196) |  |  | (2,835) |  |  | (2,560) | \nNet earnings |  | 5,199 |  |  | 4,372 |  |  | 10,347 |  |  | 9,350 | \nEarnings attributable to noncontrolling interests |  | (129) |  |  | (106) |  |  | (250) |  |  | (222) | \nNet earnings attributable to UnitedHealth Group common shareholders |  | $ | 5,070 |  |  | $ | 4,266 |  |  | $ | 10,097 |  |  | $ | 9,128 | \nEarnings per share attributable to UnitedHealth Group common shareholders: |  |  |  |  |  |  |  | \nBasic |  | $ | 5.41 |  |  | $ | 4.52 |  |  | $ | 10.75 |  |  | $ | 9.66 | \nDiluted |  | $ | 5.34 |  |  | $ | 4.46 |  |  | $ | 10.61 |  |  | $ | 9.55 | \nBasic weighted-average number of common shares outstanding |  | 937 |  |  | 944 |  |  | 939 |  |  | 945 | \nDilutive effect of common share equivalents |  | 13 |  |  | 12 |  |  | 13 |  |  | 11 | \nDiluted weighted-average number of common shares outstanding |  | 950 |  |  | 956 |  |  | 952 |  |  | 956 | \nAnti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents |  | 3 |  |  | 1 |  |  | 3 |  |  | 2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n(in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nNet earnings |  | $ | 5,199 |  |  | $ | 4,372 |  |  | $ | 10,347 |  |  | $ | 9,350 | \nOther comprehensive (loss) income: |  |  |  |  |  |  |  | \nGross unrealized (losses) gains on investment securities during the period |  | (1,331) |  |  | 251 |  |  | (3,354) |  |  | (513) | \nIncome tax effect |  | 304 |  |  | (58) |  |  | 769 |  |  | 116 | \nTotal unrealized (losses) gains, net of tax |  | (1,027) |  |  | 193 |  |  | (2,585) |  |  | (397) | \nGross reclassification adjustment for net realized gains included in net earnings |  | (1) |  |  | (9) |  |  | (4) |  |  | (16) | \nIncome tax effect |  | \u2014 |  |  | 2 |  |  | 1 |  |  | 4 | \nTotal reclassification adjustment, net of tax |  | (1) |  |  | (7) |  |  | (3) |  |  | (12) | \nTotal foreign currency translation (losses) gains |  | (676) |  |  | 554 |  |  | 242 |  |  | 137 | \nOther comprehensive (loss) income |  | (1,704) |  |  | 740 |  |  | (2,346) |  |  | (272) | \nComprehensive income |  | 3,495 |  |  | 5,112 |  |  | 8,001 |  |  | 9,078 | \nComprehensive income attributable to noncontrolling interests |  | (129) |  |  | (106) |  |  | (250) |  |  | (222) | \nComprehensive income attributable to UnitedHealth Group common shareholders |  | $ | 3,366 |  |  | $ | 5,006 |  |  | $ | 7,751 |  |  | $ | 8,856 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Common Stock |  | Additional Paid-In Capital |  | Retained Earnings |  | Accumulated Other Comprehensive(Loss) Income |  | Nonredeemable Noncontrolling Interests |  | TotalEquity\nThree months ended June 30,(in millions) |  | Shares |  | Amount |  |  |  | Net Unrealized (Losses) Gains on Investments |  | Foreign Currency Translation (Losses) Gains |  | \nBalance at March 31, 2022 |  | 939 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 78,782 |  |  | $ | (1,137) |  |  | $ | (4,889) |  |  | $ | 3,362 |  |  | $ | 76,128 | \nNet earnings |  |  |  |  |  |  |  | 5,070 |  |  |  |  |  |  | 94 |  |  | 5,164 | \nOther comprehensive loss |  |  |  |  |  |  |  |  |  | (1,028) |  |  | (676) |  |  |  |  | (1,704) | \nIssuances of common stock, and related tax effects |  | 1 |  |  | \u2014 |  |  | 174 |  |  |  |  |  |  |  |  |  |  | 174 | \nShare-based compensation |  |  |  |  |  | 194 |  |  |  |  |  |  |  |  |  |  | 194 | \nCommon share repurchases |  | (5) |  |  | \u2014 |  |  | (733) |  |  | (1,767) |  |  |  |  |  |  |  |  | (2,500) | \nCash dividends paid on common shares ($1.65per share) |  |  |  |  |  |  |  | (1,545) |  |  |  |  |  |  |  |  | (1,545) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | 365 |  |  |  |  |  |  |  |  |  |  | 365 | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 12 |  |  | 12 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (83) |  |  | (83) | \nBalance at June 30, 2022 |  | 935 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 80,540 |  |  | $ | (2,165) |  |  | $ | (5,565) |  |  | $ | 3,385 |  |  | $ | 76,205 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at March 31, 2021 |  | 944 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 71,220 |  |  | $ | 741 |  |  | $ | (5,567) |  |  | $ | 2,909 |  |  | $ | 69,313 | \nNet earnings |  |  |  |  |  |  |  | 4,266 |  |  |  |  |  |  | 88 |  |  | 4,354 | \nOther comprehensive income |  |  |  |  |  |  |  |  |  | 186 |  |  | 554 |  |  |  |  | 740 | \nIssuances of common stock, and related tax effects |  | 2 |  |  | \u2014 |  |  | 292 |  |  |  |  |  |  |  |  |  |  | 292 | \nShare-based compensation |  |  |  |  |  | 158 |  |  |  |  |  |  |  |  |  |  | 158 | \nCommon share repurchases |  | (3) |  |  | \u2014 |  |  | (221) |  |  | (1,029) |  |  |  |  |  |  |  |  | (1,250) | \nCash dividends paid on common shares ($1.45per share) |  |  |  |  |  |  |  | (1,367) |  |  |  |  |  |  |  |  | (1,367) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | (229) |  |  |  |  |  |  |  |  |  |  | (229) | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 85 |  |  | 85 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (74) |  |  | (74) | \nBalance at June 30, 2021 |  | 943 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 73,090 |  |  | $ | 927 |  |  | $ | (5,013) |  |  | $ | 3,008 |  |  | $ | 72,022 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Common Stock |  | Additional Paid-In Capital |  | Retained Earnings |  | Accumulated Other ComprehensiveIncome (Loss) |  | Nonredeemable Noncontrolling Interests |  | TotalEquity\nSix months ended June 30,(in millions) |  | Shares |  | Amount |  |  |  | Net Unrealized Gains (Losses) on Investments |  | Foreign Currency Translation (Losses) Gains |  | \nBalance at January 1, 2022 |  | 941 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 77,134 |  |  | $ | 423 |  |  | $ | (5,807) |  |  | $ | 3,285 |  |  | $ | 75,045 | \nNet earnings |  |  |  |  |  |  |  | 10,097 |  |  |  |  |  |  | 182 |  |  | 10,279 | \nOther comprehensive (loss) income |  |  |  |  |  |  |  |  |  | (2,588) |  |  | 242 |  |  |  |  | (2,346) | \nIssuances of common stock, and related tax effects |  | 4 |  |  | \u2014 |  |  | 507 |  |  |  |  |  |  |  |  |  |  | 507 | \nShare-based compensation |  |  |  |  |  | 476 |  |  |  |  |  |  |  |  |  |  | 476 | \nCommon share repurchases |  | (10) |  |  | \u2014 |  |  | (1,217) |  |  | (3,783) |  |  |  |  |  |  |  |  | (5,000) | \nCash dividends paid on common shares ($3.10per share) |  |  |  |  |  |  |  | (2,908) |  |  |  |  |  |  |  |  | (2,908) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | 234 |  |  |  |  |  |  |  |  |  |  | 234 | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 103 |  |  | 103 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (185) |  |  | (185) | \nBalance at June 30, 2022 |  | 935 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 80,540 |  |  | $ | (2,165) |  |  | $ | (5,565) |  |  | $ | 3,385 |  |  | $ | 76,205 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at January 1, 2021 |  | 946 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 69,295 |  |  | $ | 1,336 |  |  | $ | (5,150) |  |  | $ | 2,837 |  |  | $ | 68,328 | \nNet earnings |  |  |  |  |  |  |  | 9,128 |  |  |  |  |  |  | 168 |  |  | 9,296 | \nOther comprehensive (loss) income |  |  |  |  |  |  |  |  |  | (409) |  |  | 137 |  |  |  |  | (272) | \nIssuances of common stock, and related tax effects |  | 5 |  |  | \u2014 |  |  | 548 |  |  |  |  |  |  |  |  |  |  | 548 | \nShare-based compensation |  |  |  |  |  | 400 |  |  |  |  |  |  |  |  |  |  | 400 | \nCommon share repurchases |  | (8) |  |  | \u2014 |  |  | (221) |  |  | (2,679) |  |  |  |  |  |  |  |  | (2,900) | \nCash dividends paid on common shares ($2.70per share) |  |  |  |  |  |  |  | (2,548) |  |  |  |  |  |  |  |  | (2,548) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | (727) |  |  | (106) |  |  |  |  |  |  |  |  | (833) | \nAcquisitions and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 151 |  |  | 151 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (148) |  |  | (148) | \nBalance at June 30, 2021 |  | 943 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 73,090 |  |  | $ | 927 |  |  | $ | (5,013) |  |  | $ | 3,008 |  |  | $ | 72,022 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30,\n(in millions) |  | 2022 |  | 2021\nOperating activities |  |  |  | \nNet earnings |  | $ | 10,347 |  |  | $ | 9,350 | \nNoncash items: |  |  |  | \nDepreciation and amortization |  | 1,590 |  |  | 1,536 | \nDeferred income taxes |  | (15) |  |  | 327 | \nShare-based compensation |  | 504 |  |  | 426 | \nOther, net |  | 215 |  |  | (214) | \nNet change in other operating items, net of effects from acquisitions and changes in AARP balances: |  |  |  | \nAccounts receivable |  | (4,204) |  |  | (1,218) | \nOther assets |  | (643) |  |  | (1,523) | \nMedical costs payable |  | 4,029 |  |  | 3,086 | \nAccounts payable and other liabilities |  | 807 |  |  | 298 | \nUnearned revenues |  | (440) |  |  | (523) | \nCash flows from operating activities |  | 12,190 |  |  | 11,545 | \nInvesting activities |  |  |  | \nPurchases of investments |  | (8,903) |  |  | (8,847) | \nSales of investments |  | 2,348 |  |  | 1,408 | \nMaturities of investments |  | 3,189 |  |  | 4,650 | \nCash paid for acquisitions, net of cash assumed |  | (7,150) |  |  | (4,642) | \nPurchases of property, equipment and capitalized software |  | (1,212) |  |  | (1,130) | \nOther, net |  | (532) |  |  | (648) | \nCash flows used for investing activities |  | (12,260) |  |  | (9,209) | \nFinancing activities |  |  |  | \nCommon share repurchases |  | (5,000) |  |  | (2,900) | \nCash dividends paid |  | (2,908) |  |  | (2,548) | \nProceeds from common stock issuances |  | 756 |  |  | 764 | \nRepayments of long-term debt |  | (1,100) |  |  | (1,900) | \nProceeds from (repayments of) short-term borrowings, net |  | 1,340 |  |  | (176) | \nProceeds from issuance of long-term debt |  | 5,922 |  |  | 6,934 | \nCustomer funds administered |  | 5,786 |  |  | 2,395 | \nPurchases of redeemable noncontrolling interests |  | (97) |  |  | (1,338) | \nOther, net |  | (1,449) |  |  | (662) | \nCash flows from financing activities |  | 3,250 |  |  | 569 | \nEffect of exchange rate changes on cash and cash equivalents |  | 57 |  |  | 6 | \nIncrease in cash and cash equivalents |  | 3,237 |  |  | 2,911 | \nCash and cash equivalents, beginning of period |  | 21,375 |  |  | 16,921 | \nCash and cash equivalents, end of period |  | $ | 24,612 |  |  | $ | 19,832 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | AmortizedCost |  | GrossUnrealizedGains |  | GrossUnrealizedLosses |  | FairValue\nJune 30, 2022 |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 3,808 |  |  | $ | 1 |  |  | $ | (209) |  |  | $ | 3,600 | \nState and municipal obligations |  | 7,725 |  |  | 25 |  |  | (381) |  |  | 7,369 | \nCorporate obligations |  | 22,080 |  |  | 5 |  |  | (1,515) |  |  | 20,570 | \nU.S. agency mortgage-backed securities |  | 6,275 |  |  | 2 |  |  | (537) |  |  | 5,740 | \nNon-U.S. agency mortgage-backed securities |  | 2,926 |  |  | \u2014 |  |  | (201) |  |  | 2,725 | \nTotal debt securities - available-for-sale |  | 42,814 |  |  | 33 |  |  | (2,843) |  |  | 40,004 | \nDebt securities - held-to-maturity: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 544 |  |  | \u2014 |  |  | (11) |  |  | 533 | \nState and municipal obligations |  | 29 |  |  | \u2014 |  |  | (2) |  |  | 27 | \nCorporate obligations |  | 141 |  |  | \u2014 |  |  | \u2014 |  |  | 141 | \nTotal debt securities - held-to-maturity |  | 714 |  |  | \u2014 |  |  | (13) |  |  | 701 | \nTotal debt securities |  | $ | 43,528 |  |  | $ | 33 |  |  | $ | (2,856) |  |  | $ | 40,705 | \nDecember 31, 2021 |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 3,206 |  |  | $ | 23 |  |  | $ | (31) |  |  | $ | 3,198 | \nState and municipal obligations |  | 6,829 |  |  | 297 |  |  | (20) |  |  | 7,106 | \nCorporate obligations |  | 20,947 |  |  | 372 |  |  | (145) |  |  | 21,174 | \nU.S. agency mortgage-backed securities |  | 5,868 |  |  | 88 |  |  | (55) |  |  | 5,901 | \nNon-U.S. agency mortgage-backed securities |  | 2,819 |  |  | 42 |  |  | (23) |  |  | 2,838 | \nTotal debt securities - available-for-sale |  | 39,669 |  |  | 822 |  |  | (274) |  |  | 40,217 | \nDebt securities - held-to-maturity: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 511 |  |  | 2 |  |  | (2) |  |  | 511 | \nState and municipal obligations |  | 30 |  |  | 2 |  |  | \u2014 |  |  | 32 | \nCorporate obligations |  | 100 |  |  | \u2014 |  |  | \u2014 |  |  | 100 | \nTotal debt securities - held-to-maturity |  | 641 |  |  | 4 |  |  | (2) |  |  | 643 | \nTotal debt securities |  | $ | 40,310 |  |  | $ | 826 |  |  | $ | (276) |  |  | $ | 40,860 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Available-for-Sale |  | Held-to-Maturity\n(in millions) |  | AmortizedCost |  | FairValue |  | AmortizedCost |  | FairValue\nDue in one year or less |  | $ | 3,439 |  |  | $ | 3,422 |  |  | $ | 385 |  |  | $ | 381 | \nDue after one year through five years |  | 13,237 |  |  | 12,672 |  |  | 295 |  |  | 288 | \nDue after five years through ten years |  | 12,332 |  |  | 11,213 |  |  | 14 |  |  | 13 | \nDue after ten years |  | 4,605 |  |  | 4,232 |  |  | 20 |  |  | 19 | \nU.S. agency mortgage-backed securities |  | 6,275 |  |  | 5,740 |  |  | \u2014 |  |  | \u2014 | \nNon-U.S. agency mortgage-backed securities |  | 2,926 |  |  | 2,725 |  |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 42,814 |  |  | $ | 40,004 |  |  | $ | 714 |  |  | $ | 701 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Less Than 12 Months |  | 12 Months or Greater |  | Total\n(in millions) |  | FairValue |  | GrossUnrealizedLosses |  | FairValue |  | GrossUnrealizedLosses |  | FairValue |  | GrossUnrealizedLosses\nJune 30, 2022 |  |  |  |  |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 2,921 |  |  | $ | (152) |  |  | $ | 474 |  |  | $ | (57) |  |  | $ | 3,395 |  |  | $ | (209) | \nState and municipal obligations |  | 4,807 |  |  | (355) |  |  | 209 |  |  | (26) |  |  | 5,016 |  |  | (381) | \nCorporate obligations |  | 16,894 |  |  | (1,200) |  |  | 2,261 |  |  | (315) |  |  | 19,155 |  |  | (1,515) | \nU.S. agency mortgage-backed securities |  | 4,323 |  |  | (356) |  |  | 1,201 |  |  | (181) |  |  | 5,524 |  |  | (537) | \nNon-U.S. agency mortgage-backed securities |  | 2,354 |  |  | (151) |  |  | 354 |  |  | (50) |  |  | 2,708 |  |  | (201) | \nTotal debt securities - available-for-sale |  | $ | 31,299 |  |  | $ | (2,214) |  |  | $ | 4,499 |  |  | $ | (629) |  |  | $ | 35,798 |  |  | $ | (2,843) | \nDecember 31, 2021 |  |  |  |  |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 1,976 |  |  | $ | (18) |  |  | $ | 249 |  |  | $ | (13) |  |  | $ | 2,225 |  |  | $ | (31) | \nState and municipal obligations |  | 1,386 |  |  | (19) |  |  | 31 |  |  | (1) |  |  | 1,417 |  |  | (20) | \nCorporate obligations |  | 9,357 |  |  | (130) |  |  | 376 |  |  | (15) |  |  | 9,733 |  |  | (145) | \nU.S. agency mortgage-backed securities |  | 3,078 |  |  | (52) |  |  | 116 |  |  | (3) |  |  | 3,194 |  |  | (55) | \nNon-U.S. agency mortgage-backed securities |  | 1,321 |  |  | (18) |  |  | 114 |  |  | (5) |  |  | 1,435 |  |  | (23) | \nTotal debt securities - available-for-sale |  | $ | 17,118 |  |  | $ | (237) |  |  | $ | 886 |  |  | $ | (37) |  |  | $ | 18,004 |  |  | $ | (274) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | OtherObservableInputs(Level 2) |  | UnobservableInputs(Level 3) |  | TotalFair and CarryingValue\nJune 30, 2022 |  |  |  |  |  |  |  | \nCash and cash equivalents |  | $ | 24,546 |  |  | $ | 66 |  |  | $ | \u2014 |  |  | $ | 24,612 | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 3,432 |  |  | 168 |  |  | \u2014 |  |  | 3,600 | \nState and municipal obligations |  | \u2014 |  |  | 7,369 |  |  | \u2014 |  |  | 7,369 | \nCorporate obligations |  | 35 |  |  | 20,342 |  |  | 193 |  |  | 20,570 | \nU.S. agency mortgage-backed securities |  | \u2014 |  |  | 5,740 |  |  | \u2014 |  |  | 5,740 | \nNon-U.S. agency mortgage-backed securities |  | \u2014 |  |  | 2,725 |  |  | \u2014 |  |  | 2,725 | \nTotal debt securities - available-for-sale |  | 3,467 |  |  | 36,344 |  |  | 193 |  |  | 40,004 | \nEquity securities |  | 1,894 |  |  | 18 |  |  | 68 |  |  | 1,980 | \nAssets under management |  | 1,655 |  |  | 2,268 |  |  | 94 |  |  | 4,017 | \nTotal assets at fair value |  | $ | 31,562 |  |  | $ | 38,696 |  |  | $ | 355 |  |  | $ | 70,613 | \nPercentage of total assets at fair value |  | 45 | % |  | 54 | % |  | 1 | % |  | 100 | %\nDecember 31, 2021 |  |  |  |  |  |  |  | \nCash and cash equivalents |  | $ | 21,359 |  |  | $ | 16 |  |  | $ | \u2014 |  |  | $ | 21,375 | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 3,017 |  |  | 181 |  |  | \u2014 |  |  | 3,198 | \nState and municipal obligations |  | \u2014 |  |  | 7,106 |  |  | \u2014 |  |  | 7,106 | \nCorporate obligations |  | 40 |  |  | 20,916 |  |  | 218 |  |  | 21,174 | \nU.S. agency mortgage-backed securities |  | \u2014 |  |  | 5,901 |  |  | \u2014 |  |  | 5,901 | \nNon-U.S. agency mortgage-backed securities |  | \u2014 |  |  | 2,838 |  |  | \u2014 |  |  | 2,838 | \nTotal debt securities - available-for-sale |  | 3,057 |  |  | 36,942 |  |  | 218 |  |  | 40,217 | \nEquity securities |  | 2,090 |  |  | 23 |  |  | 64 |  |  | 2,177 | \nAssets under management |  | 1,972 |  |  | 2,376 |  |  | 101 |  |  | 4,449 | \nTotal assets at fair value |  | $ | 28,478 |  |  | $ | 39,357 |  |  | $ | 383 |  |  | $ | 68,218 | \nPercentage of total assets at fair value |  | 42 | % |  | 57 | % |  | 1 | % |  | 100 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | OtherObservableInputs(Level 2) |  | UnobservableInputs(Level 3) |  | TotalFairValue |  | Total Carrying Value\nJune 30, 2022 |  |  |  |  |  |  |  |  |  | \nDebt securities - held-to-maturity |  | $ | 597 |  |  | $ | 104 |  |  | $ | \u2014 |  |  | $ | 701 |  |  | $ | 714 | \nLong-term debt and other financing obligations |  | $ | \u2014 |  |  | $ | 48,549 |  |  | $ | \u2014 |  |  | $ | 48,549 |  |  | $ | 50,041 | \nDecember 31, 2021 |  |  |  |  |  |  |  |  |  | \nDebt securities - held-to-maturity |  | $ | 534 |  |  | $ | 102 |  |  | $ | 7 |  |  | $ | 643 |  |  | $ | 641 | \nLong-term debt and other financing obligations |  | $ | \u2014 |  |  | $ | 52,583 |  |  | $ | \u2014 |  |  | $ | 52,583 |  |  | $ | 46,003 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | 2022 |  | 2021\nMedical costs payable, beginning of period |  | $ | 24,483 |  |  | $ | 21,872 | \nAcquisitions |  | 171 |  |  | 46 | \nReported medical costs: |  |  |  | \nCurrent year |  | 104,936 |  |  | 92,570 | \nPrior years |  | (320) |  |  | (1,120) | \nTotal reported medical costs |  | 104,616 |  |  | 91,450 | \nMedical payments: |  |  |  | \nPayments for current year |  | (78,937) |  |  | (69,808) | \nPayments for prior years |  | (21,355) |  |  | (18,429) | \nTotal medical payments |  | (100,292) |  |  | (88,237) | \nMedical costs payable, end of period |  | $ | 28,978 |  |  | $ | 25,131 |   |  |  |  |  |  |  |  | \n(in millions, except percentages) |  | Par Value\n3.700% notes due May 2027 |  | $ | 600 | \n4.000% notes due May 2029 |  | 900 | \n4.200% notes due May 2032 |  | 1,500 | \n4.750% notes due May 2052 |  | 2,000 | \n4.950% notes due May 2062 |  | 1,000 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPayment Date |  | Amount per Share |  | Total Amount Paid\n |  |  |  | (in millions)\nMarch 22 |  | $ | 1.45 |  |  | $ | 1,363 | \nJune 28 |  | 1.65 |  |  | 1,545 |   |  |  |  |  |  |  |  | \n(in millions) |  | \nCash and cash equivalents |  | $ | 457 | \nAccounts receivable and other current assets |  | 585 | \nProperty, equipment and other long-term assets |  | 1,494 | \nIntangible assets |  | 1,810 | \nTotal identifiable assets acquired |  | 4,346 | \nMedical costs payable |  | (171) | \nAccounts payable and other current liabilities |  | (590) | \nOther long-term liabilities |  | (605) | \nTotal identifiable liabilities acquired |  | (1,366) | \nTotal net identifiable assets |  | 2,980 | \nGoodwill |  | 8,309 | \nRedeemable noncontrolling interests |  | (3,101) | \nNonredeemable noncontrolling interests |  | (103) | \nNet assets acquired |  | $ | 8,085 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except years) |  | Fair Value |  | Weighted-Average Useful Life\nCustomer-related |  | $ | 915 |  |  | 9years\nTrademarks and technology |  | 800 |  |  | 9years\nOther |  | 80 |  |  | 11years\nTotal acquired finite-lived intangible assets |  | $ | 1,795 |  |  | 9years  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Optum |  |  |  | \n(in millions) |  | UnitedHealthcare |  | Optum Health |  | Optum Insight |  | Optum Rx |  | Optum Eliminations |  | Optum |  | Corporate\u00a0andEliminations |  | Consolidated\nThree Months Ended June 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 59,368 |  |  | $ | 4,528 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 4,528 |  |  | $ | \u2014 |  |  | $ | 63,896 | \nProducts |  | \u2014 |  |  | 6 |  |  | 58 |  |  | 9,432 |  |  | \u2014 |  |  | 9,496 |  |  | \u2014 |  |  | 9,496 | \nServices |  | 2,542 |  |  | 2,740 |  |  | 1,034 |  |  | 329 |  |  | \u2014 |  |  | 4,103 |  |  | \u2014 |  |  | 6,645 | \nTotal revenues - unaffiliated customers |  | 61,910 |  |  | 7,274 |  |  | 1,092 |  |  | 9,761 |  |  | \u2014 |  |  | 18,127 |  |  | \u2014 |  |  | 80,037 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 10,224 |  |  | 2,181 |  |  | 15,038 |  |  | (588) |  |  | 26,855 |  |  | (26,855) |  |  | \u2014 | \nInvestment and other income |  | 195 |  |  | 85 |  |  | 9 |  |  | 6 |  |  | \u2014 |  |  | 100 |  |  | \u2014 |  |  | 295 | \nTotal revenues |  | $ | 62,105 |  |  | $ | 17,583 |  |  | $ | 3,282 |  |  | $ | 24,805 |  |  | $ | (588) |  |  | $ | 45,082 |  |  | $ | (26,855) |  |  | $ | 80,332 | \nEarnings from operations |  | $ | 3,850 |  |  | $ | 1,399 |  |  | $ | 839 |  |  | $ | 1,044 |  |  | $ | \u2014 |  |  | $ | 3,282 |  |  | $ | \u2014 |  |  | $ | 7,132 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (467) |  |  | (467) | \nEarnings before income taxes |  | $ | 3,850 |  |  | $ | 1,399 |  |  | $ | 839 |  |  | $ | 1,044 |  |  | $ | \u2014 |  |  | $ | 3,282 |  |  | $ | (467) |  |  | $ | 6,665 | \nThree Months Ended June 30, 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 52,858 |  |  | $ | 3,375 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 3,375 |  |  | $ | \u2014 |  |  | $ | 56,233 | \nProducts |  | \u2014 |  |  | 9 |  |  | 33 |  |  | 8,391 |  |  | \u2014 |  |  | 8,433 |  |  | \u2014 |  |  | 8,433 | \nServices |  | 2,440 |  |  | 2,461 |  |  | 930 |  |  | 268 |  |  | \u2014 |  |  | 3,659 |  |  | \u2014 |  |  | 6,099 | \nTotal revenues - unaffiliated customers |  | 55,298 |  |  | 5,845 |  |  | 963 |  |  | 8,659 |  |  | \u2014 |  |  | 15,467 |  |  | \u2014 |  |  | 70,765 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 7,221 |  |  | 1,921 |  |  | 13,792 |  |  | (478) |  |  | 22,456 |  |  | (22,456) |  |  | \u2014 | \nInvestment and other income |  | 176 |  |  | 234 |  |  | 73 |  |  | 73 |  |  | \u2014 |  |  | 380 |  |  | \u2014 |  |  | 556 | \nTotal revenues |  | $ | 55,474 |  |  | $ | 13,300 |  |  | $ | 2,957 |  |  | $ | 22,524 |  |  | $ | (478) |  |  | $ | 38,303 |  |  | $ | (22,456) |  |  | $ | 71,321 | \nEarnings from operations |  | $ | 3,095 |  |  | $ | 1,128 |  |  | $ | 762 |  |  | $ | 993 |  |  | $ | \u2014 |  |  | $ | 2,883 |  |  | $ | \u2014 |  |  | $ | 5,978 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (410) |  |  | (410) | \nEarnings before income taxes |  | $ | 3,095 |  |  | $ | 1,128 |  |  | $ | 762 |  |  | $ | 993 |  |  | $ | \u2014 |  |  | $ | 2,883 |  |  | $ | (410) |  |  | $ | 5,568 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Optum |  |  |  | \n(in millions) |  | UnitedHealthcare |  | Optum Health |  | Optum Insight |  | Optum Rx |  | Optum Eliminations |  | Optum |  | Corporate\u00a0andEliminations |  | Consolidated\nSix Months Ended June 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 119,305 |  |  | $ | 8,661 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 8,661 |  |  | $ | \u2014 |  |  | $ | 127,966 | \nProducts |  | \u2014 |  |  | 12 |  |  | 98 |  |  | 18,726 |  |  | \u2014 |  |  | 18,836 |  |  | \u2014 |  |  | 18,836 | \nServices |  | 5,057 |  |  | 5,298 |  |  | 2,008 |  |  | 654 |  |  | \u2014 |  |  | 7,960 |  |  | \u2014 |  |  | 13,017 | \nTotal revenues - unaffiliated customers |  | 124,362 |  |  | 13,971 |  |  | 2,106 |  |  | 19,380 |  |  | \u2014 |  |  | 35,457 |  |  | \u2014 |  |  | 159,819 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 20,053 |  |  | 4,319 |  |  | 29,329 |  |  | (1,141) |  |  | 52,560 |  |  | (52,560) |  |  | \u2014 | \nInvestment and other income |  | 338 |  |  | 241 |  |  | 76 |  |  | 7 |  |  | \u2014 |  |  | 324 |  |  | \u2014 |  |  | 662 | \nTotal revenues |  | $ | 124,700 |  |  | $ | 34,265 |  |  | $ | 6,501 |  |  | $ | 48,716 |  |  | $ | (1,141) |  |  | $ | 88,341 |  |  | $ | (52,560) |  |  | $ | 160,481 | \nEarnings from operations |  | $ | 7,648 |  |  | $ | 2,765 |  |  | $ | 1,686 |  |  | $ | 1,983 |  |  | $ | \u2014 |  |  | $ | 6,434 |  |  | $ | \u2014 |  |  | $ | 14,082 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (900) |  |  | (900) | \nEarnings before income taxes |  | $ | 7,648 |  |  | $ | 2,765 |  |  | $ | 1,686 |  |  | $ | 1,983 |  |  | $ | \u2014 |  |  | $ | 6,434 |  |  | $ | (900) |  |  | $ | 13,182 | \nSix Months Ended June 30, 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 105,416 |  |  | $ | 6,303 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 6,303 |  |  | $ | \u2014 |  |  | $ | 111,719 | \nProducts |  | \u2014 |  |  | 17 |  |  | 70 |  |  | 16,686 |  |  | \u2014 |  |  | 16,773 |  |  | \u2014 |  |  | 16,773 | \nServices |  | 4,790 |  |  | 4,797 |  |  | 1,891 |  |  | 539 |  |  | \u2014 |  |  | 7,227 |  |  | \u2014 |  |  | 12,017 | \nTotal revenues - unaffiliated customers |  | 110,206 |  |  | 11,117 |  |  | 1,961 |  |  | 17,225 |  |  | \u2014 |  |  | 30,303 |  |  | \u2014 |  |  | 140,509 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 14,173 |  |  | 3,742 |  |  | 26,796 |  |  | (953) |  |  | 43,758 |  |  | (43,758) |  |  | \u2014 | \nInvestment and other income |  | 382 |  |  | 413 |  |  | 106 |  |  | 107 |  |  | \u2014 |  |  | 626 |  |  | \u2014 |  |  | 1,008 | \nTotal revenues |  | $ | 110,588 |  |  | $ | 25,703 |  |  | $ | 5,809 |  |  | $ | 44,128 |  |  | $ | (953) |  |  | $ | 74,687 |  |  | $ | (43,758) |  |  | $ | 141,517 | \nEarnings from operations |  | $ | 7,203 |  |  | $ | 2,090 |  |  | $ | 1,541 |  |  | $ | 1,883 |  |  | $ | \u2014 |  |  | $ | 5,514 |  |  | $ | \u2014 |  |  | $ | 12,717 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (807) |  |  | (807) | \nEarnings before income taxes |  | $ | 7,203 |  |  | $ | 2,090 |  |  | $ | 1,541 |  |  | $ | 1,883 |  |  | $ | \u2014 |  |  | $ | 5,514 |  |  | $ | (807) |  |  | $ | 11,910 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except percentages and per share data) |  | Three Months EndedJune 30, |  | Increase/(Decrease) |  | Six Months EndedJune 30, |  | Increase/(Decrease)\n | 2022 |  | 2021 |  | 2022 vs. 2021 |  | 2022 |  | 2021 |  | 2022 vs. 2021\nRevenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 63,896 |  |  | $ | 56,233 |  |  | $ | 7,663 |  |  | 14 | % |  | $ | 127,966 |  |  | $ | 111,719 |  |  | $ | 16,247 |  |  | 15 | %\nProducts |  | 9,496 |  |  | 8,433 |  |  | 1,063 |  |  | 13 |  |  | 18,836 |  |  | 16,773 |  |  | 2,063 |  |  | 12 | \nServices |  | 6,645 |  |  | 6,099 |  |  | 546 |  |  | 9 |  |  | 13,017 |  |  | 12,017 |  |  | 1,000 |  |  | 8 | \nInvestment and other income |  | 295 |  |  | 556 |  |  | (261) |  |  | (47) |  |  | 662 |  |  | 1,008 |  |  | (346) |  |  | (34) | \nTotal revenues |  | 80,332 |  |  | 71,321 |  |  | 9,011 |  |  | 13 |  |  | 160,481 |  |  | 141,517 |  |  | 18,964 |  |  | 13 | \nOperating costs: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMedical costs |  | 52,093 |  |  | 46,546 |  |  | 5,547 |  |  | 12 |  |  | 104,616 |  |  | 91,450 |  |  | 13,166 |  |  | 14 | \nOperating costs |  | 11,709 |  |  | 10,359 |  |  | 1,350 |  |  | 13 |  |  | 23,110 |  |  | 20,582 |  |  | 2,528 |  |  | 12 | \nCost of products sold |  | 8,596 |  |  | 7,660 |  |  | 936 |  |  | 12 |  |  | 17,083 |  |  | 15,232 |  |  | 1,851 |  |  | 12 | \nDepreciation and amortization |  | 802 |  |  | 778 |  |  | 24 |  |  | 3 |  |  | 1,590 |  |  | 1,536 |  |  | 54 |  |  | 4 | \nTotal operating costs |  | 73,200 |  |  | 65,343 |  |  | 7,857 |  |  | 12 |  |  | 146,399 |  |  | 128,800 |  |  | 17,599 |  |  | 14 | \nEarnings from operations |  | 7,132 |  |  | 5,978 |  |  | 1,154 |  |  | 19 |  |  | 14,082 |  |  | 12,717 |  |  | 1,365 |  |  | 11 | \nInterest expense |  | (467) |  |  | (410) |  |  | (57) |  |  | 14 |  |  | (900) |  |  | (807) |  |  | (93) |  |  | 12 | \nEarnings before income taxes |  | 6,665 |  |  | 5,568 |  |  | 1,097 |  |  | 20 |  |  | 13,182 |  |  | 11,910 |  |  | 1,272 |  |  | 11 | \nProvision for income taxes |  | (1,466) |  |  | (1,196) |  |  | (270) |  |  | 23 |  |  | (2,835) |  |  | (2,560) |  |  | (275) |  |  | 11 | \nNet earnings |  | 5,199 |  |  | 4,372 |  |  | 827 |  |  | 19 |  |  | 10,347 |  |  | 9,350 |  |  | 997 |  |  | 11 | \nEarnings attributable to noncontrolling interests |  | (129) |  |  | (106) |  |  | (23) |  |  | 22 |  |  | (250) |  |  | (222) |  |  | (28) |  |  | 13 | \nNet earnings attributable to UnitedHealth Group common shareholders |  | $ | 5,070 |  |  | $ | 4,266 |  |  | $ | 804 |  |  | 19 | % |  | $ | 10,097 |  |  | $ | 9,128 |  |  | $ | 969 |  |  | 11 | %\nDiluted earnings per share attributable to UnitedHealth Group common shareholders |  | $ | 5.34 |  |  | $ | 4.46 |  |  | $ | 0.88 |  |  | 20 | % |  | $ | 10.61 |  |  | $ | 9.55 |  |  | $ | 1.06 |  |  | 11 | %\nMedical care ratio (a) |  | 81.5 | % |  | 82.8 | % |  | (1.3) | % |  |  |  | 81.8 | % |  | 81.9 | % |  | (0.1) | % |  | \nOperating cost ratio |  | 14.6 |  |  | 14.5 |  |  | 0.1 |  |  |  |  | 14.4 |  |  | 14.5 |  |  | (0.1) |  |  | \nOperating margin |  | 8.9 |  |  | 8.4 |  |  | 0.5 |  |  |  |  | 8.8 |  |  | 9.0 |  |  | (0.2) |  |  | \nTax rate |  | 22.0 |  |  | 21.5 |  |  | 0.5 |  |  |  |  | 21.5 |  |  | 21.5 |  |  | \u2014 |  |  | \nNet earnings margin (b) |  | 6.3 |  |  | 6.0 |  |  | 0.3 |  |  |  |  | 6.3 |  |  | 6.5 |  |  | (0.2) |  |  | \nReturn on equity (c) |  | 27.9 | % |  | 25.2 | % |  | 2.7 | % |  |  |  | 27.9 | % |  | 27.3 | % |  | 0.6 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months EndedJune 30, |  | Increase/(Decrease) |  | Six Months EndedJune 30, |  | Increase/(Decrease)\n(in millions, except percentages) |  | 2022 |  | 2021 |  | 2022 vs. 2021 |  | 2022 |  | 2021 |  | 2022 vs. 2021\nRevenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nUnitedHealthcare |  | $ | 62,105 |  |  | $ | 55,474 |  |  | $ | 6,631 |  |  | 12 | % |  | $ | 124,700 |  |  | $ | 110,588 |  |  | $ | 14,112 |  |  | 13 | %\nOptum Health |  | 17,583 |  |  | 13,300 |  |  | 4,283 |  |  | 32 |  |  | 34,265 |  |  | 25,703 |  |  | 8,562 |  |  | 33 | \nOptum Insight |  | 3,282 |  |  | 2,957 |  |  | 325 |  |  | 11 |  |  | 6,501 |  |  | 5,809 |  |  | 692 |  |  | 12 | \nOptum Rx |  | 24,805 |  |  | 22,524 |  |  | 2,281 |  |  | 10 |  |  | 48,716 |  |  | 44,128 |  |  | 4,588 |  |  | 10 | \nOptum eliminations |  | (588) |  |  | (478) |  |  | (110) |  |  | 23 |  |  | (1,141) |  |  | (953) |  |  | (188) |  |  | 20 | \nOptum |  | 45,082 |  |  | 38,303 |  |  | 6,779 |  |  | 18 |  |  | 88,341 |  |  | 74,687 |  |  | 13,654 |  |  | 18 | \nEliminations |  | (26,855) |  |  | (22,456) |  |  | (4,399) |  |  | 20 |  |  | (52,560) |  |  | (43,758) |  |  | (8,802) |  |  | 20 | \nConsolidated revenues |  | $ | 80,332 |  |  | $ | 71,321 |  |  | $ | 9,011 |  |  | 13 | % |  | $ | 160,481 |  |  | $ | 141,517 |  |  | $ | 18,964 |  |  | 13 | %\nEarnings from operations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nUnitedHealthcare |  | $ | 3,850 |  |  | $ | 3,095 |  |  | $ | 755 |  |  | 24 | % |  | $ | 7,648 |  |  | $ | 7,203 |  |  | $ | 445 |  |  | 6 | %\nOptum Health |  | 1,399 |  |  | 1,128 |  |  | 271 |  |  | 24 |  |  | 2,765 |  |  | 2,090 |  |  | 675 |  |  | 32 | \nOptum Insight |  | 839 |  |  | 762 |  |  | 77 |  |  | 10 |  |  | 1,686 |  |  | 1,541 |  |  | 145 |  |  | 9 | \nOptum Rx |  | 1,044 |  |  | 993 |  |  | 51 |  |  | 5 |  |  | 1,983 |  |  | 1,883 |  |  | 100 |  |  | 5 | \nOptum |  | 3,282 |  |  | 2,883 |  |  | 399 |  |  | 14 |  |  | 6,434 |  |  | 5,514 |  |  | 920 |  |  | 17 | \nConsolidated earnings from operations |  | $ | 7,132 |  |  | $ | 5,978 |  |  | $ | 1,154 |  |  | 19 | % |  | $ | 14,082 |  |  | $ | 12,717 |  |  | $ | 1,365 |  |  | 11 | %\nOperating margin |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nUnitedHealthcare |  | 6.2 | % |  | 5.6 | % |  | 0.6 | % |  |  |  | 6.1 | % |  | 6.5 | % |  | (0.4) | % |  | \nOptum Health |  | 8.0 |  |  | 8.5 |  |  | (0.5) |  |  |  |  | 8.1 |  |  | 8.1 |  |  | \u2014 |  |  | \nOptum Insight |  | 25.6 |  |  | 25.8 |  |  | (0.2) |  |  |  |  | 25.9 |  |  | 26.5 |  |  | (0.6) |  |  | \nOptum Rx |  | 4.2 |  |  | 4.4 |  |  | (0.2) |  |  |  |  | 4.1 |  |  | 4.3 |  |  | (0.2) |  |  | \nOptum |  | 7.3 |  |  | 7.5 |  |  | (0.2) |  |  |  |  | 7.3 |  |  | 7.4 |  |  | (0.1) |  |  | \nConsolidated operating margin |  | 8.9 | % |  | 8.4 | % |  | 0.5 | % |  |  |  | 8.8 | % |  | 9.0 | % |  | (0.2) | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Increase/(Decrease) |  | Six Months Ended June 30, |  | Increase/(Decrease)\n(in millions, except percentages) |  | 2022 |  | 2021 |  | 2022 vs. 2021 |  | 2022 |  | 2021 |  | 2022 vs. 2021\nUnitedHealthcare Employer & Individual - Domestic |  | $ | 15,567 |  |  | $ | 14,942 |  |  | $ | 625 |  |  | 4 | % |  | $ | 31,389 |  |  | $ | 29,574 |  |  | $ | 1,815 |  |  | 6 | %\nUnitedHealthcare Employer & Individual - Global (a) |  | 2,247 |  |  | 2,118 |  |  | 129 |  |  | 6 |  |  | 4,380 |  |  | 4,153 |  |  | 227 |  |  | 5 | \nUnitedHealthcare Employer & Individual - Total (a) |  | 17,814 |  |  | 17,060 |  |  | 754 |  |  | 4 |  |  | 35,769 |  |  | 33,727 |  |  | 2,042 |  |  | 6 | \nUnitedHealthcare Medicare & Retirement |  | 28,625 |  |  | 25,304 |  |  | 3,321 |  |  | 13 |  |  | 57,725 |  |  | 50,778 |  |  | 6,947 |  |  | 14 | \nUnitedHealthcare Community & State |  | 15,666 |  |  | 13,110 |  |  | 2,556 |  |  | 19 |  |  | 31,206 |  |  | 26,083 |  |  | 5,123 |  |  | 20 | \nTotal UnitedHealthcare revenues |  | $ | 62,105 |  |  | $ | 55,474 |  |  | $ | 6,631 |  |  | 12 | % |  | $ | 124,700 |  |  | $ | 110,588 |  |  | $ | 14,112 |  |  | 13 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30, |  | Increase/(Decrease)\n(in thousands, except percentages) |  | 2022 |  | 2021 |  | 2022 vs. 2021\nCommercial - domestic: |  |  |  |  |  |  |  | \nRisk-based |  | 8,010 |  |  | 7,840 |  |  | 170 |  |  | 2 | %\nFee-based |  | 18,480 |  |  | 18,395 |  |  | 85 |  |  | \u2014 | \nTotal commercial - domestic |  | 26,490 |  |  | 26,235 |  |  | 255 |  |  | 1 | \nMedicare Advantage |  | 6,945 |  |  | 6,385 |  |  | 560 |  |  | 9 | \nMedicaid |  | 7,990 |  |  | 7,130 |  |  | 860 |  |  | 12 | \nMedicare Supplement (Standardized) |  | 4,355 |  |  | 4,390 |  |  | (35) |  |  | (1) | \nTotal community and senior |  | 19,290 |  |  | 17,905 |  |  | 1,385 |  |  | 8 | \nTotal UnitedHealthcare - domestic medical |  | 45,780 |  |  | 44,140 |  |  | 1,640 |  |  | 4 | \nCommercial - global |  | 5,465 |  |  | 5,485 |  |  | (20) |  |  | \u2014 | \nTotal UnitedHealthcare - medical |  | 51,245 |  |  | 49,625 |  |  | 1,620 |  |  | 3 | %\nSupplemental Data: |  |  |  |  |  |  |  | \nMedicare Part D stand-alone |  | 3,330 |  |  | 3,750 |  |  | (420) |  |  | (11) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30, |  | Increase/(Decrease)\n(in millions) |  | 2022 |  | 2021 |  | 2022 vs. 2021\nSources of cash: |  |  |  |  |  | \nCash provided by operating activities |  | $ | 12,190 |  |  | $ | 11,545 |  |  | $ | 645 | \nIssuances of short-term borrowings and long-term debt, net of repayments |  | 6,162 |  |  | 4,858 |  |  | 1,304 | \nProceeds from common stock issuances |  | 756 |  |  | 764 |  |  | (8) | \nCustomer funds administered |  | 5,786 |  |  | 2,395 |  |  | 3,391 | \nTotal sources of cash |  | 24,894 |  |  | 19,562 |  |  | \nUses of cash: |  |  |  |  |  | \nCommon stock repurchases |  | (5,000) |  |  | (2,900) |  |  | (2,100) | \nCash paid for acquisitions, net of cash assumed |  | (7,150) |  |  | (4,642) |  |  | (2,508) | \nPurchases of investments, net of sales and maturities |  | (3,366) |  |  | (2,789) |  |  | (577) | \nPurchases of property, equipment and capitalized software |  | (1,212) |  |  | (1,130) |  |  | (82) | \nCash dividends paid |  | (2,908) |  |  | (2,548) |  |  | (360) | \nPurchases of redeemable noncontrolling interests |  | (97) |  |  | (1,338) |  |  | 1,241 | \nOther |  | (1,981) |  |  | (1,310) |  |  | (671) | \nTotal uses of cash |  | (21,714) |  |  | (16,657) |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | 57 |  |  | 6 |  |  | 51 | \nNet increase in cash and cash equivalents |  | $ | 3,237 |  |  | $ | 2,911 |  |  | $ | 326 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Moody\u2019s |  | S&P Global |  | Fitch |  | A.M. Best\n | Ratings |  | Outlook |  | Ratings |  | Outlook |  | Ratings |  | Outlook |  | Ratings |  | Outlook\nSenior unsecured debt | A3 |  | Positive |  | A+ |  | Stable |  | A |  | Stable |  | A |  | Stable\nCommercial paper | P-2 |  | n/a |  | A-1 |  | n/a |  | F1 |  | n/a |  | AMB-1+ |  | n/a  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30, 2022\nIncrease (Decrease) in Market Interest Rate |  | InvestmentIncome\u00a0PerAnnum |  | InterestExpense\u00a0PerAnnum |  | Fair\u00a0Value\u00a0ofFinancial Assets |  | Fair\u00a0Value\u00a0ofFinancial Liabilities\n2 % |  | $ | 559 |  |  | $ | 215 |  |  | $ | (3,073) |  |  | $ | (7,035) | \n1 |  | 280 |  |  | 107 |  |  | (1,583) |  |  | (3,824) | \n(1) |  | (248) |  |  | (107) |  |  | 1,666 |  |  | 4,595 | \n(2) |  | (248) |  |  | (191) |  |  | 3,380 |  |  | 10,165 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFor the Month Ended |  | Total Number of Shares Purchased |  | Average Price Paid Per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number of Shares That May Yet Be Purchased Under The Plans or Programs\n |  | (in millions) |  |  |  | (in millions) |  | (in millions)\nApril 30, 2022 |  | 1 |  | $ | 528.52 |  |  | 1 |  | 39\nMay 31, 2022 |  | 2 |  | 492.97 |  |  | 2 |  | 37\nJune 30, 2022 |  | 2 |  | 480.23 |  |  | 2 |  | 35\nTotal |  | 5 |  | $ | 499.30 |  |  | 5 |  |   |  |  |  |  |  |  |  | \n3.1 |  | Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company\u2019s Registration Statement on Form 8-A/A filed on July 1, 2015)\n3.2 |  | Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by reference to Exhibit 3.2 to UnitedHealth Group Incorporated\u2019s Current Report on Form 8-K filed on February 26, 2021)\n4.1 |  | Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company\u2019s Registration Statement on Form S-3/A, SEC File Number 333-66013, filed on January 11, 1999)\n4.2 |  | Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998, between UnitedHealth Group Incorporated and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2001)\n4.3 |  | Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant to the Senior Indenture, dated as of November 15, 1998, amended November 6, 2000, among UnitedHealth Group Incorporated, The Bank of New York and Wilmington Trust Company (incorporated by reference to Exhibit 4.3 to the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended June\u00a030, 2007)\n4.4 |  | Indenture, dated as of February\u00a04,\u00a02008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company\u2019s Registration Statement on Form S-3, SEC File Number 333-149031, filed on February\u00a04, 2008)\n31.1 |  | Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\n32.1 |  | Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\n101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n101.SCH |  | Inline XBRL Taxonomy Extension Schema Document.\n101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document.\n101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document.\n101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document.\n101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document.\n104 |  |  | Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).  |  |  |  |  |  |  |  | \n* |  | Pursuant to Item\u00a0601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n/s/    ANDREWP. WITTY |  | Chief Executive Officer(principal executive officer) | Dated: | August 3, 2022\nAndrew P. Witty |  |  | \n |  | \n/s/    JOHNF. REX |  | Executive Vice President andChief\u00a0Financial\u00a0Officer(principal financial officer) | Dated: | August 3, 2022\nJohn F. Rex |  |  | \n |  | \n/s/THOMASE. ROOS |  | Senior Vice President andChief Accounting Officer(principal accounting officer) | Dated: | August 3, 2022\nThomas E. Roos |  |  | "}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For United Health Group, in 2022 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |   |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  |  |  |  |  |  |  | \nDelaware |  | 41-1321939\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)\nUnitedHealth Group Center |  | 55343\n9900 Bren Road East | \nMinnetonka, | Minnesota | \n(Address of principal executive offices) |  | (Zip Code)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered\nCommon Stock, $.01 par value |  | UNH |  | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 |  | Accelerated\u00a0filer | \u2610 |  | Non-accelerated filer | \u2610\nSmaller\u00a0reporting\u00a0company | \u2610 |  |  |  |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page\n |  |  |  | \nPart I. Financial\u00a0Information | \nItem\u00a01. | Financial Statements (unaudited) | 1\n |  | Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 | 1\n |  | Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2022 and 2021 | 2\n |  | Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2022 and 2021 | 3\n |  | Condensed Consolidated Statements of Changes in Equity for the Three and Nine Months Ended September 30, 2022 and 2021 | 4\n |  | Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021 | 6\n |  | Notes to the Condensed Consolidated Financial Statements | 7\n |  | 1. | Basis of Presentation | 7\n |  | 2. | Investments | 8\n |  | 3. | Fair Value | 10\n |  | 4. | Medical Costs Payable | 11\n |  | 5. | Short-Term Borrowings and Long-Term Debt | 11\n |  | 6. | Dividends | 12\n |  | 7. | Commitments and Contingencies | 12\n |  | 8. | Business Combinations | 13\n |  | 9. | Segment Financial Information | 14\nItem\u00a02. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 17\nItem\u00a03. | Quantitative and Qualitative Disclosures About Market Risk | 24\nItem\u00a04. | Controls and Procedures | 25\nPart\u00a0II. Other Information | \nItem\u00a01. | Legal Proceedings | 25\nItem\u00a01A. | Risk Factors | 25\nItem\u00a02. | Unregistered Sales of Equity Securities and Use of Proceeds | 26\nItem\u00a06. | Exhibits | 27\nSignatures | 28  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except per share data) |  | September 30,2022 |  | December 31,2021\nAssets |  |  |  | \nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 38,845 |  |  | $ | 21,375 | \nShort-term investments |  | 3,682 |  |  | 2,532 | \nAccounts receivable, net |  | 17,047 |  |  | 14,216 | \nOther current receivables, net |  | 13,684 |  |  | 13,866 | \nAssets under management |  | 4,022 |  |  | 4,449 | \nPrepaid expenses and other current assets |  | 5,657 |  |  | 5,320 | \nTotal current assets |  | 82,937 |  |  | 61,758 | \nLong-term investments |  | 41,557 |  |  | 43,114 | \nProperty, equipment and capitalized software, net |  | 9,469 |  |  | 8,969 | \nGoodwill |  | 83,904 |  |  | 75,795 | \nOther intangible assets, net |  | 10,785 |  |  | 10,044 | \nOther assets |  | 14,412 |  |  | 12,526 | \nTotal assets |  | $ | 243,064 |  |  | $ | 212,206 | \nLiabilities, redeemable noncontrolling interests and equity |  |  |  | \nCurrent liabilities: |  |  |  | \nMedical costs payable |  | $ | 29,064 |  |  | $ | 24,483 | \nAccounts payable and accrued liabilities |  | 27,232 |  |  | 24,643 | \nShort-term borrowings and current maturities of long-term debt |  | 3,229 |  |  | 3,620 | \nUnearned revenues |  | 12,847 |  |  | 2,571 | \nOther current liabilities |  | 28,563 |  |  | 22,975 | \nTotal current liabilities |  | 100,935 |  |  | 78,292 | \nLong-term debt, less current maturities |  | 45,438 |  |  | 42,383 | \nDeferred income taxes |  | 1,659 |  |  | 3,265 | \nOther liabilities |  | 12,111 |  |  | 11,787 | \nTotal liabilities |  | 160,143 |  |  | 135,727 | \nCommitments and contingencies (Note 7) |  |  |  | \nRedeemable noncontrolling interests |  | 4,857 |  |  | 1,434 | \nEquity: |  |  |  | \nPreferred stock, $0.001par value -10shares authorized;noshares issued or outstanding |  | \u2014 |  |  | \u2014 | \nCommon stock, $0.01par value -3,000shares authorized;935and941issued and outstanding |  | 10 |  |  | 10 | \nRetained earnings |  | 83,722 |  |  | 77,134 | \nAccumulated other comprehensive loss |  | (9,086) |  |  | (5,384) | \nNonredeemable noncontrolling interests |  | 3,418 |  |  | 3,285 | \nTotal equity |  | 78,064 |  |  | 75,045 | \nTotal liabilities, redeemable noncontrolling interests and equity |  | $ | 243,064 |  |  | $ | 212,206 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n(in millions, except per share data) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nRevenues: |  |  |  |  |  |  |  | \nPremiums |  | $ | 64,491 |  |  | $ | 56,967 |  |  | $ | 192,457 |  |  | $ | 168,686 | \nProducts |  | 9,190 |  |  | 8,703 |  |  | 28,026 |  |  | 25,476 | \nServices |  | 6,700 |  |  | 6,164 |  |  | 19,717 |  |  | 18,181 | \nInvestment and other income |  | 513 |  |  | 503 |  |  | 1,175 |  |  | 1,511 | \nTotal revenues |  | 80,894 |  |  | 72,337 |  |  | 241,375 |  |  | 213,854 | \nOperating costs: |  |  |  |  |  |  |  | \nMedical costs |  | 52,635 |  |  | 47,302 |  |  | 157,251 |  |  | 138,752 | \nOperating costs |  | 11,663 |  |  | 10,725 |  |  | 34,773 |  |  | 31,307 | \nCost of products sold |  | 8,306 |  |  | 7,802 |  |  | 25,389 |  |  | 23,034 | \nDepreciation and amortization |  | 828 |  |  | 796 |  |  | 2,418 |  |  | 2,332 | \nTotal operating costs |  | 73,432 |  |  | 66,625 |  |  | 219,831 |  |  | 195,425 | \nEarnings from operations |  | 7,462 |  |  | 5,712 |  |  | 21,544 |  |  | 18,429 | \nInterest expense |  | (516) |  |  | (422) |  |  | (1,416) |  |  | (1,229) | \nEarnings before income taxes |  | 6,946 |  |  | 5,290 |  |  | 20,128 |  |  | 17,200 | \nProvision for income taxes |  | (1,562) |  |  | (1,099) |  |  | (4,397) |  |  | (3,659) | \nNet earnings |  | 5,384 |  |  | 4,191 |  |  | 15,731 |  |  | 13,541 | \nEarnings attributable to noncontrolling interests |  | (122) |  |  | (105) |  |  | (372) |  |  | (327) | \nNet earnings attributable to UnitedHealth Group common shareholders |  | $ | 5,262 |  |  | $ | 4,086 |  |  | $ | 15,359 |  |  | $ | 13,214 | \nEarnings per share attributable to UnitedHealth Group common shareholders: |  |  |  |  |  |  |  | \nBasic |  | $ | 5.63 |  |  | $ | 4.33 |  |  | $ | 16.37 |  |  | $ | 14.00 | \nDiluted |  | $ | 5.55 |  |  | $ | 4.28 |  |  | $ | 16.15 |  |  | $ | 13.82 | \nBasic weighted-average number of common shares outstanding |  | 935 |  |  | 943 |  |  | 938 |  |  | 944 | \nDilutive effect of common share equivalents |  | 13 |  |  | 12 |  |  | 13 |  |  | 12 | \nDiluted weighted-average number of common shares outstanding |  | 948 |  |  | 955 |  |  | 951 |  |  | 956 | \nAnti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents |  | 3 |  |  | 1 |  |  | 3 |  |  | 2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n(in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021\nNet earnings |  | $ | 5,384 |  |  | $ | 4,191 |  |  | $ | 15,731 |  |  | $ | 13,541 | \nOther comprehensive loss: |  |  |  |  |  |  |  | \nGross unrealized losses on investment securities during the period |  | (1,471) |  |  | (192) |  |  | (4,825) |  |  | (705) | \nIncome tax effect |  | 340 |  |  | 59 |  |  | 1,109 |  |  | 175 | \nTotal unrealized losses, net of tax |  | (1,131) |  |  | (133) |  |  | (3,716) |  |  | (530) | \nGross reclassification adjustment for net realized losses (gains) included in net earnings |  | 138 |  |  | (20) |  |  | 134 |  |  | (36) | \nIncome tax effect |  | (32) |  |  | 4 |  |  | (31) |  |  | 8 | \nTotal reclassification adjustment, net of tax |  | 106 |  |  | (16) |  |  | 103 |  |  | (28) | \nTotal foreign currency translation losses |  | (331) |  |  | (621) |  |  | (89) |  |  | (484) | \nOther comprehensive loss |  | (1,356) |  |  | (770) |  |  | (3,702) |  |  | (1,042) | \nComprehensive income |  | 4,028 |  |  | 3,421 |  |  | 12,029 |  |  | 12,499 | \nComprehensive income attributable to noncontrolling interests |  | (122) |  |  | (105) |  |  | (372) |  |  | (327) | \nComprehensive income attributable to UnitedHealth Group common shareholders |  | $ | 3,906 |  |  | $ | 3,316 |  |  | $ | 11,657 |  |  | $ | 12,172 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Common Stock |  | Additional Paid-In Capital |  | Retained Earnings |  | Accumulated Other Comprehensive(Loss) Income |  | Nonredeemable Noncontrolling Interests |  | TotalEquity\nThree months ended September 30,(in millions) |  | Shares |  | Amount |  |  |  | Net Unrealized (Losses) Gains on Investments |  | Foreign Currency Translation Losses |  | \nBalance at June 30, 2022 |  | 935 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 80,540 |  |  | $ | (2,165) |  |  | $ | (5,565) |  |  | $ | 3,385 |  |  | $ | 76,205 | \nNet earnings |  |  |  |  |  |  |  | 5,262 |  |  |  |  |  |  | 99 |  |  | 5,361 | \nOther comprehensive loss |  |  |  |  |  |  |  |  |  | (1,025) |  |  | (331) |  |  |  |  | (1,356) | \nIssuances of common stock, and related tax effects |  | 2 |  |  | \u2014 |  |  | 294 |  |  |  |  |  |  |  |  |  |  | 294 | \nShare-based compensation |  |  |  |  |  | 163 |  |  |  |  |  |  |  |  |  |  | 163 | \nCommon share repurchases |  | (2) |  |  | \u2014 |  |  | (462) |  |  | (538) |  |  |  |  |  |  |  |  | (1,000) | \nCash dividends paid on common shares ($1.65per share) |  |  |  |  |  |  |  | (1,542) |  |  |  |  |  |  |  |  | (1,542) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  | 5 | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 32 |  |  | 32 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (98) |  |  | (98) | \nBalance at September 30, 2022 |  | 935 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 83,722 |  |  | $ | (3,190) |  |  | $ | (5,896) |  |  | $ | 3,418 |  |  | $ | 78,064 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at June 30, 2021 |  | 943 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 73,090 |  |  | $ | 927 |  |  | $ | (5,013) |  |  | $ | 3,008 |  |  | $ | 72,022 | \nNet earnings |  |  |  |  |  |  |  | 4,086 |  |  |  |  |  |  | 86 |  |  | 4,172 | \nOther comprehensive loss |  |  |  |  |  |  |  |  |  | (149) |  |  | (621) |  |  |  |  | (770) | \nIssuances of common stock, and related tax effects |  | 1 |  |  | \u2014 |  |  | 291 |  |  |  |  |  |  |  |  |  |  | 291 | \nShare-based compensation |  |  |  |  |  | 159 |  |  |  |  |  |  |  |  |  |  | 159 | \nCommon share repurchases |  | (2) |  |  | \u2014 |  |  | (365) |  |  | (685) |  |  |  |  |  |  |  |  | (1,050) | \nCash dividends paid on common shares ($1.45per share) |  |  |  |  |  |  |  | (1,367) |  |  |  |  |  |  |  |  | (1,367) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | (85) |  |  |  |  |  |  |  |  |  |  | (85) | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (26) |  |  | (26) | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (87) |  |  | (87) | \nBalance at September 30, 2021 |  | 942 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 75,124 |  |  | $ | 778 |  |  | $ | (5,634) |  |  | $ | 2,981 |  |  | $ | 73,259 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Common Stock |  | Additional Paid-In Capital |  | Retained Earnings |  | Accumulated Other ComprehensiveIncome (Loss) |  | Nonredeemable Noncontrolling Interests |  | TotalEquity\nNine months ended September 30,(in millions) |  | Shares |  | Amount |  |  |  | Net Unrealized Gains (Losses) on Investments |  | Foreign Currency Translation Losses |  | \nBalance at January 1, 2022 |  | 941 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 77,134 |  |  | $ | 423 |  |  | $ | (5,807) |  |  | $ | 3,285 |  |  | $ | 75,045 | \nNet earnings |  |  |  |  |  |  |  | 15,359 |  |  |  |  |  |  | 281 |  |  | 15,640 | \nOther comprehensive loss |  |  |  |  |  |  |  |  |  | (3,613) |  |  | (89) |  |  |  |  | (3,702) | \nIssuances of common stock, and related tax effects |  | 6 |  |  | \u2014 |  |  | 801 |  |  |  |  |  |  |  |  |  |  | 801 | \nShare-based compensation |  |  |  |  |  | 639 |  |  |  |  |  |  |  |  |  |  | 639 | \nCommon share repurchases |  | (12) |  |  | \u2014 |  |  | (1,679) |  |  | (4,321) |  |  |  |  |  |  |  |  | (6,000) | \nCash dividends paid on common shares ($4.75per share) |  |  |  |  |  |  |  | (4,450) |  |  |  |  |  |  |  |  | (4,450) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | 239 |  |  |  |  |  |  |  |  |  |  | 239 | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 135 |  |  | 135 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (283) |  |  | (283) | \nBalance at September 30, 2022 |  | 935 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 83,722 |  |  | $ | (3,190) |  |  | $ | (5,896) |  |  | $ | 3,418 |  |  | $ | 78,064 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at January 1, 2021 |  | 946 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 69,295 |  |  | $ | 1,336 |  |  | $ | (5,150) |  |  | $ | 2,837 |  |  | $ | 68,328 | \nNet earnings |  |  |  |  |  |  |  | 13,214 |  |  |  |  |  |  | 254 |  |  | 13,468 | \nOther comprehensive loss |  |  |  |  |  |  |  |  |  | (558) |  |  | (484) |  |  |  |  | (1,042) | \nIssuances of common stock, and related tax effects |  | 6 |  |  | \u2014 |  |  | 839 |  |  |  |  |  |  |  |  |  |  | 839 | \nShare-based compensation |  |  |  |  |  | 559 |  |  |  |  |  |  |  |  |  |  | 559 | \nCommon share repurchases |  | (10) |  |  | \u2014 |  |  | (586) |  |  | (3,364) |  |  |  |  |  |  |  |  | (3,950) | \nCash dividends paid on common shares ($4.15per share) |  |  |  |  |  |  |  | (3,915) |  |  |  |  |  |  |  |  | (3,915) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | (812) |  |  | (106) |  |  |  |  |  |  |  |  | (918) | \nAcquisitions and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 125 |  |  | 125 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (235) |  |  | (235) | \nBalance at September 30, 2021 |  | 942 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 75,124 |  |  | $ | 778 |  |  | $ | (5,634) |  |  | $ | 2,981 |  |  | $ | 73,259 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30,\n(in millions) |  | 2022 |  | 2021\nOperating activities |  |  |  | \nNet earnings |  | $ | 15,731 |  |  | $ | 13,541 | \nNoncash items: |  |  |  | \nDepreciation and amortization |  | 2,418 |  |  | 2,332 | \nDeferred income taxes |  | (590) |  |  | 373 | \nShare-based compensation |  | 675 |  |  | 591 | \nOther, net |  | \u2014 |  |  | (195) | \nNet change in other operating items, net of effects from acquisitions and changes in AARP balances: |  |  |  | \nAccounts receivable |  | (2,563) |  |  | (847) | \nOther assets |  | (741) |  |  | (1,435) | \nMedical costs payable |  | 4,192 |  |  | 3,925 | \nAccounts payable and other liabilities |  | 1,416 |  |  | 1,171 | \nUnearned revenues |  | 10,201 |  |  | (331) | \nCash flows from operating activities |  | 30,739 |  |  | 19,125 | \nInvesting activities |  |  |  | \nPurchases of investments |  | (14,183) |  |  | (12,827) | \nSales of investments |  | 5,376 |  |  | 2,569 | \nMaturities of investments |  | 4,740 |  |  | 6,556 | \nCash paid for acquisitions, net of cash assumed |  | (7,154) |  |  | (4,727) | \nPurchases of property, equipment and capitalized software |  | (1,936) |  |  | (1,759) | \nOther, net |  | 50 |  |  | (900) | \nCash flows used for investing activities |  | (13,107) |  |  | (11,088) | \nFinancing activities |  |  |  | \nCommon share repurchases |  | (6,000) |  |  | (3,950) | \nCash dividends paid |  | (4,450) |  |  | (3,915) | \nProceeds from common stock issuances |  | 1,084 |  |  | 1,077 | \nRepayments of long-term debt |  | (2,100) |  |  | (1,900) | \nRepayments of short-term borrowings, net |  | (16) |  |  | (1,301) | \nProceeds from issuance of long-term debt |  | 5,922 |  |  | 6,934 | \nCustomer funds administered |  | 7,028 |  |  | 1,402 | \nPurchases of redeemable noncontrolling interests |  | (176) |  |  | (1,338) | \nOther, net |  | (1,458) |  |  | (837) | \nCash flows used for financing activities |  | (166) |  |  | (3,828) | \nEffect of exchange rate changes on cash and cash equivalents |  | 4 |  |  | (45) | \nIncrease in cash and cash equivalents |  | 17,470 |  |  | 4,164 | \nCash and cash equivalents, beginning of period |  | 21,375 |  |  | 16,921 | \nCash and cash equivalents, end of period |  | $ | 38,845 |  |  | $ | 21,085 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | AmortizedCost |  | GrossUnrealizedGains |  | GrossUnrealizedLosses |  | FairValue\nSeptember 30, 2022 |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 3,752 |  |  | $ | \u2014 |  |  | $ | (299) |  |  | $ | 3,453 | \nState and municipal obligations |  | 7,380 |  |  | 2 |  |  | (621) |  |  | 6,761 | \nCorporate obligations |  | 22,533 |  |  | 1 |  |  | (2,057) |  |  | 20,477 | \nU.S. agency mortgage-backed securities |  | 6,868 |  |  | 1 |  |  | (875) |  |  | 5,994 | \nNon-U.S. agency mortgage-backed securities |  | 3,164 |  |  | \u2014 |  |  | (295) |  |  | 2,869 | \nTotal debt securities - available-for-sale |  | 43,697 |  |  | 4 |  |  | (4,147) |  |  | 39,554 | \nDebt securities - held-to-maturity: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 538 |  |  | \u2014 |  |  | (16) |  |  | 522 | \nState and municipal obligations |  | 29 |  |  | \u2014 |  |  | (4) |  |  | 25 | \nCorporate obligations |  | 74 |  |  | \u2014 |  |  | \u2014 |  |  | 74 | \nTotal debt securities - held-to-maturity |  | 641 |  |  | \u2014 |  |  | (20) |  |  | 621 | \nTotal debt securities |  | $ | 44,338 |  |  | $ | 4 |  |  | $ | (4,167) |  |  | $ | 40,175 | \nDecember 31, 2021 |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 3,206 |  |  | $ | 23 |  |  | $ | (31) |  |  | $ | 3,198 | \nState and municipal obligations |  | 6,829 |  |  | 297 |  |  | (20) |  |  | 7,106 | \nCorporate obligations |  | 20,947 |  |  | 372 |  |  | (145) |  |  | 21,174 | \nU.S. agency mortgage-backed securities |  | 5,868 |  |  | 88 |  |  | (55) |  |  | 5,901 | \nNon-U.S. agency mortgage-backed securities |  | 2,819 |  |  | 42 |  |  | (23) |  |  | 2,838 | \nTotal debt securities - available-for-sale |  | 39,669 |  |  | 822 |  |  | (274) |  |  | 40,217 | \nDebt securities - held-to-maturity: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 511 |  |  | 2 |  |  | (2) |  |  | 511 | \nState and municipal obligations |  | 30 |  |  | 2 |  |  | \u2014 |  |  | 32 | \nCorporate obligations |  | 100 |  |  | \u2014 |  |  | \u2014 |  |  | 100 | \nTotal debt securities - held-to-maturity |  | 641 |  |  | 4 |  |  | (2) |  |  | 643 | \nTotal debt securities |  | $ | 40,310 |  |  | $ | 826 |  |  | $ | (276) |  |  | $ | 40,860 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Available-for-Sale |  | Held-to-Maturity\n(in millions) |  | AmortizedCost |  | FairValue |  | AmortizedCost |  | FairValue\nDue in one year or less |  | $ | 3,840 |  |  | $ | 3,809 |  |  | $ | 330 |  |  | $ | 326 | \nDue after one year through five years |  | 12,565 |  |  | 11,755 |  |  | 257 |  |  | 246 | \nDue after five years through ten years |  | 12,172 |  |  | 10,608 |  |  | 34 |  |  | 32 | \nDue after ten years |  | 5,088 |  |  | 4,519 |  |  | 20 |  |  | 17 | \nU.S. agency mortgage-backed securities |  | 6,868 |  |  | 5,994 |  |  | \u2014 |  |  | \u2014 | \nNon-U.S. agency mortgage-backed securities |  | 3,164 |  |  | 2,869 |  |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 43,697 |  |  | $ | 39,554 |  |  | $ | 641 |  |  | $ | 621 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Less Than 12 Months |  | 12 Months or Greater |  | Total\n(in millions) |  | FairValue |  | GrossUnrealizedLosses |  | FairValue |  | GrossUnrealizedLosses |  | FairValue |  | GrossUnrealizedLosses\nSeptember 30, 2022 |  |  |  |  |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 2,484 |  |  | $ | (170) |  |  | $ | 866 |  |  | $ | (129) |  |  | $ | 3,350 |  |  | $ | (299) | \nState and municipal obligations |  | 5,811 |  |  | (470) |  |  | 833 |  |  | (151) |  |  | 6,644 |  |  | (621) | \nCorporate obligations |  | 15,374 |  |  | (1,292) |  |  | 4,364 |  |  | (765) |  |  | 19,738 |  |  | (2,057) | \nU.S. agency mortgage-backed securities |  | 4,201 |  |  | (517) |  |  | 1,609 |  |  | (358) |  |  | 5,810 |  |  | (875) | \nNon-U.S. agency mortgage-backed securities |  | 2,182 |  |  | (172) |  |  | 670 |  |  | (123) |  |  | 2,852 |  |  | (295) | \nTotal debt securities - available-for-sale |  | $ | 30,052 |  |  | $ | (2,621) |  |  | $ | 8,342 |  |  | $ | (1,526) |  |  | $ | 38,394 |  |  | $ | (4,147) | \nDecember 31, 2021 |  |  |  |  |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 1,976 |  |  | $ | (18) |  |  | $ | 249 |  |  | $ | (13) |  |  | $ | 2,225 |  |  | $ | (31) | \nState and municipal obligations |  | 1,386 |  |  | (19) |  |  | 31 |  |  | (1) |  |  | 1,417 |  |  | (20) | \nCorporate obligations |  | 9,357 |  |  | (130) |  |  | 376 |  |  | (15) |  |  | 9,733 |  |  | (145) | \nU.S. agency mortgage-backed securities |  | 3,078 |  |  | (52) |  |  | 116 |  |  | (3) |  |  | 3,194 |  |  | (55) | \nNon-U.S. agency mortgage-backed securities |  | 1,321 |  |  | (18) |  |  | 114 |  |  | (5) |  |  | 1,435 |  |  | (23) | \nTotal debt securities - available-for-sale |  | $ | 17,118 |  |  | $ | (237) |  |  | $ | 886 |  |  | $ | (37) |  |  | $ | 18,004 |  |  | $ | (274) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | OtherObservableInputs(Level 2) |  | UnobservableInputs(Level 3) |  | TotalFair and CarryingValue\nSeptember 30, 2022 |  |  |  |  |  |  |  | \nCash and cash equivalents |  | $ | 38,671 |  |  | $ | 174 |  |  | $ | \u2014 |  |  | $ | 38,845 | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 3,302 |  |  | 151 |  |  | \u2014 |  |  | 3,453 | \nState and municipal obligations |  | \u2014 |  |  | 6,761 |  |  | \u2014 |  |  | 6,761 | \nCorporate obligations |  | 85 |  |  | 20,213 |  |  | 179 |  |  | 20,477 | \nU.S. agency mortgage-backed securities |  | \u2014 |  |  | 5,994 |  |  | \u2014 |  |  | 5,994 | \nNon-U.S. agency mortgage-backed securities |  | \u2014 |  |  | 2,869 |  |  | \u2014 |  |  | 2,869 | \nTotal debt securities - available-for-sale |  | 3,387 |  |  | 35,988 |  |  | 179 |  |  | 39,554 | \nEquity securities |  | 1,901 |  |  | 17 |  |  | 68 |  |  | 1,986 | \nAssets under management |  | 1,727 |  |  | 2,207 |  |  | 88 |  |  | 4,022 | \nTotal assets at fair value |  | $ | 45,686 |  |  | $ | 38,386 |  |  | $ | 335 |  |  | $ | 84,407 | \nPercentage of total assets at fair value |  | 54 | % |  | 45 | % |  | 1 | % |  | 100 | %\nDecember 31, 2021 |  |  |  |  |  |  |  | \nCash and cash equivalents |  | $ | 21,359 |  |  | $ | 16 |  |  | $ | \u2014 |  |  | $ | 21,375 | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 3,017 |  |  | 181 |  |  | \u2014 |  |  | 3,198 | \nState and municipal obligations |  | \u2014 |  |  | 7,106 |  |  | \u2014 |  |  | 7,106 | \nCorporate obligations |  | 40 |  |  | 20,916 |  |  | 218 |  |  | 21,174 | \nU.S. agency mortgage-backed securities |  | \u2014 |  |  | 5,901 |  |  | \u2014 |  |  | 5,901 | \nNon-U.S. agency mortgage-backed securities |  | \u2014 |  |  | 2,838 |  |  | \u2014 |  |  | 2,838 | \nTotal debt securities - available-for-sale |  | 3,057 |  |  | 36,942 |  |  | 218 |  |  | 40,217 | \nEquity securities |  | 2,090 |  |  | 23 |  |  | 64 |  |  | 2,177 | \nAssets under management |  | 1,972 |  |  | 2,376 |  |  | 101 |  |  | 4,449 | \nTotal assets at fair value |  | $ | 28,478 |  |  | $ | 39,357 |  |  | $ | 383 |  |  | $ | 68,218 | \nPercentage of total assets at fair value |  | 42 | % |  | 57 | % |  | 1 | % |  | 100 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | OtherObservableInputs(Level 2) |  | UnobservableInputs(Level 3) |  | TotalFairValue |  | Total Carrying Value\nSeptember 30, 2022 |  |  |  |  |  |  |  |  |  | \nDebt securities - held-to-maturity |  | $ | 534 |  |  | $ | 87 |  |  | $ | \u2014 |  |  | $ | 621 |  |  | $ | 641 | \nLong-term debt and other financing obligations |  | $ | \u2014 |  |  | $ | 43,705 |  |  | $ | \u2014 |  |  | $ | 43,705 |  |  | $ | 48,667 | \nDecember 31, 2021 |  |  |  |  |  |  |  |  |  | \nDebt securities - held-to-maturity |  | $ | 534 |  |  | $ | 102 |  |  | $ | 7 |  |  | $ | 643 |  |  | $ | 641 | \nLong-term debt and other financing obligations |  | $ | \u2014 |  |  | $ | 52,583 |  |  | $ | \u2014 |  |  | $ | 52,583 |  |  | $ | 46,003 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | 2022 |  | 2021\nMedical costs payable, beginning of period |  | $ | 24,483 |  |  | $ | 21,872 | \nAcquisitions |  | 177 |  |  | 88 | \nReported medical costs: |  |  |  | \nCurrent year |  | 157,601 |  |  | 140,052 | \nPrior years |  | (350) |  |  | (1,300) | \nTotal reported medical costs |  | 157,251 |  |  | 138,752 | \nMedical payments: |  |  |  | \nPayments for current year |  | (130,788) |  |  | (116,135) | \nPayments for prior years |  | (22,059) |  |  | (18,659) | \nTotal medical payments |  | (152,847) |  |  | (134,794) | \nMedical costs payable, end of period |  | $ | 29,064 |  |  | $ | 25,918 |   |  |  |  |  |  |  |  | \n(in millions, except percentages) |  | Par Value\n3.700% notes due May 2027 |  | $ | 600 | \n4.000% notes due May 2029 |  | 900 | \n4.200% notes due May 2032 |  | 1,500 | \n4.750% notes due May 2052 |  | 2,000 | \n4.950% notes due May 2062 |  | 1,000 |   |  |  |  |  |  |  |  | \n(in millions, except percentages) |  | Par Value\n5.000% notes due October 2024 |  | $ | 500 | \n5.150% notes due October 2025 |  | 750 | \n5.250% notes due February 2028 |  | 1,000 | \n5.300% notes due February 2030 |  | 1,250 | \n5.350% notes due February 2033 |  | 2,000 | \n5.875% notes due February 2053 |  | 2,000 | \n6.050% notes due February 2063 |  | 1,500 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPayment Date |  | Amount per Share |  | Total Amount Paid\n |  |  |  | (in millions)\nMarch 22 |  | $ | 1.45 |  |  | $ | 1,363 | \nJune 28 |  | 1.65 |  |  | 1,545 | \nSeptember 20 |  | 1.65 |  |  | 1,542 |   |  |  |  |  |  |  |  | \n(in millions) |  | \nCash and cash equivalents |  | $ | 517 | \nAccounts receivable and other current assets |  | 550 | \nProperty, equipment and other long-term assets |  | 1,529 | \nOther intangible assets |  | 1,815 | \nTotal identifiable assets acquired |  | 4,411 | \nMedical costs payable |  | (177) | \nAccounts payable and other current liabilities |  | (660) | \nOther long-term liabilities |  | (580) | \nTotal identifiable liabilities acquired |  | (1,417) | \nTotal net identifiable assets |  | 2,994 | \nGoodwill |  | 8,393 | \nRedeemable noncontrolling interests |  | (3,104) | \nNonredeemable noncontrolling interests |  | (133) | \nNet assets acquired |  | $ | 8,150 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except years) |  | Fair Value |  | Weighted-Average Useful Life\nCustomer-related |  | $ | 915 |  |  | 9years\nTrademarks and technology |  | 802 |  |  | 9years\nOther |  | 83 |  |  | 11years\nTotal acquired finite-lived intangible assets |  | $ | 1,800 |  |  | 9years  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Optum |  |  |  | \n(in millions) |  | UnitedHealthcare |  | Optum Health |  | Optum Insight |  | Optum Rx |  | Optum Eliminations |  | Optum |  | Corporate\u00a0andEliminations |  | Consolidated\nThree Months Ended September 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 59,375 |  |  | $ | 5,116 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,116 |  |  | $ | \u2014 |  |  | $ | 64,491 | \nProducts |  | \u2014 |  |  | 2 |  |  | 37 |  |  | 9,151 |  |  | \u2014 |  |  | 9,190 |  |  | \u2014 |  |  | 9,190 | \nServices |  | 2,435 |  |  | 2,756 |  |  | 1,067 |  |  | 442 |  |  | \u2014 |  |  | 4,265 |  |  | \u2014 |  |  | 6,700 | \nTotal revenues - unaffiliated customers |  | 61,810 |  |  | 7,874 |  |  | 1,104 |  |  | 9,593 |  |  | \u2014 |  |  | 18,571 |  |  | \u2014 |  |  | 80,381 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 10,302 |  |  | 2,566 |  |  | 15,592 |  |  | (800) |  |  | 27,660 |  |  | (27,660) |  |  | \u2014 | \nInvestment and other income |  | 185 |  |  | 287 |  |  | 23 |  |  | 18 |  |  | \u2014 |  |  | 328 |  |  | \u2014 |  |  | 513 | \nTotal revenues |  | $ | 61,995 |  |  | $ | 18,463 |  |  | $ | 3,693 |  |  | $ | 25,203 |  |  | $ | (800) |  |  | $ | 46,559 |  |  | $ | (27,660) |  |  | $ | 80,894 | \nEarnings from operations |  | $ | 3,799 |  |  | $ | 1,575 |  |  | $ | 1,007 |  |  | $ | 1,081 |  |  | $ | \u2014 |  |  | $ | 3,663 |  |  | $ | \u2014 |  |  | $ | 7,462 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (516) |  |  | (516) | \nEarnings before income taxes |  | $ | 3,799 |  |  | $ | 1,575 |  |  | $ | 1,007 |  |  | $ | 1,081 |  |  | $ | \u2014 |  |  | $ | 3,663 |  |  | $ | (516) |  |  | $ | 6,946 | \nThree Months Ended September 30, 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 53,345 |  |  | $ | 3,622 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 3,622 |  |  | $ | \u2014 |  |  | $ | 56,967 | \nProducts |  | \u2014 |  |  | 8 |  |  | 37 |  |  | 8,658 |  |  | \u2014 |  |  | 8,703 |  |  | \u2014 |  |  | 8,703 | \nServices |  | 2,407 |  |  | 2,515 |  |  | 970 |  |  | 272 |  |  | \u2014 |  |  | 3,757 |  |  | \u2014 |  |  | 6,164 | \nTotal revenues - unaffiliated customers |  | 55,752 |  |  | 6,145 |  |  | 1,007 |  |  | 8,930 |  |  | \u2014 |  |  | 16,082 |  |  | \u2014 |  |  | 71,834 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 7,441 |  |  | 2,037 |  |  | 14,400 |  |  | (503) |  |  | 23,375 |  |  | (23,375) |  |  | \u2014 | \nInvestment and other income |  | 175 |  |  | 226 |  |  | 95 |  |  | 7 |  |  | \u2014 |  |  | 328 |  |  | \u2014 |  |  | 503 | \nTotal revenues |  | $ | 55,927 |  |  | $ | 13,812 |  |  | $ | 3,139 |  |  | $ | 23,337 |  |  | $ | (503) |  |  | $ | 39,785 |  |  | $ | (23,375) |  |  | $ | 72,337 | \nEarnings from operations |  | $ | 2,651 |  |  | $ | 1,143 |  |  | $ | 906 |  |  | $ | 1,012 |  |  | $ | \u2014 |  |  | $ | 3,061 |  |  | $ | \u2014 |  |  | $ | 5,712 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (422) |  |  | (422) | \nEarnings before income taxes |  | $ | 2,651 |  |  | $ | 1,143 |  |  | $ | 906 |  |  | $ | 1,012 |  |  | $ | \u2014 |  |  | $ | 3,061 |  |  | $ | (422) |  |  | $ | 5,290 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Optum |  |  |  | \n(in millions) |  | UnitedHealthcare |  | Optum Health |  | Optum Insight |  | Optum Rx |  | Optum Eliminations |  | Optum |  | Corporate\u00a0andEliminations |  | Consolidated\nNine Months Ended September 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 178,680 |  |  | $ | 13,777 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 13,777 |  |  | $ | \u2014 |  |  | $ | 192,457 | \nProducts |  | \u2014 |  |  | 14 |  |  | 135 |  |  | 27,877 |  |  | \u2014 |  |  | 28,026 |  |  | \u2014 |  |  | 28,026 | \nServices |  | 7,492 |  |  | 8,054 |  |  | 3,075 |  |  | 1,096 |  |  | \u2014 |  |  | 12,225 |  |  | \u2014 |  |  | 19,717 | \nTotal revenues - unaffiliated customers |  | 186,172 |  |  | 21,845 |  |  | 3,210 |  |  | 28,973 |  |  | \u2014 |  |  | 54,028 |  |  | \u2014 |  |  | 240,200 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 30,355 |  |  | 6,885 |  |  | 44,921 |  |  | (1,941) |  |  | 80,220 |  |  | (80,220) |  |  | \u2014 | \nInvestment and other income |  | 523 |  |  | 528 |  |  | 99 |  |  | 25 |  |  | \u2014 |  |  | 652 |  |  | \u2014 |  |  | 1,175 | \nTotal revenues |  | $ | 186,695 |  |  | $ | 52,728 |  |  | $ | 10,194 |  |  | $ | 73,919 |  |  | $ | (1,941) |  |  | $ | 134,900 |  |  | $ | (80,220) |  |  | $ | 241,375 | \nEarnings from operations |  | $ | 11,447 |  |  | $ | 4,340 |  |  | $ | 2,693 |  |  | $ | 3,064 |  |  | $ | \u2014 |  |  | $ | 10,097 |  |  | $ | \u2014 |  |  | $ | 21,544 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,416) |  |  | (1,416) | \nEarnings before income taxes |  | $ | 11,447 |  |  | $ | 4,340 |  |  | $ | 2,693 |  |  | $ | 3,064 |  |  | $ | \u2014 |  |  | $ | 10,097 |  |  | $ | (1,416) |  |  | $ | 20,128 | \nNine Months Ended September 30, 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 158,761 |  |  | $ | 9,925 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 9,925 |  |  | $ | \u2014 |  |  | $ | 168,686 | \nProducts |  | \u2014 |  |  | 25 |  |  | 107 |  |  | 25,344 |  |  | \u2014 |  |  | 25,476 |  |  | \u2014 |  |  | 25,476 | \nServices |  | 7,197 |  |  | 7,312 |  |  | 2,861 |  |  | 811 |  |  | \u2014 |  |  | 10,984 |  |  | \u2014 |  |  | 18,181 | \nTotal revenues - unaffiliated customers |  | 165,958 |  |  | 17,262 |  |  | 2,968 |  |  | 26,155 |  |  | \u2014 |  |  | 46,385 |  |  | \u2014 |  |  | 212,343 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 21,614 |  |  | 5,779 |  |  | 41,196 |  |  | (1,456) |  |  | 67,133 |  |  | (67,133) |  |  | \u2014 | \nInvestment and other income |  | 557 |  |  | 639 |  |  | 201 |  |  | 114 |  |  | \u2014 |  |  | 954 |  |  | \u2014 |  |  | 1,511 | \nTotal revenues |  | $ | 166,515 |  |  | $ | 39,515 |  |  | $ | 8,948 |  |  | $ | 67,465 |  |  | $ | (1,456) |  |  | $ | 114,472 |  |  | $ | (67,133) |  |  | $ | 213,854 | \nEarnings from operations |  | $ | 9,854 |  |  | $ | 3,233 |  |  | $ | 2,447 |  |  | $ | 2,895 |  |  | $ | \u2014 |  |  | $ | 8,575 |  |  | $ | \u2014 |  |  | $ | 18,429 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,229) |  |  | (1,229) | \nEarnings before income taxes |  | $ | 9,854 |  |  | $ | 3,233 |  |  | $ | 2,447 |  |  | $ | 2,895 |  |  | $ | \u2014 |  |  | $ | 8,575 |  |  | $ | (1,229) |  |  | $ | 17,200 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except percentages and per share data) |  | Three Months EndedSeptember 30, |  | Increase/(Decrease) |  | Nine Months EndedSeptember 30, |  | Increase/(Decrease)\n | 2022 |  | 2021 |  | 2022 vs. 2021 |  | 2022 |  | 2021 |  | 2022 vs. 2021\nRevenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 64,491 |  |  | $ | 56,967 |  |  | $ | 7,524 |  |  | 13 | % |  | $ | 192,457 |  |  | $ | 168,686 |  |  | $ | 23,771 |  |  | 14 | %\nProducts |  | 9,190 |  |  | 8,703 |  |  | 487 |  |  | 6 |  |  | 28,026 |  |  | 25,476 |  |  | 2,550 |  |  | 10 | \nServices |  | 6,700 |  |  | 6,164 |  |  | 536 |  |  | 9 |  |  | 19,717 |  |  | 18,181 |  |  | 1,536 |  |  | 8 | \nInvestment and other income |  | 513 |  |  | 503 |  |  | 10 |  |  | 2 |  |  | 1,175 |  |  | 1,511 |  |  | (336) |  |  | (22) | \nTotal revenues |  | 80,894 |  |  | 72,337 |  |  | 8,557 |  |  | 12 |  |  | 241,375 |  |  | 213,854 |  |  | 27,521 |  |  | 13 | \nOperating costs: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMedical costs |  | 52,635 |  |  | 47,302 |  |  | 5,333 |  |  | 11 |  |  | 157,251 |  |  | 138,752 |  |  | 18,499 |  |  | 13 | \nOperating costs |  | 11,663 |  |  | 10,725 |  |  | 938 |  |  | 9 |  |  | 34,773 |  |  | 31,307 |  |  | 3,466 |  |  | 11 | \nCost of products sold |  | 8,306 |  |  | 7,802 |  |  | 504 |  |  | 6 |  |  | 25,389 |  |  | 23,034 |  |  | 2,355 |  |  | 10 | \nDepreciation and amortization |  | 828 |  |  | 796 |  |  | 32 |  |  | 4 |  |  | 2,418 |  |  | 2,332 |  |  | 86 |  |  | 4 | \nTotal operating costs |  | 73,432 |  |  | 66,625 |  |  | 6,807 |  |  | 10 |  |  | 219,831 |  |  | 195,425 |  |  | 24,406 |  |  | 12 | \nEarnings from operations |  | 7,462 |  |  | 5,712 |  |  | 1,750 |  |  | 31 |  |  | 21,544 |  |  | 18,429 |  |  | 3,115 |  |  | 17 | \nInterest expense |  | (516) |  |  | (422) |  |  | (94) |  |  | 22 |  |  | (1,416) |  |  | (1,229) |  |  | (187) |  |  | 15 | \nEarnings before income taxes |  | 6,946 |  |  | 5,290 |  |  | 1,656 |  |  | 31 |  |  | 20,128 |  |  | 17,200 |  |  | 2,928 |  |  | 17 | \nProvision for income taxes |  | (1,562) |  |  | (1,099) |  |  | (463) |  |  | 42 |  |  | (4,397) |  |  | (3,659) |  |  | (738) |  |  | 20 | \nNet earnings |  | 5,384 |  |  | 4,191 |  |  | 1,193 |  |  | 28 |  |  | 15,731 |  |  | 13,541 |  |  | 2,190 |  |  | 16 | \nEarnings attributable to noncontrolling interests |  | (122) |  |  | (105) |  |  | (17) |  |  | 16 |  |  | (372) |  |  | (327) |  |  | (45) |  |  | 14 | \nNet earnings attributable to UnitedHealth Group common shareholders |  | $ | 5,262 |  |  | $ | 4,086 |  |  | $ | 1,176 |  |  | 29 | % |  | $ | 15,359 |  |  | $ | 13,214 |  |  | $ | 2,145 |  |  | 16 | %\nDiluted earnings per share attributable to UnitedHealth Group common shareholders |  | $ | 5.55 |  |  | $ | 4.28 |  |  | $ | 1.27 |  |  | 30 | % |  | $ | 16.15 |  |  | $ | 13.82 |  |  | $ | 2.33 |  |  | 17 | %\nMedical care ratio (a) |  | 81.6 | % |  | 83.0 | % |  | (1.4) | % |  |  |  | 81.7 | % |  | 82.3 | % |  | (0.6) | % |  | \nOperating cost ratio |  | 14.4 |  |  | 14.8 |  |  | (0.4) |  |  |  |  | 14.4 |  |  | 14.6 |  |  | (0.2) |  |  | \nOperating margin |  | 9.2 |  |  | 7.9 |  |  | 1.3 |  |  |  |  | 8.9 |  |  | 8.6 |  |  | 0.3 |  |  | \nTax rate |  | 22.5 |  |  | 20.8 |  |  | 1.7 |  |  |  |  | 21.8 |  |  | 21.3 |  |  | 0.5 |  |  | \nNet earnings margin (b) |  | 6.5 |  |  | 5.6 |  |  | 0.9 |  |  |  |  | 6.4 |  |  | 6.2 |  |  | 0.2 |  |  | \nReturn on equity (c) |  | 28.5 | % |  | 23.5 | % |  | 5.0 | % |  |  |  | 28.1 | % |  | 26.0 | % |  | 2.1 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months EndedSeptember 30, |  | Increase/(Decrease) |  | Nine Months EndedSeptember 30, |  | Increase/(Decrease)\n(in millions, except percentages) |  | 2022 |  | 2021 |  | 2022 vs. 2021 |  | 2022 |  | 2021 |  | 2022 vs. 2021\nRevenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nUnitedHealthcare |  | $ | 61,995 |  |  | $ | 55,927 |  |  | $ | 6,068 |  |  | 11 | % |  | $ | 186,695 |  |  | $ | 166,515 |  |  | $ | 20,180 |  |  | 12 | %\nOptum Health |  | 18,463 |  |  | 13,812 |  |  | 4,651 |  |  | 34 |  |  | 52,728 |  |  | 39,515 |  |  | 13,213 |  |  | 33 | \nOptum Insight |  | 3,693 |  |  | 3,139 |  |  | 554 |  |  | 18 |  |  | 10,194 |  |  | 8,948 |  |  | 1,246 |  |  | 14 | \nOptum Rx |  | 25,203 |  |  | 23,337 |  |  | 1,866 |  |  | 8 |  |  | 73,919 |  |  | 67,465 |  |  | 6,454 |  |  | 10 | \nOptum eliminations |  | (800) |  |  | (503) |  |  | (297) |  |  | 59 |  |  | (1,941) |  |  | (1,456) |  |  | (485) |  |  | 33 | \nOptum |  | 46,559 |  |  | 39,785 |  |  | 6,774 |  |  | 17 |  |  | 134,900 |  |  | 114,472 |  |  | 20,428 |  |  | 18 | \nEliminations |  | (27,660) |  |  | (23,375) |  |  | (4,285) |  |  | 18 |  |  | (80,220) |  |  | (67,133) |  |  | (13,087) |  |  | 19 | \nConsolidated revenues |  | $ | 80,894 |  |  | $ | 72,337 |  |  | $ | 8,557 |  |  | 12 | % |  | $ | 241,375 |  |  | $ | 213,854 |  |  | $ | 27,521 |  |  | 13 | %\nEarnings from operations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nUnitedHealthcare |  | $ | 3,799 |  |  | $ | 2,651 |  |  | $ | 1,148 |  |  | 43 | % |  | $ | 11,447 |  |  | $ | 9,854 |  |  | $ | 1,593 |  |  | 16 | %\nOptum Health |  | 1,575 |  |  | 1,143 |  |  | 432 |  |  | 38 |  |  | 4,340 |  |  | 3,233 |  |  | 1,107 |  |  | 34 | \nOptum Insight |  | 1,007 |  |  | 906 |  |  | 101 |  |  | 11 |  |  | 2,693 |  |  | 2,447 |  |  | 246 |  |  | 10 | \nOptum Rx |  | 1,081 |  |  | 1,012 |  |  | 69 |  |  | 7 |  |  | 3,064 |  |  | 2,895 |  |  | 169 |  |  | 6 | \nOptum |  | 3,663 |  |  | 3,061 |  |  | 602 |  |  | 20 |  |  | 10,097 |  |  | 8,575 |  |  | 1,522 |  |  | 18 | \nConsolidated earnings from operations |  | $ | 7,462 |  |  | $ | 5,712 |  |  | $ | 1,750 |  |  | 31 | % |  | $ | 21,544 |  |  | $ | 18,429 |  |  | $ | 3,115 |  |  | 17 | %\nOperating margin |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nUnitedHealthcare |  | 6.1 | % |  | 4.7 | % |  | 1.4 | % |  |  |  | 6.1 | % |  | 5.9 | % |  | 0.2 | % |  | \nOptum Health |  | 8.5 |  |  | 8.3 |  |  | 0.2 |  |  |  |  | 8.2 |  |  | 8.2 |  |  | \u2014 |  |  | \nOptum Insight |  | 27.3 |  |  | 28.9 |  |  | (1.6) |  |  |  |  | 26.4 |  |  | 27.3 |  |  | (0.9) |  |  | \nOptum Rx |  | 4.3 |  |  | 4.3 |  |  | \u2014 |  |  |  |  | 4.1 |  |  | 4.3 |  |  | (0.2) |  |  | \nOptum |  | 7.9 |  |  | 7.7 |  |  | 0.2 |  |  |  |  | 7.5 |  |  | 7.5 |  |  | \u2014 |  |  | \nConsolidated operating margin |  | 9.2 | % |  | 7.9 | % |  | 1.3 | % |  |  |  | 8.9 | % |  | 8.6 | % |  | 0.3 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Increase/(Decrease) |  | Nine Months Ended September 30, |  | Increase/(Decrease)\n(in millions, except percentages) |  | 2022 |  | 2021 |  | 2022 vs. 2021 |  | 2022 |  | 2021 |  | 2022 vs. 2021\nUnitedHealthcare Employer & Individual - Domestic |  | $ | 15,929 |  |  | $ | 15,094 |  |  | $ | 835 |  |  | 6 | % |  | $ | 47,318 |  |  | $ | 44,668 |  |  | $ | 2,650 |  |  | 6 | %\nUnitedHealthcare Employer & Individual - Global (a) |  | 2,120 |  |  | 2,139 |  |  | (19) |  |  | (1) |  |  | 6,500 |  |  | 6,292 |  |  | 208 |  |  | 3 | \nUnitedHealthcare Employer & Individual - Total (a) |  | 18,049 |  |  | 17,233 |  |  | 816 |  |  | 5 |  |  | 53,818 |  |  | 50,960 |  |  | 2,858 |  |  | 6 | \nUnitedHealthcare Medicare & Retirement |  | 27,895 |  |  | 24,931 |  |  | 2,964 |  |  | 12 |  |  | 85,620 |  |  | 75,709 |  |  | 9,911 |  |  | 13 | \nUnitedHealthcare Community & State |  | 16,051 |  |  | 13,763 |  |  | 2,288 |  |  | 17 |  |  | 47,257 |  |  | 39,846 |  |  | 7,411 |  |  | 19 | \nTotal UnitedHealthcare revenues |  | $ | 61,995 |  |  | $ | 55,927 |  |  | $ | 6,068 |  |  | 11 | % |  | $ | 186,695 |  |  | $ | 166,515 |  |  | $ | 20,180 |  |  | 12 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30, |  | Increase/(Decrease)\n(in thousands, except percentages) |  | 2022 |  | 2021 |  | 2022 vs. 2021\nCommercial - domestic: |  |  |  |  |  |  |  | \nRisk-based |  | 8,055 |  |  | 7,960 |  |  | 95 |  |  | 1 | %\nFee-based |  | 18,500 |  |  | 18,595 |  |  | (95) |  |  | (1) | \nTotal commercial - domestic |  | 26,555 |  |  | 26,555 |  |  | \u2014 |  |  | \u2014 | \nMedicare Advantage |  | 7,035 |  |  | 6,455 |  |  | 580 |  |  | 9 | \nMedicaid |  | 8,005 |  |  | 7,510 |  |  | 495 |  |  | 7 | \nMedicare Supplement (Standardized) |  | 4,370 |  |  | 4,405 |  |  | (35) |  |  | (1) | \nTotal community and senior |  | 19,410 |  |  | 18,370 |  |  | 1,040 |  |  | 6 | \nTotal UnitedHealthcare - domestic medical |  | 45,965 |  |  | 44,925 |  |  | 1,040 |  |  | 2 | \nCommercial - global |  | 5,360 |  |  | 5,490 |  |  | (130) |  |  | (2) | \nTotal UnitedHealthcare - medical |  | 51,325 |  |  | 50,415 |  |  | 910 |  |  | 2 | %\nSupplemental Data: |  |  |  |  |  |  |  | \nMedicare Part D stand-alone |  | 3,310 |  |  | 3,725 |  |  | (415) |  |  | (11) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30, |  | Increase/(Decrease)\n(in millions) |  | 2022 |  | 2021 |  | 2022 vs. 2021\nSources of cash: |  |  |  |  |  | \nCash provided by operating activities |  | $ | 30,739 |  |  | $ | 19,125 |  |  | $ | 11,614 | \nIssuances of short-term borrowings and long-term debt, net of repayments |  | 3,806 |  |  | 3,733 |  |  | 73 | \nProceeds from common stock issuances |  | 1,084 |  |  | 1,077 |  |  | 7 | \nCustomer funds administered |  | 7,028 |  |  | 1,402 |  |  | 5,626 | \nOther |  | 50 |  |  | \u2014 |  |  | 50 | \nTotal sources of cash |  | 42,707 |  |  | 25,337 |  |  | \nUses of cash: |  |  |  |  |  | \nCommon stock repurchases |  | (6,000) |  |  | (3,950) |  |  | (2,050) | \nCash paid for acquisitions, net of cash assumed |  | (7,154) |  |  | (4,727) |  |  | (2,427) | \nPurchases of investments, net of sales and maturities |  | (4,067) |  |  | (3,702) |  |  | (365) | \nPurchases of property, equipment and capitalized software |  | (1,936) |  |  | (1,759) |  |  | (177) | \nCash dividends paid |  | (4,450) |  |  | (3,915) |  |  | (535) | \nPurchases of redeemable noncontrolling interests |  | (176) |  |  | (1,338) |  |  | 1,162 | \nOther |  | (1,458) |  |  | (1,737) |  |  | 279 | \nTotal uses of cash |  | (25,241) |  |  | (21,128) |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | 4 |  |  | (45) |  |  | 49 | \nNet increase in cash and cash equivalents |  | $ | 17,470 |  |  | $ | 4,164 |  |  | $ | 13,306 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Moody\u2019s |  | S&P Global |  | Fitch |  | A.M. Best\n | Ratings |  | Outlook |  | Ratings |  | Outlook |  | Ratings |  | Outlook |  | Ratings |  | Outlook\nSenior unsecured debt | A3 |  | Positive |  | A+ |  | Stable |  | A |  | Stable |  | A |  | Stable\nCommercial paper | P-2 |  | n/a |  | A-1 |  | n/a |  | F1 |  | n/a |  | AMB-1+ |  | n/a  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30, 2022\nIncrease (Decrease) in Market Interest Rate |  | InvestmentIncome\u00a0PerAnnum |  | InterestExpense\u00a0PerAnnum |  | Fair\u00a0Value\u00a0ofFinancial Assets |  | Fair\u00a0Value\u00a0ofFinancial Liabilities\n2 % |  | $ | 845 |  |  | $ | 186 |  |  | $ | (3,027) |  |  | $ | (6,014) | \n1 |  | 422 |  |  | 93 |  |  | (1,563) |  |  | (3,261) | \n(1) |  | (422) |  |  | (93) |  |  | 1,656 |  |  | 3,894 | \n(2) |  | (845) |  |  | (186) |  |  | 3,391 |  |  | 8,586 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFor the Month Ended |  | Total Number of Shares Purchased |  | Average Price Paid Per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number of Shares That May Yet Be Purchased Under The Plans or Programs\n |  | (in millions) |  |  |  | (in millions) |  | (in millions)\nJuly 31, 2022 |  | 0.6 |  |  | $ | 517.91 |  |  | 0.6 |  |  | 34.3\nAugust 31, 2022 |  | 0.7 |  |  | 539.26 |  |  | 0.7 |  |  | 33.6\nSeptember 30, 2022 |  | 0.6 |  |  | 518.97 |  |  | 0.6 |  |  | 33.0\nTotal |  | 1.9 |  |  | $ | 525.74 |  |  | 1.9 |  |  |   |  |  |  |  |  |  |  | \n3.1 |  | Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company\u2019s Registration Statement on Form 8-A/A filed on July 1, 2015)\n3.2 |  | Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by reference to Exhibit 3.2 to UnitedHealth Group Incorporated\u2019s Current Report on Form 8-K filed on February 26, 2021)\n4.1 |  | Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company\u2019s Registration Statement on Form S-3/A, SEC File Number 333-66013, filed on January 11, 1999)\n4.2 |  | Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998, between UnitedHealth Group Incorporated and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2001)\n4.3 |  | Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant to the Senior Indenture, dated as of November 15, 1998, amended November 6, 2000, among UnitedHealth Group Incorporated, The Bank of New York and Wilmington Trust Company (incorporated by reference to Exhibit 4.3 to the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended June\u00a030, 2007)\n4.4 |  | Indenture, dated as of February\u00a04,\u00a02008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company\u2019s Registration Statement on Form S-3, SEC File Number 333-149031, filed on February\u00a04, 2008)\n31.1 |  | Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\n32.1 |  | Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\n101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n101.SCH |  | Inline XBRL Taxonomy Extension Schema Document.\n101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document.\n101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document.\n101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document.\n101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document.\n104 |  |  | Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).  |  |  |  |  |  |  |  | \n* |  | Pursuant to Item\u00a0601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n/s/    ANDREWP. WITTY |  | Chief Executive Officer(principal executive officer) | Dated: | November 2, 2022\nAndrew P. Witty |  |  | \n |  | \n/s/    JOHNF. REX |  | Executive Vice President andChief\u00a0Financial\u00a0Officer(principal financial officer) | Dated: | November 2, 2022\nJohn F. Rex |  |  | \n |  | \n/s/THOMASE. ROOS |  | Senior Vice President andChief Accounting Officer(principal accounting officer) | Dated: | November 2, 2022\nThomas E. Roos |  |  | "}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For United Health Group, in 2023 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |   |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  |  |  |  |  |  |  | \nDelaware |  | 41-1321939\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)\nUnitedHealth Group Center |  | 55343\n9900 Bren Road East | \nMinnetonka, | Minnesota | \n(Address of principal executive offices) |  | (Zip Code)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered\nCommon Stock, $.01 par value |  | UNH |  | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 |  | Accelerated\u00a0filer | \u2610 |  | Non-accelerated filer | \u2610\nSmaller\u00a0reporting\u00a0company | \u2610 |  |  |  |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page\n |  |  |  | \nPart I. Financial\u00a0Information | \nItem\u00a01. | Financial Statements (unaudited) | 1\n |  | Condensed Consolidated Balance Sheets as ofMarch31, 2023and December 31, 2022 | 1\n |  | Condensed Consolidated Statements of Operations for the ThreeMonths EndedMarch31, 2023and 2022 | 2\n |  | Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2023 and 2022 | 3\n |  | Condensed Consolidated Statements of Changes in Equity for the ThreeMonthsEndedMarch31, 2023and 2022 | 4\n |  | Condensed Consolidated Statements of Cash Flows for theThreeMonths EndedMarch31, 2023and 2022 | 5\n |  | Notes to the Condensed Consolidated Financial Statements | 6\n |  | 1. | Basis of Presentation | 6\n |  | 2. | Investments | 7\n |  | 3. | Fair Value | 9\n |  | 4. | Medical Costs Payable | 10\n |  | 5. | Short-Term Borrowings and Long-Term Debt | 11\n |  | 6. | Commitments and Contingencies | 11\n |  | 7. | Business Combinations | 12\n |  | 8. | Segment Financial Information | 13\nItem\u00a02. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 14\nItem\u00a03. | Quantitative and Qualitative Disclosures About Market Risk | 21\nItem\u00a04. | Controls and Procedures | 22\nPart\u00a0II. Other Information | \nItem\u00a01. | Legal Proceedings | 22\nItem\u00a01A. | Risk Factors | 22\nItem\u00a02. | Unregistered Sales of Equity Securities and Use of Proceeds | 22\nItem\u00a06. | Exhibits | 23\nSignatures | 24  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except per share data) |  | March 31,2023 |  | December 31,2022\nAssets |  |  |  | \nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 41,913 |  |  | $ | 23,365 | \nShort-term investments |  | 4,584 |  |  | 4,546 | \nAccounts receivable, net |  | 22,414 |  |  | 17,681 | \nOther current receivables, net |  | 14,696 |  |  | 12,769 | \nAssets under management |  | 3,837 |  |  | 4,087 | \nPrepaid expenses and other current assets |  | 6,451 |  |  | 6,621 | \nTotal current assets |  | 93,895 |  |  | 69,069 | \nLong-term investments |  | 46,884 |  |  | 43,728 | \nProperty, equipment and capitalized software, net |  | 10,637 |  |  | 10,128 | \nGoodwill |  | 100,406 |  |  | 93,352 | \nOther intangible assets, net |  | 16,165 |  |  | 14,401 | \nOther assets |  | 15,692 |  |  | 15,027 | \nTotal assets |  | $ | 283,679 |  |  | $ | 245,705 | \nLiabilities, redeemable noncontrolling interests and equity |  |  |  | \nCurrent liabilities: |  |  |  | \nMedical costs payable |  | $ | 31,809 |  |  | $ | 29,056 | \nAccounts payable and accrued liabilities |  | 29,856 |  |  | 27,715 | \nShort-term borrowings and current maturities of long-term debt |  | 9,931 |  |  | 3,110 | \nUnearned revenues |  | 14,487 |  |  | 3,075 | \nOther current liabilities |  | 30,399 |  |  | 26,281 | \nTotal current liabilities |  | 116,482 |  |  | 89,237 | \nLong-term debt, less current maturities |  | 60,657 |  |  | 54,513 | \nDeferred income taxes |  | 2,834 |  |  | 2,769 | \nOther liabilities |  | 13,084 |  |  | 12,839 | \nTotal liabilities |  | 193,057 |  |  | 159,358 | \nCommitments and contingencies (Note 6) |  |  |  | \nRedeemable noncontrolling interests |  | 4,801 |  |  | 4,897 | \nEquity: |  |  |  | \nPreferred stock, $0.001par value -10shares authorized;noshares issued or outstanding |  | \u2014 |  |  | \u2014 | \nCommon stock, $0.01par value -3,000shares authorized;932and934issued and outstanding |  | 9 |  |  | 9 | \nRetained earnings |  | 88,852 |  |  | 86,156 | \nAccumulated other comprehensive loss |  | (7,549) |  |  | (8,393) | \nNonredeemable noncontrolling interests |  | 4,509 |  |  | 3,678 | \nTotal equity |  | 85,821 |  |  | 81,450 | \nTotal liabilities, redeemable noncontrolling interests and equity |  | $ | 283,679 |  |  | $ | 245,705 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31,\n(in millions, except per share data) |  | 2023 |  | 2022\nRevenues: |  |  |  | \nPremiums |  | $ | 72,786 |  |  | $ | 64,070 | \nProducts |  | 10,267 |  |  | 9,340 | \nServices |  | 8,080 |  |  | 6,372 | \nInvestment and other income |  | 798 |  |  | 367 | \nTotal revenues |  | 91,931 |  |  | 80,149 | \nOperating costs: |  |  |  | \nMedical costs |  | 59,845 |  |  | 52,523 | \nOperating costs |  | 13,625 |  |  | 11,401 | \nCost of products sold |  | 9,405 |  |  | 8,487 | \nDepreciation and amortization |  | 970 |  |  | 788 | \nTotal operating costs |  | 83,845 |  |  | 73,199 | \nEarnings from operations |  | 8,086 |  |  | 6,950 | \nInterest expense |  | (754) |  |  | (433) | \nEarnings before income taxes |  | 7,332 |  |  | 6,517 | \nProvision for income taxes |  | (1,558) |  |  | (1,369) | \nNet earnings |  | 5,774 |  |  | 5,148 | \nEarnings attributable to noncontrolling interests |  | (163) |  |  | (121) | \nNet earnings attributable to UnitedHealth Group common shareholders |  | $ | 5,611 |  |  | $ | 5,027 | \nEarnings per share attributable to UnitedHealth Group common shareholders: |  |  |  | \nBasic |  | $ | 6.01 |  |  | $ | 5.34 | \nDiluted |  | $ | 5.95 |  |  | $ | 5.27 | \nBasic weighted-average number of common shares outstanding |  | 933 |  |  | 941 | \nDilutive effect of common share equivalents |  | 10 |  |  | 13 | \nDiluted weighted-average number of common shares outstanding |  | 943 |  |  | 954 | \nAnti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents |  | 5 |  |  | 2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31,\n(in millions) |  | 2023 |  | 2022\nNet earnings |  | $ | 5,774 |  |  | $ | 5,148 | \nOther comprehensive income (loss): |  |  |  | \nGross unrealized gains (losses) on investment securities during the period |  | 640 |  |  | (2,023) | \nIncome tax effect |  | (147) |  |  | 465 | \nTotal unrealized gains (losses), net of tax |  | 493 |  |  | (1,558) | \nGross reclassification adjustment for net realized losses (gains) included in net earnings |  | 13 |  |  | (3) | \nIncome tax effect |  | (3) |  |  | 1 | \nTotal reclassification adjustment, net of tax |  | 10 |  |  | (2) | \nTotal foreign currency translation gains |  | 341 |  |  | 918 | \nOther comprehensive income (loss) |  | 844 |  |  | (642) | \nComprehensive income |  | 6,618 |  |  | 4,506 | \nComprehensive income attributable to noncontrolling interests |  | (163) |  |  | (121) | \nComprehensive income attributable to UnitedHealth Group common shareholders |  | $ | 6,455 |  |  | $ | 4,385 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Common Stock |  | Additional Paid-In Capital |  | Retained Earnings |  | Accumulated Other Comprehensive(Loss) Income |  | Nonredeemable Noncontrolling Interests |  | TotalEquity\nThree months ended March 31,(in millions) |  | Shares |  | Amount |  |  |  | Net Unrealized (Losses) Gains on Investments |  | Foreign Currency Translation (Losses) Gains |  | \nBalance at January 1, 2023 |  | 934 |  |  | $ | 9 |  |  | $ | \u2014 |  |  | $ | 86,156 |  |  | $ | (2,778) |  |  | $ | (5,615) |  |  | $ | 3,678 |  |  | $ | 81,450 | \nNet earnings |  |  |  |  |  |  |  | 5,611 |  |  |  |  |  |  | 113 |  |  | 5,724 | \nOther comprehensive income |  |  |  |  |  |  |  |  |  | 503 |  |  | 341 |  |  |  |  | 844 | \nIssuances of common stock, and related tax effects |  | 2 |  |  | \u2014 |  |  | 350 |  |  |  |  |  |  |  |  |  |  | 350 | \nShare-based compensation |  |  |  |  |  | 366 |  |  |  |  |  |  |  |  |  |  | 366 | \nCommon share repurchases |  | (4) |  |  | \u2014 |  |  | (633) |  |  | (1,378) |  |  |  |  |  |  |  |  | (2,011) | \nCash dividends paid on common shares ($1.65per share) |  |  |  |  |  |  |  | (1,537) |  |  |  |  |  |  |  |  | (1,537) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | (83) |  |  |  |  |  |  |  |  |  |  | (83) | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 819 |  |  | 819 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (101) |  |  | (101) | \nBalance at March 31, 2023 |  | 932 |  |  | $ | 9 |  |  | $ | \u2014 |  |  | $ | 88,852 |  |  | $ | (2,275) |  |  | $ | (5,274) |  |  | $ | 4,509 |  |  | $ | 85,821 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at January 1, 2022 |  | 941 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 77,134 |  |  | $ | 423 |  |  | $ | (5,807) |  |  | $ | 3,285 |  |  | $ | 75,045 | \nNet earnings |  |  |  |  |  |  |  | 5,027 |  |  |  |  |  |  | 88 |  |  | 5,115 | \nOther comprehensive (loss) income |  |  |  |  |  |  |  |  |  | (1,560) |  |  | 918 |  |  |  |  | (642) | \nIssuances of common stock, and related tax effects |  | 3 |  |  | \u2014 |  |  | 333 |  |  |  |  |  |  |  |  |  |  | 333 | \nShare-based compensation |  |  |  |  |  | 282 |  |  |  |  |  |  |  |  |  |  | 282 | \nCommon share repurchases |  | (5) |  |  | \u2014 |  |  | (484) |  |  | (2,016) |  |  |  |  |  |  |  |  | (2,500) | \nCash dividends paid on common shares ($1.45per share) |  |  |  |  |  |  |  | (1,363) |  |  |  |  |  |  |  |  | (1,363) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | (131) |  |  |  |  |  |  |  |  |  |  | (131) | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 91 |  |  | 91 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (102) |  |  | (102) | \nBalance at March 31, 2022 |  | 939 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 78,782 |  |  | $ | (1,137) |  |  | $ | (4,889) |  |  | $ | 3,362 |  |  | $ | 76,128 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31,\n(in millions) |  | 2023 |  | 2022\nOperating activities |  |  |  | \nNet earnings |  | $ | 5,774 |  |  | $ | 5,148 | \nNoncash items: |  |  |  | \nDepreciation and amortization |  | 970 |  |  | 788 | \nDeferred income taxes |  | (332) |  |  | 161 | \nShare-based compensation |  | 362 |  |  | 299 | \nOther, net |  | 69 |  |  | 17 | \nNet change in other operating items, net of effects from acquisitions and changes in AARP balances: |  |  |  | \nAccounts receivable |  | (4,306) |  |  | (4,521) | \nOther assets |  | (1,875) |  |  | (1,089) | \nMedical costs payable |  | 2,467 |  |  | 3,849 | \nAccounts payable and other liabilities |  | 1,796 |  |  | 589 | \nUnearned revenues |  | 11,402 |  |  | 78 | \nCash flows from operating activities |  | 16,327 |  |  | 5,319 | \nInvesting activities |  |  |  | \nPurchases of investments |  | (4,894) |  |  | (4,982) | \nSales of investments |  | 456 |  |  | 1,591 | \nMaturities of investments |  | 2,119 |  |  | 1,759 | \nCash paid for acquisitions, net of cash assumed |  | (7,826) |  |  | (1,231) | \nPurchases of property, equipment and capitalized software |  | (760) |  |  | (555) | \nOther, net |  | (115) |  |  | (255) | \nCash flows used for investing activities |  | (11,020) |  |  | (3,673) | \nFinancing activities |  |  |  | \nCommon share repurchases |  | (2,000) |  |  | (2,500) | \nCash dividends paid |  | (1,537) |  |  | (1,363) | \nProceeds from common stock issuances |  | 344 |  |  | 551 | \nRepayments of long-term debt |  | (1,375) |  |  | (1,100) | \nProceeds from short-term borrowings, net |  | 7,349 |  |  | 3,148 | \nProceeds from issuance of long-term debt |  | 6,401 |  |  | \u2014 | \nCustomer funds administered |  | 5,012 |  |  | 5,120 | \nOther, net |  | (1,004) |  |  | (1,552) | \nCash flows from financing activities |  | 13,190 |  |  | 2,304 | \nEffect of exchange rate changes on cash and cash equivalents |  | 51 |  |  | 157 | \nIncrease in cash and cash equivalents |  | 18,548 |  |  | 4,107 | \nCash and cash equivalents, beginning of period |  | 23,365 |  |  | 21,375 | \nCash and cash equivalents, end of period |  | $ | 41,913 |  |  | $ | 25,482 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | AmortizedCost |  | GrossUnrealizedGains |  | GrossUnrealizedLosses |  | FairValue\nMarch 31, 2023 |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 4,760 |  |  | $ | 5 |  |  | $ | (236) |  |  | $ | 4,529 | \nState and municipal obligations |  | 8,055 |  |  | 65 |  |  | (365) |  |  | 7,755 | \nCorporate obligations |  | 24,149 |  |  | 59 |  |  | (1,525) |  |  | 22,683 | \nU.S. agency mortgage-backed securities |  | 8,213 |  |  | 35 |  |  | (708) |  |  | 7,540 | \nNon-U.S. agency mortgage-backed securities |  | 3,156 |  |  | 1 |  |  | (283) |  |  | 2,874 | \nTotal debt securities - available-for-sale |  | 48,333 |  |  | 165 |  |  | (3,117) |  |  | 45,381 | \nDebt securities - held-to-maturity: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 594 |  |  | \u2014 |  |  | (10) |  |  | 584 | \nState and municipal obligations |  | 28 |  |  | \u2014 |  |  | (3) |  |  | 25 | \nCorporate obligations |  | 60 |  |  | \u2014 |  |  | \u2014 |  |  | 60 | \nTotal debt securities - held-to-maturity |  | 682 |  |  | \u2014 |  |  | (13) |  |  | 669 | \nTotal debt securities |  | $ | 49,015 |  |  | $ | 165 |  |  | $ | (3,130) |  |  | $ | 46,050 | \nDecember 31, 2022 |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 4,093 |  |  | $ | 1 |  |  | $ | (285) |  |  | $ | 3,809 | \nState and municipal obligations |  | 7,702 |  |  | 25 |  |  | (479) |  |  | 7,248 | \nCorporate obligations |  | 23,675 |  |  | 17 |  |  | (1,798) |  |  | 21,894 | \nU.S. agency mortgage-backed securities |  | 7,379 |  |  | 15 |  |  | (808) |  |  | 6,586 | \nNon-U.S. agency mortgage-backed securities |  | 3,077 |  |  | 1 |  |  | (294) |  |  | 2,784 | \nTotal debt securities - available-for-sale |  | 45,926 |  |  | 59 |  |  | (3,664) |  |  | 42,321 | \nDebt securities - held-to-maturity: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 578 |  |  | \u2014 |  |  | (14) |  |  | 564 | \nState and municipal obligations |  | 29 |  |  | \u2014 |  |  | (3) |  |  | 26 | \nCorporate obligations |  | 89 |  |  | \u2014 |  |  | \u2014 |  |  | 89 | \nTotal debt securities - held-to-maturity |  | 696 |  |  | \u2014 |  |  | (17) |  |  | 679 | \nTotal debt securities |  | $ | 46,622 |  |  | $ | 59 |  |  | $ | (3,681) |  |  | $ | 43,000 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Available-for-Sale |  | Held-to-Maturity\n(in millions) |  | AmortizedCost |  | FairValue |  | AmortizedCost |  | FairValue\nDue in one year or less |  | $ | 4,722 |  |  | $ | 4,691 |  |  | $ | 377 |  |  | $ | 376 | \nDue after one year through five years |  | 14,356 |  |  | 13,708 |  |  | 261 |  |  | 254 | \nDue after five years through ten years |  | 12,240 |  |  | 11,217 |  |  | 24 |  |  | 22 | \nDue after ten years |  | 5,646 |  |  | 5,351 |  |  | 20 |  |  | 17 | \nU.S. agency mortgage-backed securities |  | 8,213 |  |  | 7,540 |  |  | \u2014 |  |  | \u2014 | \nNon-U.S. agency mortgage-backed securities |  | 3,156 |  |  | 2,874 |  |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 48,333 |  |  | $ | 45,381 |  |  | $ | 682 |  |  | $ | 669 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Less Than 12 Months |  | 12 Months or Greater |  | Total\n(in millions) |  | FairValue |  | GrossUnrealizedLosses |  | FairValue |  | GrossUnrealizedLosses |  | FairValue |  | GrossUnrealizedLosses\nMarch 31, 2023 |  |  |  |  |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 1,279 |  |  | $ | (12) |  |  | $ | 1,825 |  |  | $ | (224) |  |  | $ | 3,104 |  |  | $ | (236) | \nState and municipal obligations |  | 1,898 |  |  | (30) |  |  | 3,110 |  |  | (335) |  |  | 5,008 |  |  | (365) | \nCorporate obligations |  | 6,337 |  |  | (178) |  |  | 12,443 |  |  | (1,347) |  |  | 18,780 |  |  | (1,525) | \nU.S. agency mortgage-backed securities |  | 1,589 |  |  | (55) |  |  | 4,274 |  |  | (653) |  |  | 5,863 |  |  | (708) | \nNon-U.S. agency mortgage-backed securities |  | 783 |  |  | (26) |  |  | 1,989 |  |  | (257) |  |  | 2,772 |  |  | (283) | \nTotal debt securities - available-for-sale |  | $ | 11,886 |  |  | $ | (301) |  |  | $ | 23,641 |  |  | $ | (2,816) |  |  | $ | 35,527 |  |  | $ | (3,117) | \nDecember 31, 2022 |  |  |  |  |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 2,007 |  |  | $ | (96) |  |  | $ | 1,290 |  |  | $ | (189) |  |  | $ | 3,297 |  |  | $ | (285) | \nState and municipal obligations |  | 4,630 |  |  | (288) |  |  | 1,178 |  |  | (191) |  |  | 5,808 |  |  | (479) | \nCorporate obligations |  | 13,003 |  |  | (893) |  |  | 6,637 |  |  | (905) |  |  | 19,640 |  |  | (1,798) | \nU.S. agency mortgage-backed securities |  | 3,561 |  |  | (345) |  |  | 2,239 |  |  | (463) |  |  | 5,800 |  |  | (808) | \nNon-U.S. agency mortgage-backed securities |  | 1,698 |  |  | (128) |  |  | 976 |  |  | (166) |  |  | 2,674 |  |  | (294) | \nTotal debt securities - available-for-sale |  | $ | 24,899 |  |  | $ | (1,750) |  |  | $ | 12,320 |  |  | $ | (1,914) |  |  | $ | 37,219 |  |  | $ | (3,664) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | OtherObservableInputs(Level 2) |  | UnobservableInputs(Level 3) |  | TotalFair and CarryingValue\nMarch 31, 2023 |  |  |  |  |  |  |  | \nCash and cash equivalents |  | $ | 41,851 |  |  | $ | 62 |  |  | $ | \u2014 |  |  | $ | 41,913 | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 4,122 |  |  | 407 |  |  | \u2014 |  |  | 4,529 | \nState and municipal obligations |  | \u2014 |  |  | 7,755 |  |  | \u2014 |  |  | 7,755 | \nCorporate obligations |  | 16 |  |  | 22,486 |  |  | 181 |  |  | 22,683 | \nU.S. agency mortgage-backed securities |  | \u2014 |  |  | 7,540 |  |  | \u2014 |  |  | 7,540 | \nNon-U.S. agency mortgage-backed securities |  | \u2014 |  |  | 2,874 |  |  | \u2014 |  |  | 2,874 | \nTotal debt securities - available-for-sale |  | 4,138 |  |  | 41,062 |  |  | 181 |  |  | 45,381 | \nEquity securities |  | 2,128 |  |  | 35 |  |  | 70 |  |  | 2,233 | \nAssets under management |  | 1,491 |  |  | 2,245 |  |  | 101 |  |  | 3,837 | \nTotal assets at fair value |  | $ | 49,608 |  |  | $ | 43,404 |  |  | $ | 352 |  |  | $ | 93,364 | \nPercentage of total assets at fair value |  | 53 | % |  | 46 | % |  | 1 | % |  | 100 | %\nDecember 31, 2022 |  |  |  |  |  |  |  | \nCash and cash equivalents |  | $ | 23,202 |  |  | $ | 163 |  |  | $ | \u2014 |  |  | $ | 23,365 | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 3,505 |  |  | 304 |  |  | \u2014 |  |  | 3,809 | \nState and municipal obligations |  | \u2014 |  |  | 7,248 |  |  | \u2014 |  |  | 7,248 | \nCorporate obligations |  | 7 |  |  | 21,695 |  |  | 192 |  |  | 21,894 | \nU.S. agency mortgage-backed securities |  | \u2014 |  |  | 6,586 |  |  | \u2014 |  |  | 6,586 | \nNon-U.S. agency mortgage-backed securities |  | \u2014 |  |  | 2,784 |  |  | \u2014 |  |  | 2,784 | \nTotal debt securities - available-for-sale |  | 3,512 |  |  | 38,617 |  |  | 192 |  |  | 42,321 | \nEquity securities |  | 2,043 |  |  | 35 |  |  | 70 |  |  | 2,148 | \nAssets under management |  | 1,788 |  |  | 2,203 |  |  | 96 |  |  | 4,087 | \nTotal assets at fair value |  | $ | 30,545 |  |  | $ | 41,018 |  |  | $ | 358 |  |  | $ | 71,921 | \nPercentage of total assets at fair value |  | 42 | % |  | 57 | % |  | 1 | % |  | 100 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | OtherObservableInputs(Level 2) |  | UnobservableInputs(Level 3) |  | TotalFairValue |  | Total Carrying Value\nMarch 31, 2023 |  |  |  |  |  |  |  |  |  | \nDebt securities - held-to-maturity |  | $ | 595 |  |  | $ | 74 |  |  | $ | \u2014 |  |  | $ | 669 |  |  | $ | 682 | \nLong-term debt and other financing obligations |  | $ | \u2014 |  |  | $ | 60,307 |  |  | $ | \u2014 |  |  | $ | 60,307 |  |  | $ | 62,360 | \nDecember 31, 2022 |  |  |  |  |  |  |  |  |  | \nDebt securities - held-to-maturity |  | $ | 577 |  |  | $ | 102 |  |  | $ | \u2014 |  |  | $ | 679 |  |  | $ | 696 | \nLong-term debt and other financing obligations |  | $ | \u2014 |  |  | $ | 53,626 |  |  | $ | \u2014 |  |  | $ | 53,626 |  |  | $ | 56,823 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | 2023 |  | 2022\nMedical costs payable, beginning of period |  | $ | 29,056 |  |  | $ | 24,483 | \nAcquisitions |  | 1 |  |  | 8 | \nReported medical costs: |  |  |  | \nCurrent year |  | 60,315 |  |  | 52,813 | \nPrior years |  | (470) |  |  | (290) | \nTotal reported medical costs |  | 59,845 |  |  | 52,523 | \nMedical payments: |  |  |  | \nPayments for current year |  | (35,087) |  |  | (29,589) | \nPayments for prior years |  | (22,006) |  |  | (18,749) | \nTotal medical payments |  | (57,093) |  |  | (48,338) | \nMedical costs payable, end of period |  | $ | 31,809 |  |  | $ | 28,676 |   |  |  |  |  |  |  |  | \n(in millions, except percentages) |  | Par Value\n4.250% notes due January 2029 |  | $ | 1,250 | \n4.500% notes due April 2033 |  | 1,500 | \n5.050% notes due April 2053 |  | 2,000 | \n5.200% notes due April 2063 |  | 1,750 |   |  |  |  |  |  |  |  | \n(in millions) |  | \nCash and cash equivalents |  | $ | 142 | \nAccounts receivable and other current assets |  | 530 | \nProperty, equipment and other long-term assets |  | 659 | \nOther intangible assets |  | 2,141 | \nTotal identifiable assets acquired |  | 3,472 | \nMedical costs payable |  | (1) | \nAccounts payable and other current liabilities |  | (467) | \nOther long-term liabilities |  | (698) | \nTotal identifiable liabilities acquired |  | (1,166) | \nTotal net identifiable assets |  | 2,306 | \nGoodwill |  | 6,646 | \nRedeemable noncontrolling interests |  | (130) | \nNonredeemable noncontrolling interests |  | (819) | \nNet assets acquired |  | $ | 8,003 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except years) |  | Fair Value |  | Weighted-Average Useful Life\nAcquired finite-lived intangible assets: |  |  |  | \nCustomer-related |  | $ | 234 |  |  | 13years\nTrademarks and technology |  | 220 |  | 5years\nOther |  | 10 |  | 11years\nTotal acquired finite-lived intangible assets |  | 464 |  |  | 9years\nTotal acquired indefinite-lived intangible assets - operating licenses and certificates |  | 1,677 |  |  | \nTotal acquired intangible assets |  | $ | 2,141 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Optum |  |  |  | \n(in millions) |  | UnitedHealthcare |  | Optum Health |  | Optum Insight |  | Optum Rx |  | Optum Eliminations |  | Optum |  | Corporate\u00a0andEliminations |  | Consolidated\nThree Months Ended March 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 67,458 |  |  | $ | 5,328 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,328 |  |  | $ | \u2014 |  |  | $ | 72,786 | \nProducts |  | \u2014 |  |  | 44 |  |  | 40 |  |  | 10,183 |  |  | \u2014 |  |  | 10,267 |  |  | \u2014 |  |  | 10,267 | \nServices |  | 2,555 |  |  | 3,089 |  |  | 1,926 |  |  | 510 |  |  | \u2014 |  |  | 5,525 |  |  | \u2014 |  |  | 8,080 | \nTotal revenues - unaffiliated customers |  | 70,013 |  |  | 8,461 |  |  | 1,966 |  |  | 10,693 |  |  | \u2014 |  |  | 21,120 |  |  | \u2014 |  |  | 91,133 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 14,266 |  |  | 2,510 |  |  | 16,679 |  |  | (859) |  |  | 32,596 |  |  | (32,596) |  |  | \u2014 | \nInvestment and other income |  | 455 |  |  | 277 |  |  | 20 |  |  | 46 |  |  | \u2014 |  |  | 343 |  |  | \u2014 |  |  | 798 | \nTotal revenues |  | $ | 70,468 |  |  | $ | 23,004 |  |  | $ | 4,496 |  |  | $ | 27,418 |  |  | $ | (859) |  |  | $ | 54,059 |  |  | $ | (32,596) |  |  | $ | 91,931 | \nEarnings from operations |  | $ | 4,343 |  |  | $ | 1,776 |  |  | $ | 907 |  |  | $ | 1,060 |  |  | $ | \u2014 |  |  | $ | 3,743 |  |  | $ | \u2014 |  |  | $ | 8,086 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (754) |  |  | (754) | \nEarnings before income taxes |  | $ | 4,343 |  |  | $ | 1,776 |  |  | $ | 907 |  |  | $ | 1,060 |  |  | $ | \u2014 |  |  | $ | 3,743 |  |  | $ | (754) |  |  | $ | 7,332 | \nThree Months Ended March 31, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 59,937 |  |  | $ | 4,133 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 4,133 |  |  | $ | \u2014 |  |  | $ | 64,070 | \nProducts |  | \u2014 |  |  | 6 |  |  | 40 |  |  | 9,294 |  |  | \u2014 |  |  | 9,340 |  |  | \u2014 |  |  | 9,340 | \nServices |  | 2,515 |  |  | 2,558 |  |  | 974 |  |  | 325 |  |  | \u2014 |  |  | 3,857 |  |  | \u2014 |  |  | 6,372 | \nTotal revenues - unaffiliated customers |  | 62,452 |  |  | 6,697 |  |  | 1,014 |  |  | 9,619 |  |  | \u2014 |  |  | 17,330 |  |  | \u2014 |  |  | 79,782 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 9,829 |  |  | 2,138 |  |  | 14,291 |  |  | (553) |  |  | 25,705 |  |  | (25,705) |  |  | \u2014 | \nInvestment and other income |  | 143 |  |  | 156 |  |  | 67 |  |  | 1 |  |  | \u2014 |  |  | 224 |  |  | \u2014 |  |  | 367 | \nTotal revenues |  | $ | 62,595 |  |  | $ | 16,682 |  |  | $ | 3,219 |  |  | $ | 23,911 |  |  | $ | (553) |  |  | $ | 43,259 |  |  | $ | (25,705) |  |  | $ | 80,149 | \nEarnings from operations |  | $ | 3,798 |  |  | $ | 1,366 |  |  | $ | 847 |  |  | $ | 939 |  |  | $ | \u2014 |  |  | $ | 3,152 |  |  | $ | \u2014 |  |  | $ | 6,950 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (433) |  |  | (433) | \nEarnings before income taxes |  | $ | 3,798 |  |  | $ | 1,366 |  |  | $ | 847 |  |  | $ | 939 |  |  | $ | \u2014 |  |  | $ | 3,152 |  |  | $ | (433) |  |  | $ | 6,517 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except percentages and per share data) |  | Three Months EndedMarch 31, |  | Increase/(Decrease)\n | 2023 |  | 2022 |  | 2023 vs. 2022\nRevenues: |  |  |  |  |  |  |  | \nPremiums |  | $ | 72,786 |  |  | $ | 64,070 |  |  | $ | 8,716 |  |  | 14 | %\nProducts |  | 10,267 |  |  | 9,340 |  |  | 927 |  |  | 10 | \nServices |  | 8,080 |  |  | 6,372 |  |  | 1,708 |  |  | 27 | \nInvestment and other income |  | 798 |  |  | 367 |  |  | 431 |  |  | 117 | \nTotal revenues |  | 91,931 |  |  | 80,149 |  |  | 11,782 |  |  | 15 | \nOperating costs: |  |  |  |  |  |  |  | \nMedical costs |  | 59,845 |  |  | 52,523 |  |  | 7,322 |  |  | 14 | \nOperating costs |  | 13,625 |  |  | 11,401 |  |  | 2,224 |  |  | 20 | \nCost of products sold |  | 9,405 |  |  | 8,487 |  |  | 918 |  |  | 11 | \nDepreciation and amortization |  | 970 |  |  | 788 |  |  | 182 |  |  | 23 | \nTotal operating costs |  | 83,845 |  |  | 73,199 |  |  | 10,646 |  |  | 15 | \nEarnings from operations |  | 8,086 |  |  | 6,950 |  |  | 1,136 |  |  | 16 | \nInterest expense |  | (754) |  |  | (433) |  |  | (321) |  |  | 74 | \nEarnings before income taxes |  | 7,332 |  |  | 6,517 |  |  | 815 |  |  | 13 | \nProvision for income taxes |  | (1,558) |  |  | (1,369) |  |  | (189) |  |  | 14 | \nNet earnings |  | 5,774 |  |  | 5,148 |  |  | 626 |  |  | 12 | \nEarnings attributable to noncontrolling interests |  | (163) |  |  | (121) |  |  | (42) |  |  | 35 | \nNet earnings attributable to UnitedHealth Group common shareholders |  | $ | 5,611 |  |  | $ | 5,027 |  |  | $ | 584 |  |  | 12 | %\nDiluted earnings per share attributable to UnitedHealth Group common shareholders |  | $ | 5.95 |  |  | $ | 5.27 |  |  | $ | 0.68 |  |  | 13 | %\nMedical care ratio (a) |  | 82.2 | % |  | 82.0 | % |  | 0.2 | % |  | \nOperating cost ratio |  | 14.8 |  |  | 14.2 |  |  | 0.6 |  |  | \nOperating margin |  | 8.8 |  |  | 8.7 |  |  | 0.1 |  |  | \nTax rate |  | 21.2 |  |  | 21.0 |  |  | 0.2 |  |  | \nNet earnings margin (b) |  | 6.1 |  |  | 6.3 |  |  | (0.2) |  |  | \nReturn on equity (c) |  | 28.2 | % |  | 27.8 | % |  | 0.4 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months EndedMarch 31, |  | Increase/(Decrease)\n(in millions, except percentages) |  | 2023 |  | 2022 |  | 2023 vs. 2022\nRevenues |  |  |  |  |  |  |  | \nUnitedHealthcare |  | $ | 70,468 |  |  | $ | 62,595 |  |  | $ | 7,873 |  |  | 13 | %\nOptum Health |  | 23,004 |  |  | 16,682 |  |  | 6,322 |  |  | 38 | \nOptum Insight |  | 4,496 |  |  | 3,219 |  |  | 1,277 |  |  | 40 | \nOptum Rx |  | 27,418 |  |  | 23,911 |  |  | 3,507 |  |  | 15 | \nOptum eliminations |  | (859) |  |  | (553) |  |  | (306) |  |  | 55 | \nOptum |  | 54,059 |  |  | 43,259 |  |  | 10,800 |  |  | 25 | \nEliminations |  | (32,596) |  |  | (25,705) |  |  | (6,891) |  |  | 27 | \nConsolidated revenues |  | $ | 91,931 |  |  | $ | 80,149 |  |  | $ | 11,782 |  |  | 15 | %\nEarnings from operations |  |  |  |  |  |  |  | \nUnitedHealthcare |  | $ | 4,343 |  |  | $ | 3,798 |  |  | $ | 545 |  |  | 14 | %\nOptum Health |  | 1,776 |  |  | 1,366 |  |  | 410 |  |  | 30 | \nOptum Insight |  | 907 |  |  | 847 |  |  | 60 |  |  | 7 | \nOptum Rx |  | 1,060 |  |  | 939 |  |  | 121 |  |  | 13 | \nOptum |  | 3,743 |  |  | 3,152 |  |  | 591 |  |  | 19 | \nConsolidated earnings from operations |  | $ | 8,086 |  |  | $ | 6,950 |  |  | $ | 1,136 |  |  | 16 | %\nOperating margin |  |  |  |  |  |  |  | \nUnitedHealthcare |  | 6.2 | % |  | 6.1 | % |  | 0.1 | % |  | \nOptum Health |  | 7.7 |  |  | 8.2 |  |  | (0.5) |  |  | \nOptum Insight |  | 20.2 |  |  | 26.3 |  |  | (6.1) |  |  | \nOptum Rx |  | 3.9 |  |  | 3.9 |  |  | \u2014 |  |  | \nOptum |  | 6.9 |  |  | 7.3 |  |  | (0.4) |  |  | \nConsolidated operating margin |  | 8.8 | % |  | 8.7 | % |  | 0.1 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, |  | Increase/(Decrease)\n(in millions, except percentages) |  | 2023 |  | 2022 |  | 2023 vs. 2022\nUnitedHealthcare Employer & Individual - Domestic |  | $ | 16,544 |  |  | $ | 15,822 |  |  | $ | 722 |  |  | 5 | %\nUnitedHealthcare Employer & Individual - Global |  | 2,163 |  |  | 2,133 |  |  | 30 |  |  | 1 | \nUnitedHealthcare Employer & Individual - Total |  | 18,707 |  |  | 17,955 |  |  | 752 |  |  | 4 | \nUnitedHealthcare Medicare & Retirement |  | 33,006 |  |  | 29,100 |  |  | 3,906 |  |  | 13 | \nUnitedHealthcare Community & State |  | 18,755 |  |  | 15,540 |  |  | 3,215 |  |  | 21 | \nTotal UnitedHealthcare revenues |  | $ | 70,468 |  |  | $ | 62,595 |  |  | $ | 7,873 |  |  | 13 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31, |  | Increase/(Decrease)\n(in thousands, except percentages) |  | 2023 |  | 2022 |  | 2023 vs. 2022\nCommercial - Domestic: |  |  |  |  |  |  |  | \nRisk-based |  | 8,025 |  |  | 7,950 |  |  | 75 |  |  | 1 | %\nFee-based |  | 19,325 |  |  | 18,460 |  |  | 865 |  |  | 5 | \nTotal Commercial - Domestic |  | 27,350 |  |  | 26,410 |  |  | 940 |  |  | 4 | \nMedicare Advantage |  | 7,545 |  |  | 6,890 |  |  | 655 |  |  | 10 | \nMedicaid |  | 8,380 |  |  | 7,810 |  |  | 570 |  |  | 7 | \nMedicare Supplement (Standardized) |  | 4,320 |  |  | 4,355 |  |  | (35) |  |  | (1) | \nTotal Community and Senior |  | 20,245 |  |  | 19,055 |  |  | 1,190 |  |  | 6 | \nTotal UnitedHealthcare - Domestic Medical |  | 47,595 |  |  | 45,465 |  |  | 2,130 |  |  | 5 | \nCommercial - Global |  | 5,295 |  |  | 5,500 |  |  | (205) |  |  | (4) | \nTotal UnitedHealthcare - Medical |  | 52,890 |  |  | 50,965 |  |  | 1,925 |  |  | 4 | %\nSupplemental Data: |  |  |  |  |  |  |  | \nMedicare Part D stand-alone |  | 3,380 |  |  | 3,360 |  |  | 20 |  |  | 1 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, |  | Increase/(Decrease)\n(in millions) |  | 2023 |  | 2022 |  | 2023 vs. 2022\nSources of cash: |  |  |  |  |  | \nCash provided by operating activities |  | $ | 16,327 |  |  | $ | 5,319 |  |  | $ | 11,008 | \nIssuances of short-term borrowings and long-term debt, net of repayments |  | 12,375 |  |  | 2,048 |  |  | 10,327 | \nProceeds from common stock issuances |  | 344 |  |  | 551 |  |  | (207) | \nCustomer funds administered |  | 5,012 |  |  | 5,120 |  |  | (108) | \nTotal sources of cash |  | 34,058 |  |  | 13,038 |  |  | \nUses of cash: |  |  |  |  |  | \nCommon stock repurchases |  | (2,000) |  |  | (2,500) |  |  | 500 | \nCash paid for acquisitions, net of cash assumed |  | (7,826) |  |  | (1,231) |  |  | (6,595) | \nPurchases of investments, net of sales and maturities |  | (2,319) |  |  | (1,632) |  |  | (687) | \nPurchases of property, equipment and capitalized software |  | (760) |  |  | (555) |  |  | (205) | \nCash dividends paid |  | (1,537) |  |  | (1,363) |  |  | (174) | \nOther |  | (1,119) |  |  | (1,807) |  |  | 688 | \nTotal uses of cash |  | (15,561) |  |  | (9,088) |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | 51 |  |  | 157 |  |  | (106) | \nNet increase in cash and cash equivalents |  | $ | 18,548 |  |  | $ | 4,107 |  |  | $ | 14,441 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Moody\u2019s |  | S&P Global |  | Fitch |  | A.M. Best\n | Ratings |  | Outlook |  | Ratings |  | Outlook |  | Ratings |  | Outlook |  | Ratings |  | Outlook\nSenior unsecured debt | A3 |  | Positive |  | A+ |  | Stable |  | A |  | Stable |  | A |  | Stable\nCommercial paper | P-2 |  | n/a |  | A-1 |  | n/a |  | F1 |  | n/a |  | AMB-1+ |  | n/a  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31, 2023\nIncrease (Decrease) in Market Interest Rate |  | InvestmentIncome\u00a0PerAnnum |  | InterestExpense\u00a0PerAnnum |  | Fair\u00a0Value\u00a0ofFinancial Assets |  | Fair\u00a0Value\u00a0ofFinancial Liabilities\n2 % |  | $ | 1,027 |  |  | $ | 487 |  |  | $ | (3,684) |  |  | $ | (8,701) | \n1 |  | 513 |  |  | 244 |  |  | (1,894) |  |  | (4,741) | \n(1) |  | (513) |  |  | (216) |  |  | 1,979 |  |  | 5,729 | \n(2) |  | (1,027) |  |  | (428) |  |  | 4,008 |  |  | 12,724 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFor the Month Ended |  | Total Number of Shares Purchased |  | Average Price Paid Per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number of Shares That May Yet Be Purchased Under The Plans or Programs\n |  | (in millions) |  |  |  | (in millions) |  | (in millions)\nJanuary 31, 2023 |  | 1.3 |  |  | $ | 495.21 |  |  | 1.3 |  |  | 29.8\nFebruary 28, 2023 |  | 1.5 |  |  | 485.22 |  |  | 1.5 |  |  | 28.3\nMarch 31, 2023 |  | 1.3 |  |  | 473.89 |  |  | 1.3 |  |  | 27.0\nTotal |  | 4.1 |  |  | $ | 484.83 |  |  | 4.1 |  |  |   |  |  |  |  |  |  |  | \n3.1 |  | Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company\u2019s Registration Statement on Form 8-A/A filed on July 1, 2015)\n3.2 |  | Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by reference to Exhibit 3.2 to UnitedHealth Group Incorporated\u2019s Current Report on Form 8-K filed on February 26, 2021)\n4.1 |  | Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company\u2019s Registration Statement on Form S-3/A, SEC File Number 333-66013, filed on January 11, 1999)\n4.2 |  | Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998, between UnitedHealth Group Incorporated and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2001)\n4.3 |  | Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant to the Senior Indenture, dated as of November 15, 1998, amended November 6, 2000, among UnitedHealth Group Incorporated, The Bank of New York and Wilmington Trust Company (incorporated by reference to Exhibit 4.3 to the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended June\u00a030, 2007)\n4.4 |  | Indenture, dated as of February\u00a04,\u00a02008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company\u2019s Registration Statement on Form S-3, SEC File Number 333-149031, filed on February\u00a04, 2008)\n31.1 |  | Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\n32.1 |  | Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\n101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n101.SCH |  | Inline XBRL Taxonomy Extension Schema Document.\n101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document.\n101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document.\n101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document.\n101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document.\n104 |  |  | Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).  |  |  |  |  |  |  |  | \n* |  | Pursuant to Item\u00a0601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n/s/    ANDREWWITTY |  | Chief Executive Officer(principal executive officer) | Dated: | May  3, 2023\nAndrew Witty |  |  | \n |  | \n/s/    JOHNREX |  | Executive Vice President andChief\u00a0Financial\u00a0Officer(principal financial officer) | Dated: | May  3, 2023\nJohn Rex |  |  | \n |  | \n/s/THOMASROOS |  | Senior Vice President andChief Accounting Officer(principal accounting officer) | Dated: | May  3, 2023\nThomas Roos |  |  | "}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For United Health Group, in 2023 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |   |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  |  |  |  |  |  |  | \nDelaware |  | 41-1321939\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)\nUnitedHealth Group Center |  | 55343\n9900 Bren Road East | \nMinnetonka, | Minnesota | \n(Address of principal executive offices) |  | (Zip Code)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered\nCommon Stock, $.01 par value |  | UNH |  | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 |  | Accelerated\u00a0filer | \u2610 |  | Non-accelerated filer | \u2610\nSmaller\u00a0reporting\u00a0company | \u2610 |  |  |  |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page\n |  |  |  | \nPart I. Financial\u00a0Information | \nItem\u00a01. | Financial Statements (unaudited) | 1\n |  | Condensed Consolidated Balance Sheets as ofJune30, 2023 and December 31, 2022 | 1\n |  | Condensed Consolidated Statements of Operations for the Threeand SixMonths EndedJune30, 2023 and 2022 | 2\n |  | Condensed Consolidated Statements of Comprehensive Income for the Threeand SixMonths EndedJune 30, 2023 and 2022 | 3\n |  | Condensed Consolidated Statements of Changes in Equity for the Threeand SixMonths EndedJune 30, 2023 and 2022 | 4\n |  | Condensed Consolidated Statements of Cash Flows for theSixMonths EndedJune 30, 2023 and 2022 | 6\n |  | Notes to the Condensed Consolidated Financial Statements | 7\n |  | 1. | Basis of Presentation | 7\n |  | 2. | Investments | 8\n |  | 3. | Fair Value | 10\n |  | 4. | Medical Costs Payable | 11\n |  | 5. | Short-Term Borrowings and Long-Term Debt | 11\n |  | 6. | Dividends | 12\n |  | 7. | Commitments and Contingencies | 12\n |  | 8. | Business Combinations | 13\n |  | 9. | Segment Financial Information | 14\nItem\u00a02. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 16\nItem\u00a03. | Quantitative and Qualitative Disclosures About Market Risk | 24\nItem\u00a04. | Controls and Procedures | 24\nPart\u00a0II. Other Information | \nItem\u00a01. | Legal Proceedings | 24\nItem\u00a01A. | Risk Factors | 24\nItem\u00a02. | Unregistered Sales of Equity Securities and Use of Proceeds | 25\nItem5. | Other Information | 25\nItem\u00a06. | Exhibits | 26\nSignatures | 27  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except per share data) |  | June 30,2023 |  | December 31,2022\nAssets |  |  |  | \nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 41,813 |  |  | $ | 23,365 | \nShort-term investments |  | 4,466 |  |  | 4,546 | \nAccounts receivable, net |  | 17,952 |  |  | 17,681 | \nOther current receivables, net |  | 16,131 |  |  | 12,769 | \nAssets under management |  | 3,623 |  |  | 4,087 | \nPrepaid expenses and other current assets |  | 5,884 |  |  | 6,621 | \nTotal current assets |  | 89,869 |  |  | 69,069 | \nLong-term investments |  | 45,988 |  |  | 43,728 | \nProperty, equipment and capitalized software, net |  | 10,926 |  |  | 10,128 | \nGoodwill |  | 101,669 |  |  | 93,352 | \nOther intangible assets, net |  | 15,643 |  |  | 14,401 | \nOther assets |  | 16,069 |  |  | 15,027 | \nTotal assets |  | $ | 280,164 |  |  | $ | 245,705 | \nLiabilities, redeemable noncontrolling interests and equity |  |  |  | \nCurrent liabilities: |  |  |  | \nMedical costs payable |  | $ | 31,947 |  |  | $ | 29,056 | \nAccounts payable and accrued liabilities |  | 29,516 |  |  | 27,715 | \nShort-term borrowings and current maturities of long-term debt |  | 6,321 |  |  | 3,110 | \nUnearned revenues |  | 14,852 |  |  | 3,075 | \nOther current liabilities |  | 30,345 |  |  | 26,281 | \nTotal current liabilities |  | 112,981 |  |  | 89,237 | \nLong-term debt, less current maturities |  | 59,268 |  |  | 54,513 | \nDeferred income taxes |  | 2,498 |  |  | 2,769 | \nOther liabilities |  | 13,261 |  |  | 12,839 | \nTotal liabilities |  | 188,008 |  |  | 159,358 | \nCommitments and contingencies (Note 7) |  |  |  | \nRedeemable noncontrolling interests |  | 4,788 |  |  | 4,897 | \nEquity: |  |  |  | \nPreferred stock, $0.001par value -10shares authorized;noshares issued or outstanding |  | \u2014 |  |  | \u2014 | \nCommon stock, $0.01par value -3,000shares authorized;927and934issued and outstanding |  | 9 |  |  | 9 | \nRetained earnings |  | 89,994 |  |  | 86,156 | \nAccumulated other comprehensive loss |  | (7,650) |  |  | (8,393) | \nNonredeemable noncontrolling interests |  | 5,015 |  |  | 3,678 | \nTotal equity |  | 87,368 |  |  | 81,450 | \nTotal liabilities, redeemable noncontrolling interests and equity |  | $ | 280,164 |  |  | $ | 245,705 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months EndedJune 30,\n(in millions, except per share data) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nRevenues: |  |  |  |  |  |  |  | \nPremiums |  | $ | 72,474 |  |  | $ | 63,896 |  |  | $ | 145,260 |  |  | $ | 127,966 | \nProducts |  | 10,651 |  |  | 9,496 |  |  | 20,918 |  |  | 18,836 | \nServices |  | 8,663 |  |  | 6,645 |  |  | 16,743 |  |  | 13,017 | \nInvestment and other income |  | 1,115 |  |  | 295 |  |  | 1,913 |  |  | 662 | \nTotal revenues |  | 92,903 |  |  | 80,332 |  |  | 184,834 |  |  | 160,481 | \nOperating costs: |  |  |  |  |  |  |  | \nMedical costs |  | 60,268 |  |  | 52,093 |  |  | 120,113 |  |  | 104,616 | \nOperating costs |  | 13,809 |  |  | 11,709 |  |  | 27,434 |  |  | 23,110 | \nCost of products sold |  | 9,748 |  |  | 8,596 |  |  | 19,153 |  |  | 17,083 | \nDepreciation and amortization |  | 1,021 |  |  | 802 |  |  | 1,991 |  |  | 1,590 | \nTotal operating costs |  | 84,846 |  |  | 73,200 |  |  | 168,691 |  |  | 146,399 | \nEarnings from operations |  | 8,057 |  |  | 7,132 |  |  | 16,143 |  |  | 14,082 | \nInterest expense |  | (828) |  |  | (467) |  |  | (1,582) |  |  | (900) | \nEarnings before income taxes |  | 7,229 |  |  | 6,665 |  |  | 14,561 |  |  | 13,182 | \nProvision for income taxes |  | (1,572) |  |  | (1,466) |  |  | (3,130) |  |  | (2,835) | \nNet earnings |  | 5,657 |  |  | 5,199 |  |  | 11,431 |  |  | 10,347 | \nEarnings attributable to noncontrolling interests |  | (183) |  |  | (129) |  |  | (346) |  |  | (250) | \nNet earnings attributable to UnitedHealth Group common shareholders |  | $ | 5,474 |  |  | $ | 5,070 |  |  | 11,085 |  |  | $ | 10,097 | \nEarnings per share attributable to UnitedHealth Group common shareholders: |  |  |  |  |  |  |  | \nBasic |  | $ | 5.89 |  |  | $ | 5.41 |  |  | $ | 11.91 |  |  | $ | 10.75 | \nDiluted |  | $ | 5.82 |  |  | $ | 5.34 |  |  | $ | 11.77 |  |  | $ | 10.61 | \nBasic weighted-average number of common shares outstanding |  | 930 |  |  | 937 |  |  | 931 |  |  | 939 | \nDilutive effect of common share equivalents |  | 10 |  |  | 13 |  |  | 11 |  |  | 13 | \nDiluted weighted-average number of common shares outstanding |  | 940 |  |  | 950 |  |  | 942 |  |  | 952 | \nAnti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents |  | 7 |  |  | 3 |  |  | 6 |  |  | 3 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months EndedJune 30,\n(in millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nNet earnings |  | $ | 5,657 |  |  | $ | 5,199 |  |  | $ | 11,431 |  |  | $ | 10,347 | \nOther comprehensive (loss) income: |  |  |  |  |  |  |  | \nGross unrealized (losses) gains on investment securities during the period |  | (431) |  |  | (1,331) |  |  | 209 |  |  | (3,354) | \nIncome tax effect |  | 99 |  |  | 304 |  |  | (48) |  |  | 769 | \nTotal unrealized (losses) gains, net of tax |  | (332) |  |  | (1,027) |  |  | 161 |  |  | (2,585) | \nGross reclassification adjustment for net realized gains included in net earnings |  | (47) |  |  | (1) |  |  | (34) |  |  | (4) | \nIncome tax effect |  | 11 |  |  | \u2014 |  |  | 8 |  |  | 1 | \nTotal reclassification adjustment, net of tax |  | (36) |  |  | (1) |  |  | (26) |  |  | (3) | \nTotal foreign currency translation gains (losses) |  | 267 |  |  | (676) |  |  | 608 |  |  | 242 | \nOther comprehensive (loss) income |  | (101) |  |  | (1,704) |  |  | 743 |  |  | (2,346) | \nComprehensive income |  | 5,556 |  |  | 3,495 |  |  | 12,174 |  |  | 8,001 | \nComprehensive income attributable to noncontrolling interests |  | (183) |  |  | (129) |  |  | (346) |  |  | (250) | \nComprehensive income attributable to UnitedHealth Group common shareholders |  | $ | 5,373 |  |  | $ | 3,366 |  |  | $ | 11,828 |  |  | $ | 7,751 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Common Stock |  | Additional Paid-In Capital |  | Retained Earnings |  | Accumulated Other Comprehensive(Loss) Income |  | Nonredeemable Noncontrolling Interests |  | TotalEquity\nThree months ended June 30,(in millions) |  | Shares |  | Amount |  |  |  | Net Unrealized (Losses) Gains on Investments |  | Foreign Currency Translation (Losses) Gains |  | \nBalance at March 31, 2023 |  | 932 |  |  | $ | 9 |  |  | $ | \u2014 |  |  | $ | 88,852 |  |  | $ | (2,275) |  |  | $ | (5,274) |  |  | $ | 4,509 |  |  | $ | 85,821 | \nNet earnings |  |  |  |  |  |  |  | 5,474 |  |  |  |  |  |  | 139 |  |  | 5,613 | \nOther comprehensive (loss) income |  |  |  |  |  |  |  |  |  | (368) |  |  | 267 |  |  |  |  | (101) | \nIssuances of common stock, and related tax effects |  | 1 |  |  | \u2014 |  |  | 218 |  |  |  |  |  |  |  |  |  |  | 218 | \nShare-based compensation |  |  |  |  |  | 232 |  |  |  |  |  |  |  |  |  |  | 232 | \nCommon share repurchases |  | (6) |  |  | \u2014 |  |  | (442) |  |  | (2,585) |  |  |  |  |  |  |  |  | (3,027) | \nCash dividends paid on common shares ($1.88per share) |  |  |  |  |  |  |  | (1,747) |  |  |  |  |  |  |  |  | (1,747) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | (8) |  |  |  |  |  |  |  |  |  |  | (8) | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 478 |  |  | 478 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (111) |  |  | (111) | \nBalance at June 30, 2023 |  | 927 |  |  | $ | 9 |  |  | $ | \u2014 |  |  | $ | 89,994 |  |  | $ | (2,643) |  |  | $ | (5,007) |  |  | $ | 5,015 |  |  | $ | 87,368 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at March 31, 2022 |  | 939 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 78,782 |  |  | $ | (1,137) |  |  | $ | (4,889) |  |  | $ | 3,362 |  |  | $ | 76,128 | \nNet earnings |  |  |  |  |  |  |  | 5,070 |  |  |  |  |  |  | 94 |  |  | 5,164 | \nOther comprehensive loss |  |  |  |  |  |  |  |  |  | (1,028) |  |  | (676) |  |  |  |  | (1,704) | \nIssuances of common stock, and related tax effects |  | 1 |  |  | \u2014 |  |  | 174 |  |  |  |  |  |  |  |  |  |  | 174 | \nShare-based compensation |  |  |  |  |  | 194 |  |  |  |  |  |  |  |  |  |  | 194 | \nCommon share repurchases |  | (5) |  |  | \u2014 |  |  | (733) |  |  | (1,767) |  |  |  |  |  |  |  |  | (2,500) | \nCash dividends paid on common shares ($1.65per share) |  |  |  |  |  |  |  | (1,545) |  |  |  |  |  |  |  |  | (1,545) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | 365 |  |  |  |  |  |  |  |  |  |  | 365 | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 12 |  |  | 12 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (83) |  |  | (83) | \nBalance at June 30, 2022 |  | 935 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 80,540 |  |  | $ | (2,165) |  |  | $ | (5,565) |  |  | $ | 3,385 |  |  | $ | 76,205 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Common Stock |  | Additional Paid-In Capital |  | Retained Earnings |  | Accumulated Other Comprehensive(Loss) Income |  | Nonredeemable Noncontrolling Interests |  | TotalEquity\nSix months ended March 31,(in millions) |  | Shares |  | Amount |  |  |  | Net Unrealized (Losses) Gains on Investments |  | Foreign Currency Translation (Losses) Gains |  | \nBalance at January 1, 2023 |  | 934 |  |  | $ | 9 |  |  | $ | \u2014 |  |  | $ | 86,156 |  |  | $ | (2,778) |  |  | $ | (5,615) |  |  | $ | 3,678 |  |  | $ | 81,450 | \nNet earnings |  |  |  |  |  |  |  | 11,085 |  |  |  |  |  |  | 252 |  |  | 11,337 | \nOther comprehensive income |  |  |  |  |  |  |  |  |  | 135 |  |  | 608 |  |  |  |  | 743 | \nIssuances of common stock, and related tax effects |  | 3 |  |  | \u2014 |  |  | 568 |  |  |  |  |  |  |  |  |  |  | 568 | \nShare-based compensation |  |  |  |  |  | 598 |  |  |  |  |  |  |  |  |  |  | 598 | \nCommon share repurchases |  | (10) |  |  | \u2014 |  |  | (1,075) |  |  | (3,963) |  |  |  |  |  |  |  |  | (5,038) | \nCash dividends paid on common shares ($3.53per share) |  |  |  |  |  |  |  | (3,284) |  |  |  |  |  |  |  |  | (3,284) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | (91) |  |  |  |  |  |  |  |  |  |  | (91) | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,297 |  |  | 1,297 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (212) |  |  | (212) | \nBalance at June 30, 2023 |  | 927 |  |  | $ | 9 |  |  | $ | \u2014 |  |  | $ | 89,994 |  |  | $ | (2,643) |  |  | $ | (5,007) |  |  | $ | 5,015 |  |  | $ | 87,368 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at January 1, 2022 |  | 941 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 77,134 |  |  | $ | 423 |  |  | $ | (5,807) |  |  | $ | 3,285 |  |  | $ | 75,045 | \nNet earnings |  |  |  |  |  |  |  | 10,097 |  |  |  |  |  |  | 182 |  |  | 10,279 | \nOther comprehensive (loss) income |  |  |  |  |  |  |  |  |  | (2,588) |  |  | 242 |  |  |  |  | (2,346) | \nIssuances of common stock, and related tax effects |  | 4 |  |  | \u2014 |  |  | 507 |  |  |  |  |  |  |  |  |  |  | 507 | \nShare-based compensation |  |  |  |  |  | 476 |  |  |  |  |  |  |  |  |  |  | 476 | \nCommon share repurchases |  | (10) |  |  | \u2014 |  |  | (1,217) |  |  | (3,783) |  |  |  |  |  |  |  |  | (5,000) | \nCash dividends paid on common shares ($3.10per share) |  |  |  |  |  |  |  | (2,908) |  |  |  |  |  |  |  |  | (2,908) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | 234 |  |  |  |  |  |  |  |  |  |  | 234 | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 103 |  |  | 103 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (185) |  |  | (185) | \nBalance at June 30, 2022 |  | 935 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 80,540 |  |  | $ | (2,165) |  |  | $ | (5,565) |  |  | $ | 3,385 |  |  | $ | 76,205 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months EndedJune 30,\n(in millions) |  | 2023 |  | 2022\nOperating activities |  |  |  | \nNet earnings |  | $ | 11,431 |  |  | $ | 10,347 | \nNoncash items: |  |  |  | \nDepreciation and amortization |  | 1,991 |  |  | 1,590 | \nDeferred income taxes |  | (482) |  |  | (15) | \nShare-based compensation |  | 604 |  |  | 504 | \nOther, net |  | (91) |  |  | 215 | \nNet change in other operating items, net of effects from acquisitions and changes in AARP balances: |  |  |  | \nAccounts receivable |  | 197 |  |  | (4,204) | \nOther assets |  | (2,001) |  |  | (643) | \nMedical costs payable |  | 2,408 |  |  | 4,029 | \nAccounts payable and other liabilities |  | 1,547 |  |  | 807 | \nUnearned revenues |  | 11,755 |  |  | (440) | \nCash flows from operating activities |  | 27,359 |  |  | 12,190 | \nInvesting activities |  |  |  | \nPurchases of investments |  | (9,225) |  |  | (8,903) | \nSales of investments |  | 3,188 |  |  | 2,348 | \nMaturities of investments |  | 4,463 |  |  | 3,189 | \nCash paid for acquisitions, net of cash assumed |  | (8,161) |  |  | (7,150) | \nPurchases of property, equipment and capitalized software |  | (1,589) |  |  | (1,212) | \nOther, net |  | (424) |  |  | (532) | \nCash flows used for investing activities |  | (11,748) |  |  | (12,260) | \nFinancing activities |  |  |  | \nCommon share repurchases |  | (5,000) |  |  | (5,000) | \nCash dividends paid |  | (3,284) |  |  | (2,908) | \nProceeds from common stock issuances |  | 628 |  |  | 756 | \nRepayments of long-term debt |  | (2,125) |  |  | (1,100) | \nProceeds from short-term borrowings, net |  | 3,426 |  |  | 1,340 | \nProceeds from issuance of long-term debt |  | 6,394 |  |  | 5,922 | \nCustomer funds administered |  | 4,069 |  |  | 5,786 | \nOther, net |  | (1,377) |  |  | (1,546) | \nCash flows from financing activities |  | 2,731 |  |  | 3,250 | \nEffect of exchange rate changes on cash and cash equivalents |  | 106 |  |  | 57 | \nIncrease in cash and cash equivalents |  | 18,448 |  |  | 3,237 | \nCash and cash equivalents, beginning of period |  | 23,365 |  |  | 21,375 | \nCash and cash equivalents, end of period |  | $ | 41,813 |  |  | $ | 24,612 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | AmortizedCost |  | GrossUnrealizedGains |  | GrossUnrealizedLosses |  | FairValue\nJune 30, 2023 |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 4,990 |  |  | $ | \u2014 |  |  | $ | (283) |  |  | $ | 4,707 | \nState and municipal obligations |  | 7,334 |  |  | 10 |  |  | (427) |  |  | 6,917 | \nCorporate obligations |  | 23,582 |  |  | 11 |  |  | (1,643) |  |  | 21,950 | \nU.S. agency mortgage-backed securities |  | 8,504 |  |  | 5 |  |  | (799) |  |  | 7,710 | \nNon-U.S. agency mortgage-backed securities |  | 3,148 |  |  | \u2014 |  |  | (304) |  |  | 2,844 | \nTotal debt securities - available-for-sale |  | 47,558 |  |  | 26 |  |  | (3,456) |  |  | 44,128 | \nDebt securities - held-to-maturity: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 466 |  |  | \u2014 |  |  | (11) |  |  | 455 | \nState and municipal obligations |  | 28 |  |  | \u2014 |  |  | (3) |  |  | 25 | \nCorporate obligations |  | 246 |  |  | \u2014 |  |  | \u2014 |  |  | 246 | \nTotal debt securities - held-to-maturity |  | 740 |  |  | \u2014 |  |  | (14) |  |  | 726 | \nTotal debt securities |  | $ | 48,298 |  |  | $ | 26 |  |  | $ | (3,470) |  |  | $ | 44,854 | \nDecember 31, 2022 |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 4,093 |  |  | $ | 1 |  |  | $ | (285) |  |  | $ | 3,809 | \nState and municipal obligations |  | 7,702 |  |  | 25 |  |  | (479) |  |  | 7,248 | \nCorporate obligations |  | 23,675 |  |  | 17 |  |  | (1,798) |  |  | 21,894 | \nU.S. agency mortgage-backed securities |  | 7,379 |  |  | 15 |  |  | (808) |  |  | 6,586 | \nNon-U.S. agency mortgage-backed securities |  | 3,077 |  |  | 1 |  |  | (294) |  |  | 2,784 | \nTotal debt securities - available-for-sale |  | 45,926 |  |  | 59 |  |  | (3,664) |  |  | 42,321 | \nDebt securities - held-to-maturity: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 578 |  |  | \u2014 |  |  | (14) |  |  | 564 | \nState and municipal obligations |  | 29 |  |  | \u2014 |  |  | (3) |  |  | 26 | \nCorporate obligations |  | 89 |  |  | \u2014 |  |  | \u2014 |  |  | 89 | \nTotal debt securities - held-to-maturity |  | 696 |  |  | \u2014 |  |  | (17) |  |  | 679 | \nTotal debt securities |  | $ | 46,622 |  |  | $ | 59 |  |  | $ | (3,681) |  |  | $ | 43,000 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Available-for-Sale |  | Held-to-Maturity\n(in millions) |  | AmortizedCost |  | FairValue |  | AmortizedCost |  | FairValue\nDue in one year or less |  | $ | 4,646 |  |  | $ | 4,613 |  |  | $ | 466 |  |  | $ | 461 | \nDue after one year through five years |  | 14,748 |  |  | 13,935 |  |  | 225 |  |  | 219 | \nDue after five years through ten years |  | 11,332 |  |  | 10,206 |  |  | 31 |  |  | 30 | \nDue after ten years |  | 5,180 |  |  | 4,820 |  |  | 18 |  |  | 16 | \nU.S. agency mortgage-backed securities |  | 8,504 |  |  | 7,710 |  |  | \u2014 |  |  | \u2014 | \nNon-U.S. agency mortgage-backed securities |  | 3,148 |  |  | 2,844 |  |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 47,558 |  |  | $ | 44,128 |  |  | $ | 740 |  |  | $ | 726 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Less Than 12 Months |  | 12 Months or Greater |  | Total\n(in millions) |  | FairValue |  | GrossUnrealizedLosses |  | FairValue |  | GrossUnrealizedLosses |  | FairValue |  | GrossUnrealizedLosses\nJune 30, 2023 |  |  |  |  |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 2,300 |  |  | $ | (28) |  |  | $ | 1,902 |  |  | $ | (255) |  |  | $ | 4,202 |  |  | $ | (283) | \nState and municipal obligations |  | 2,769 |  |  | (46) |  |  | 3,324 |  |  | (381) |  |  | 6,093 |  |  | (427) | \nCorporate obligations |  | 6,346 |  |  | (122) |  |  | 13,974 |  |  | (1,521) |  |  | 20,320 |  |  | (1,643) | \nU.S. agency mortgage-backed securities |  | 3,111 |  |  | (79) |  |  | 4,314 |  |  | (720) |  |  | 7,425 |  |  | (799) | \nNon-U.S. agency mortgage-backed securities |  | 577 |  |  | (15) |  |  | 2,239 |  |  | (289) |  |  | 2,816 |  |  | (304) | \nTotal debt securities - available-for-sale |  | $ | 15,103 |  |  | $ | (290) |  |  | $ | 25,753 |  |  | $ | (3,166) |  |  | $ | 40,856 |  |  | $ | (3,456) | \nDecember 31, 2022 |  |  |  |  |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 2,007 |  |  | $ | (96) |  |  | $ | 1,290 |  |  | $ | (189) |  |  | $ | 3,297 |  |  | $ | (285) | \nState and municipal obligations |  | 4,630 |  |  | (288) |  |  | 1,178 |  |  | (191) |  |  | 5,808 |  |  | (479) | \nCorporate obligations |  | 13,003 |  |  | (893) |  |  | 6,637 |  |  | (905) |  |  | 19,640 |  |  | (1,798) | \nU.S. agency mortgage-backed securities |  | 3,561 |  |  | (345) |  |  | 2,239 |  |  | (463) |  |  | 5,800 |  |  | (808) | \nNon-U.S. agency mortgage-backed securities |  | 1,698 |  |  | (128) |  |  | 976 |  |  | (166) |  |  | 2,674 |  |  | (294) | \nTotal debt securities - available-for-sale |  | $ | 24,899 |  |  | $ | (1,750) |  |  | $ | 12,320 |  |  | $ | (1,914) |  |  | $ | 37,219 |  |  | $ | (3,664) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | OtherObservableInputs(Level 2) |  | UnobservableInputs(Level 3) |  | TotalFair and CarryingValue\nJune 30, 2023 |  |  |  |  |  |  |  | \nCash and cash equivalents |  | $ | 41,763 |  |  | $ | 50 |  |  | $ | \u2014 |  |  | $ | 41,813 | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 4,318 |  |  | 389 |  |  | \u2014 |  |  | 4,707 | \nState and municipal obligations |  | \u2014 |  |  | 6,917 |  |  | \u2014 |  |  | 6,917 | \nCorporate obligations |  | 36 |  |  | 21,732 |  |  | 182 |  |  | 21,950 | \nU.S. agency mortgage-backed securities |  | \u2014 |  |  | 7,710 |  |  | \u2014 |  |  | 7,710 | \nNon-U.S. agency mortgage-backed securities |  | \u2014 |  |  | 2,844 |  |  | \u2014 |  |  | 2,844 | \nTotal debt securities - available-for-sale |  | 4,354 |  |  | 39,592 |  |  | 182 |  |  | 44,128 | \nEquity securities |  | 2,270 |  |  | 37 |  |  | 70 |  |  | 2,377 | \nAssets under management |  | 1,332 |  |  | 2,190 |  |  | 101 |  |  | 3,623 | \nTotal assets at fair value |  | $ | 49,719 |  |  | $ | 41,869 |  |  | $ | 353 |  |  | $ | 91,941 | \nPercentage of total assets at fair value |  | 54 | % |  | 45 | % |  | 1 | % |  | 100 | %\nDecember 31, 2022 |  |  |  |  |  |  |  | \nCash and cash equivalents |  | $ | 23,202 |  |  | $ | 163 |  |  | $ | \u2014 |  |  | $ | 23,365 | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 3,505 |  |  | 304 |  |  | \u2014 |  |  | 3,809 | \nState and municipal obligations |  | \u2014 |  |  | 7,248 |  |  | \u2014 |  |  | 7,248 | \nCorporate obligations |  | 7 |  |  | 21,695 |  |  | 192 |  |  | 21,894 | \nU.S. agency mortgage-backed securities |  | \u2014 |  |  | 6,586 |  |  | \u2014 |  |  | 6,586 | \nNon-U.S. agency mortgage-backed securities |  | \u2014 |  |  | 2,784 |  |  | \u2014 |  |  | 2,784 | \nTotal debt securities - available-for-sale |  | 3,512 |  |  | 38,617 |  |  | 192 |  |  | 42,321 | \nEquity securities |  | 2,043 |  |  | 35 |  |  | 70 |  |  | 2,148 | \nAssets under management |  | 1,788 |  |  | 2,203 |  |  | 96 |  |  | 4,087 | \nTotal assets at fair value |  | $ | 30,545 |  |  | $ | 41,018 |  |  | $ | 358 |  |  | $ | 71,921 | \nPercentage of total assets at fair value |  | 42 | % |  | 57 | % |  | 1 | % |  | 100 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | OtherObservableInputs(Level 2) |  | UnobservableInputs(Level 3) |  | TotalFairValue |  | Total Carrying Value\nJune 30, 2023 |  |  |  |  |  |  |  |  |  | \nDebt securities - held-to-maturity |  | $ | 651 |  |  | $ | 75 |  |  | $ | \u2014 |  |  | $ | 726 |  |  | $ | 740 | \nLong-term debt and other financing obligations |  | $ | \u2014 |  |  | $ | 58,644 |  |  | $ | \u2014 |  |  | $ | 58,644 |  |  | $ | 61,217 | \nDecember 31, 2022 |  |  |  |  |  |  |  |  |  | \nDebt securities - held-to-maturity |  | $ | 577 |  |  | $ | 102 |  |  | $ | \u2014 |  |  | $ | 679 |  |  | $ | 696 | \nLong-term debt and other financing obligations |  | $ | \u2014 |  |  | $ | 53,626 |  |  | $ | \u2014 |  |  | $ | 53,626 |  |  | $ | 56,823 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | 2023 |  | 2022\nMedical costs payable, beginning of period |  | $ | 29,056 |  |  | $ | 24,483 | \nAcquisitions |  | 1 |  |  | 171 | \nReported medical costs: |  |  |  | \nCurrent year |  | 120,773 |  |  | 104,936 | \nPrior years |  | (660) |  |  | (320) | \nTotal reported medical costs |  | 120,113 |  |  | 104,616 | \nMedical payments: |  |  |  | \nPayments for current year |  | (91,621) |  |  | (78,937) | \nPayments for prior years |  | (25,602) |  |  | (21,355) | \nTotal medical payments |  | (117,223) |  |  | (100,292) | \nMedical costs payable, end of period |  | $ | 31,947 |  |  | $ | 28,978 |   |  |  |  |  |  |  |  | \n(in millions, except percentages) |  | Par Value\n4.250% notes due January 2029 |  | $ | 1,250 | \n4.500% notes due April 2033 |  | 1,500 | \n5.050% notes due April 2053 |  | 2,000 | \n5.200% notes due April 2063 |  | 1,750 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPayment Date |  | Amount per Share |  | Total Amount Paid\n |  |  |  | (in millions)\nMarch 21 |  | $ | 1.65 |  |  | $ | 1,537 | \nJune 27 |  | 1.88 |  |  | 1,747 |   |  |  |  |  |  |  |  | \n(in millions) |  | \nCash and cash equivalents |  | $ | 104 | \nAccounts receivable and other current assets |  | 550 | \nProperty, equipment and other long-term assets |  | 542 | \nOther intangible assets |  | 1,795 | \nTotal identifiable assets acquired |  | 2,991 | \nMedical costs payable |  | (1) | \nAccounts payable and other current liabilities |  | (473) | \nOther long-term liabilities |  | (617) | \nTotal identifiable liabilities acquired |  | (1,091) | \nTotal net identifiable assets |  | 1,900 | \nGoodwill |  | 7,734 | \nRedeemable noncontrolling interests |  | (113) | \nNonredeemable noncontrolling interests |  | (1,297) | \nNet assets acquired |  | $ | 8,224 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except years) |  | Fair Value |  | Weighted-Average Useful Life\nAcquired finite-lived intangible assets: |  |  |  | \nCustomer-related |  | $ | 223 |  |  | 12years\nTrademarks and technology |  | 171 |  |  | 5years\nOther |  | 38 |  |  | 6years\nTotal acquired finite-lived intangible assets |  | 432 |  |  | 9years\nTotal acquired indefinite-lived intangible assets - operating licenses and certificates |  | 1,363 |  |  | \nTotal acquired intangible assets |  | $ | 1,795 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Optum |  |  |  | \n(in millions) |  | UnitedHealthcare |  | Optum Health |  | Optum Insight |  | Optum Rx |  | Optum Eliminations |  | Optum |  | Corporate\u00a0andEliminations |  | Consolidated\nThree Months Ended June 30, 2023 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 67,047 |  |  | $ | 5,427 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,427 |  |  | $ | \u2014 |  |  | $ | 72,474 | \nProducts |  | \u2014 |  |  | 51 |  |  | 39 |  |  | 10,561 |  |  | \u2014 |  |  | 10,651 |  |  | \u2014 |  |  | 10,651 | \nServices |  | 2,584 |  |  | 3,541 |  |  | 1,995 |  |  | 543 |  |  | \u2014 |  |  | 6,079 |  |  | \u2014 |  |  | 8,663 | \nTotal revenues - unaffiliated customers |  | 69,631 |  |  | 9,019 |  |  | 2,034 |  |  | 11,104 |  |  | \u2014 |  |  | 22,157 |  |  | \u2014 |  |  | 91,788 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 14,454 |  |  | 2,615 |  |  | 17,496 |  |  | (893) |  |  | 33,672 |  |  | (33,672) |  |  | \u2014 | \nInvestment and other income |  | 600 |  |  | 444 |  |  | 25 |  |  | 46 |  |  | \u2014 |  |  | 515 |  |  | \u2014 |  |  | 1,115 | \nTotal revenues |  | $ | 70,231 |  |  | $ | 23,917 |  |  | $ | 4,674 |  |  | $ | 28,646 |  |  | $ | (893) |  |  | $ | 56,344 |  |  | $ | (33,672) |  |  | $ | 92,903 | \nEarnings from operations |  | $ | 4,358 |  |  | $ | 1,525 |  |  | $ | 968 |  |  | $ | 1,206 |  |  | $ | \u2014 |  |  | $ | 3,699 |  |  | $ | \u2014 |  |  | $ | 8,057 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (828) |  |  | (828) | \nEarnings before income taxes |  | $ | 4,358 |  |  | $ | 1,525 |  |  | $ | 968 |  |  | $ | 1,206 |  |  | $ | \u2014 |  |  | $ | 3,699 |  |  | $ | (828) |  |  | $ | 7,229 | \nThree Months Ended June 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 59,368 |  |  | $ | 4,528 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 4,528 |  |  | $ | \u2014 |  |  | $ | 63,896 | \nProducts |  | \u2014 |  |  | 6 |  |  | 58 |  |  | 9,432 |  |  | \u2014 |  |  | 9,496 |  |  | \u2014 |  |  | 9,496 | \nServices |  | 2,542 |  |  | 2,740 |  |  | 1,034 |  |  | 329 |  |  | \u2014 |  |  | 4,103 |  |  | \u2014 |  |  | 6,645 | \nTotal revenues - unaffiliated customers |  | 61,910 |  |  | 7,274 |  |  | 1,092 |  |  | 9,761 |  |  | \u2014 |  |  | 18,127 |  |  | \u2014 |  |  | 80,037 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 10,224 |  |  | 2,181 |  |  | 15,038 |  |  | (588) |  |  | 26,855 |  |  | (26,855) |  |  | \u2014 | \nInvestment and other income |  | 195 |  |  | 85 |  |  | 9 |  |  | 6 |  |  | \u2014 |  |  | 100 |  |  | \u2014 |  |  | 295 | \nTotal revenues |  | $ | 62,105 |  |  | $ | 17,583 |  |  | $ | 3,282 |  |  | $ | 24,805 |  |  | $ | (588) |  |  | $ | 45,082 |  |  | $ | (26,855) |  |  | $ | 80,332 | \nEarnings from operations |  | $ | 3,850 |  |  | $ | 1,399 |  |  | $ | 839 |  |  | $ | 1,044 |  |  | $ | \u2014 |  |  | $ | 3,282 |  |  | $ | \u2014 |  |  | $ | 7,132 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (467) |  |  | (467) | \nEarnings before income taxes |  | $ | 3,850 |  |  | $ | 1,399 |  |  | $ | 839 |  |  | $ | 1,044 |  |  | $ | \u2014 |  |  | $ | 3,282 |  |  | $ | (467) |  |  | $ | 6,665 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Optum |  |  |  | \n(in millions) |  | UnitedHealthcare |  | Optum Health |  | Optum Insight |  | Optum Rx |  | Optum Eliminations |  | Optum |  | Corporate\u00a0andEliminations |  | Consolidated\nSix Months Ended June 30, 2023 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 134,505 |  |  | $ | 10,755 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 10,755 |  |  | $ | \u2014 |  |  | $ | 145,260 | \nProducts |  | \u2014 |  |  | 95 |  |  | 79 |  |  | 20,744 |  |  | \u2014 |  |  | 20,918 |  |  | \u2014 |  |  | 20,918 | \nServices |  | 5,139 |  |  | 6,630 |  |  | 3,921 |  |  | 1,053 |  |  | \u2014 |  |  | 11,604 |  |  | \u2014 |  |  | 16,743 | \nTotal revenues - unaffiliated customers |  | 139,644 |  |  | 17,480 |  |  | 4,000 |  |  | 21,797 |  |  | \u2014 |  |  | 43,277 |  |  | \u2014 |  |  | 182,921 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 28,720 |  |  | 5,125 |  |  | 34,175 |  |  | (1,752) |  |  | 66,268 |  |  | (66,268) |  |  | \u2014 | \nInvestment and other income |  | 1,055 |  |  | 721 |  |  | 45 |  |  | 92 |  |  | \u2014 |  |  | 858 |  |  | \u2014 |  |  | 1,913 | \nTotal revenues |  | $ | 140,699 |  |  | $ | 46,921 |  |  | $ | 9,170 |  |  | $ | 56,064 |  |  | $ | (1,752) |  |  | $ | 110,403 |  |  | $ | (66,268) |  |  | $ | 184,834 | \nEarnings from operations |  | $ | 8,701 |  |  | $ | 3,301 |  |  | $ | 1,875 |  |  | $ | 2,266 |  |  | $ | \u2014 |  |  | $ | 7,442 |  |  | $ | \u2014 |  |  | $ | 16,143 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,582) |  |  | (1,582) | \nEarnings before income taxes |  | $ | 8,701 |  |  | $ | 3,301 |  |  | $ | 1,875 |  |  | $ | 2,266 |  |  | $ | \u2014 |  |  | $ | 7,442 |  |  | $ | (1,582) |  |  | $ | 14,561 | \nSix Months Ended June 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 119,305 |  |  | $ | 8,661 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 8,661 |  |  | $ | \u2014 |  |  | $ | 127,966 | \nProducts |  | \u2014 |  |  | 12 |  |  | 98 |  |  | 18,726 |  |  | \u2014 |  |  | 18,836 |  |  | \u2014 |  |  | 18,836 | \nServices |  | 5,057 |  |  | 5,298 |  |  | 2,008 |  |  | 654 |  |  | \u2014 |  |  | 7,960 |  |  | \u2014 |  |  | 13,017 | \nTotal revenues - unaffiliated customers |  | 124,362 |  |  | 13,971 |  |  | 2,106 |  |  | 19,380 |  |  | \u2014 |  |  | 35,457 |  |  | \u2014 |  |  | 159,819 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 20,053 |  |  | 4,319 |  |  | 29,329 |  |  | (1,141) |  |  | 52,560 |  |  | (52,560) |  |  | \u2014 | \nInvestment and other income |  | 338 |  |  | 241 |  |  | 76 |  |  | 7 |  |  | \u2014 |  |  | 324 |  |  | \u2014 |  |  | 662 | \nTotal revenues |  | $ | 124,700 |  |  | $ | 34,265 |  |  | $ | 6,501 |  |  | $ | 48,716 |  |  | $ | (1,141) |  |  | $ | 88,341 |  |  | $ | (52,560) |  |  | $ | 160,481 | \nEarnings from operations |  | $ | 7,648 |  |  | $ | 2,765 |  |  | $ | 1,686 |  |  | $ | 1,983 |  |  | $ | \u2014 |  |  | $ | 6,434 |  |  | $ | \u2014 |  |  | $ | 14,082 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (900) |  |  | (900) | \nEarnings before income taxes |  | $ | 7,648 |  |  | $ | 2,765 |  |  | $ | 1,686 |  |  | $ | 1,983 |  |  | $ | \u2014 |  |  | $ | 6,434 |  |  | $ | (900) |  |  | $ | 13,182 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except percentages and per share data) |  | Three Months EndedJune 30, |  | Increase/(Decrease) |  | Six Months EndedJune 30, |  | Increase/(Decrease)\n | 2023 |  | 2022 |  | 2023 vs. 2022 |  | 2023 |  | 2022 |  | 2023 vs. 2022\nRevenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 72,474 |  |  | $ | 63,896 |  |  | $ | 8,578 |  |  | 13 | % |  | $ | 145,260 |  |  | $ | 127,966 |  |  | $ | 17,294 |  |  | 14 | %\nProducts |  | 10,651 |  |  | 9,496 |  |  | 1,155 |  |  | 12 |  |  | 20,918 |  |  | 18,836 |  |  | 2,082 |  |  | 11 | \nServices |  | 8,663 |  |  | 6,645 |  |  | 2,018 |  |  | 30 |  |  | 16,743 |  |  | 13,017 |  |  | 3,726 |  |  | 29 | \nInvestment and other income |  | 1,115 |  |  | 295 |  |  | 820 |  |  | 278 |  |  | 1,913 |  |  | 662 |  |  | 1,251 |  |  | 189 | \nTotal revenues |  | 92,903 |  |  | 80,332 |  |  | 12,571 |  |  | 16 |  |  | 184,834 |  |  | 160,481 |  |  | 24,353 |  |  | 15 | \nOperating costs: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMedical costs |  | 60,268 |  |  | 52,093 |  |  | 8,175 |  |  | 16 |  |  | 120,113 |  |  | 104,616 |  |  | 15,497 |  |  | 15 | \nOperating costs |  | 13,809 |  |  | 11,709 |  |  | 2,100 |  |  | 18 |  |  | 27,434 |  |  | 23,110 |  |  | 4,324 |  |  | 19 | \nCost of products sold |  | 9,748 |  |  | 8,596 |  |  | 1,152 |  |  | 13 |  |  | 19,153 |  |  | 17,083 |  |  | 2,070 |  |  | 12 | \nDepreciation and amortization |  | 1,021 |  |  | 802 |  |  | 219 |  |  | 27 |  |  | 1,991 |  |  | 1,590 |  |  | 401 |  |  | 25 | \nTotal operating costs |  | 84,846 |  |  | 73,200 |  |  | 11,646 |  |  | 16 |  |  | 168,691 |  |  | 146,399 |  |  | 22,292 |  |  | 15 | \nEarnings from operations |  | 8,057 |  |  | 7,132 |  |  | 925 |  |  | 13 |  |  | 16,143 |  |  | 14,082 |  |  | 2,061 |  |  | 15 | \nInterest expense |  | (828) |  |  | (467) |  |  | (361) |  |  | 77 |  |  | (1,582) |  |  | (900) |  |  | (682) |  |  | 76 | \nEarnings before income taxes |  | 7,229 |  |  | 6,665 |  |  | 564 |  |  | 8 |  |  | 14,561 |  |  | 13,182 |  |  | 1,379 |  |  | 10 | \nProvision for income taxes |  | (1,572) |  |  | (1,466) |  |  | (106) |  |  | 7 |  |  | (3,130) |  |  | (2,835) |  |  | (295) |  |  | 10 | \nNet earnings |  | 5,657 |  |  | 5,199 |  |  | 458 |  |  | 9 |  |  | 11,431 |  |  | 10,347 |  |  | 1,084 |  |  | 10 | \nEarnings attributable to noncontrolling interests |  | (183) |  |  | (129) |  |  | (54) |  |  | 42 |  |  | (346) |  |  | (250) |  |  | (96) |  |  | 38 | \nNet earnings attributable to UnitedHealth Group common shareholders |  | $ | 5,474 |  |  | $ | 5,070 |  |  | $ | 404 |  |  | 8 | % |  | $ | 11,085 |  |  | $ | 10,097 |  |  | $ | 988 |  |  | 10 | %\nDiluted earnings per share attributable to UnitedHealth Group common shareholders |  | $ | 5.82 |  |  | $ | 5.34 |  |  | $ | 0.48 |  |  |  |  | $ | 11.77 |  |  | $ | 10.61 |  |  | $ | 1.16 |  |  | \nMedical care ratio (a) |  | 83.2 | % |  | 81.5 | % |  | 1.7 | % |  |  |  | 82.7 | % |  | 81.8 | % |  | 0.9 | % |  | \nOperating cost ratio |  | 14.9 |  |  | 14.6 |  |  | 0.3 |  |  |  |  | 14.8 |  |  | 14.4 |  |  | 0.4 |  |  | \nOperating margin |  | 8.7 |  |  | 8.9 |  |  | (0.2) |  |  |  |  | 8.7 |  |  | 8.8 |  |  | (0.1) |  |  | \nTax rate |  | 21.7 |  |  | 22.0 |  |  | (0.3) |  |  |  |  | 21.5 |  |  | 21.5 |  |  | \u2014 |  |  | \nNet earnings margin (b) |  | 5.9 |  |  | 6.3 |  |  | (0.4) |  |  |  |  | 6.0 |  |  | 6.3 |  |  | (0.3) |  |  | \nReturn on equity (c) |  | 26.8 | % |  | 27.9 | % |  | (1.1) | % |  |  |  | 27.5 | % |  | 27.9 | % |  | (0.4) | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months EndedJune 30, |  | Increase/(Decrease) |  | Six Months EndedJune 30, |  | Increase/(Decrease)\n(in millions, except percentages) |  | 2023 |  | 2022 |  | 2023 vs. 2022 |  | 2023 |  | 2022 |  | 2023 vs. 2022\nRevenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nUnitedHealthcare |  | $ | 70,231 |  |  | $ | 62,105 |  |  | $ | 8,126 |  |  | 13 | % |  | $ | 140,699 |  |  | $ | 124,700 |  |  | $ | 15,999 |  |  | 13 | %\nOptum Health |  | 23,917 |  |  | 17,583 |  |  | 6,334 |  |  | 36 |  |  | 46,921 |  |  | 34,265 |  |  | 12,656 |  |  | 37 | \nOptum Insight |  | 4,674 |  |  | 3,282 |  |  | 1,392 |  |  | 42 |  |  | 9,170 |  |  | 6,501 |  |  | 2,669 |  |  | 41 | \nOptum Rx |  | 28,646 |  |  | 24,805 |  |  | 3,841 |  |  | 15 |  |  | 56,064 |  |  | 48,716 |  |  | 7,348 |  |  | 15 | \nOptum eliminations |  | (893) |  |  | (588) |  |  | (305) |  |  | 52 |  |  | (1,752) |  |  | (1,141) |  |  | (611) |  |  | 54 | \nOptum |  | 56,344 |  |  | 45,082 |  |  | 11,262 |  |  | 25 |  |  | 110,403 |  |  | 88,341 |  |  | 22,062 |  |  | 25 | \nEliminations |  | (33,672) |  |  | (26,855) |  |  | (6,817) |  |  | 25 |  |  | (66,268) |  |  | (52,560) |  |  | (13,708) |  |  | 26 | \nConsolidated revenues |  | $ | 92,903 |  |  | $ | 80,332 |  |  | $ | 12,571 |  |  | 16 | % |  | $ | 184,834 |  |  | $ | 160,481 |  |  | $ | 24,353 |  |  | 15 | %\nEarnings from operations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nUnitedHealthcare |  | $ | 4,358 |  |  | $ | 3,850 |  |  | $ | 508 |  |  | 13 | % |  | $ | 8,701 |  |  | $ | 7,648 |  |  | $ | 1,053 |  |  | 14 | %\nOptum Health |  | 1,525 |  |  | 1,399 |  |  | 126 |  |  | 9 |  |  | 3,301 |  |  | 2,765 |  |  | 536 |  |  | 19 | \nOptum Insight |  | 968 |  |  | 839 |  |  | 129 |  |  | 15 |  |  | 1,875 |  |  | 1,686 |  |  | 189 |  |  | 11 | \nOptum Rx |  | 1,206 |  |  | 1,044 |  |  | 162 |  |  | 16 |  |  | 2,266 |  |  | 1,983 |  |  | 283 |  |  | 14 | \nOptum |  | 3,699 |  |  | 3,282 |  |  | 417 |  |  | 13 |  |  | 7,442 |  |  | 6,434 |  |  | 1,008 |  |  | 16 | \nConsolidated earnings from operations |  | $ | 8,057 |  |  | $ | 7,132 |  |  | $ | 925 |  |  | 13 | % |  | $ | 16,143 |  |  | $ | 14,082 |  |  | $ | 2,061 |  |  | 15 | %\nOperating margin |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nUnitedHealthcare |  | 6.2 | % |  | 6.2 | % |  | \u2014 | % |  |  |  | 6.2 | % |  | 6.1 | % |  | 0.1 | % |  | \nOptum Health |  | 6.4 |  |  | 8.0 |  |  | (1.6) |  |  |  |  | 7.0 |  |  | 8.1 |  |  | (1.1) |  |  | \nOptum Insight |  | 20.7 |  |  | 25.6 |  |  | (4.9) |  |  |  |  | 20.4 |  |  | 25.9 |  |  | (5.5) |  |  | \nOptum Rx |  | 4.2 |  |  | 4.2 |  |  | \u2014 |  |  |  |  | 4.0 |  |  | 4.1 |  |  | (0.1) |  |  | \nOptum |  | 6.6 |  |  | 7.3 |  |  | (0.7) |  |  |  |  | 6.7 |  |  | 7.3 |  |  | (0.6) |  |  | \nConsolidated operating margin |  | 8.7 | % |  | 8.9 | % |  | (0.2) | % |  |  |  | 8.7 | % |  | 8.8 | % |  | (0.1) | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Increase/(Decrease) |  | Six Months Ended June 30, |  | Increase/(Decrease)\n(in millions, except percentages) |  | 2023 |  | 2022 |  | 2023 vs. 2022 |  | 2023 |  | 2022 |  | 2023 vs. 2022\nUnitedHealthcare Employer & Individual - Domestic |  | $ | 16,759 |  |  | $ | 15,567 |  |  | $ | 1,192 |  |  | 8 | % |  | $ | 33,303 |  |  | $ | 31,389 |  |  | $ | 1,914 |  |  | 6 | %\nUnitedHealthcare Employer & Individual - Global |  | 2,325 |  |  | 2,247 |  |  | 78 |  |  | 3 |  |  | 4,488 |  |  | 4,380 |  |  | 108 |  |  | 2 | \nUnitedHealthcare Employer & Individual - Total |  | 19,084 |  |  | 17,814 |  |  | 1,270 |  |  | 7 |  |  | 37,791 |  |  | 35,769 |  |  | 2,022 |  |  | 6 | \nUnitedHealthcare Medicare & Retirement |  | 32,440 |  |  | 28,625 |  |  | 3,815 |  |  | 13 |  |  | 65,446 |  |  | 57,725 |  |  | 7,721 |  |  | 13 | \nUnitedHealthcare Community & State |  | 18,707 |  |  | 15,666 |  |  | 3,041 |  |  | 19 |  |  | 37,462 |  |  | 31,206 |  |  | 6,256 |  |  | 20 | \nTotal UnitedHealthcare revenues |  | $ | 70,231 |  |  | $ | 62,105 |  |  | $ | 8,126 |  |  | 13 | % |  | $ | 140,699 |  |  | $ | 124,700 |  |  | $ | 15,999 |  |  | 13 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30, |  | Increase/(Decrease)\n(in thousands, except percentages) |  | 2023 |  | 2022 |  | 2023 vs. 2022\nCommercial - Domestic: |  |  |  |  |  |  |  | \nRisk-based |  | 8,035 |  |  | 8,010 |  |  | 25 |  |  | \u2014 | %\nFee-based |  | 19,140 |  |  | 18,480 |  |  | 660 |  |  | 4 | \nTotal Commercial - Domestic |  | 27,175 |  |  | 26,490 |  |  | 685 |  |  | 3 | \nMedicare Advantage |  | 7,590 |  |  | 6,945 |  |  | 645 |  |  | 9 | \nMedicaid |  | 8,355 |  |  | 7,990 |  |  | 365 |  |  | 5 | \nMedicare Supplement (Standardized) |  | 4,330 |  |  | 4,355 |  |  | (25) |  |  | (1) | \nTotal Community and Senior |  | 20,275 |  |  | 19,290 |  |  | 985 |  |  | 5 | \nTotal UnitedHealthcare - Domestic Medical |  | 47,450 |  |  | 45,780 |  |  | 1,670 |  |  | 4 | \nCommercial - Global |  | 5,385 |  |  | 5,465 |  |  | (80) |  |  | (1) | \nTotal UnitedHealthcare - Medical |  | 52,835 |  |  | 51,245 |  |  | 1,590 |  |  | 3 | %\nSupplemental Data: |  |  |  |  |  |  |  | \nMedicare Part D stand-alone |  | 3,355 |  |  | 3,330 |  |  | 25 |  |  | 1 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30, |  | Increase/(Decrease)\n(in millions) |  | 2023 |  | 2022 |  | 2023 vs. 2022\nSources of cash: |  |  |  |  |  | \nCash provided by operating activities |  | $ | 27,359 |  |  | $ | 12,190 |  |  | $ | 15,169 | \nIssuances of short-term borrowings and long-term debt, net of repayments |  | 7,695 |  |  | 6,162 |  |  | 1,533 | \nProceeds from common stock issuances |  | 628 |  |  | 756 |  |  | (128) | \nCustomer funds administered |  | 4,069 |  |  | 5,786 |  |  | (1,717) | \nTotal sources of cash |  | 39,751 |  |  | 24,894 |  |  | \nUses of cash: |  |  |  |  |  | \nCommon stock repurchases |  | (5,000) |  |  | (5,000) |  |  | \u2014 | \nCash paid for acquisitions, net of cash assumed |  | (8,161) |  |  | (7,150) |  |  | (1,011) | \nPurchases of investments, net of sales and maturities |  | (1,574) |  |  | (3,366) |  |  | 1,792 | \nPurchases of property, equipment and capitalized software |  | (1,589) |  |  | (1,212) |  |  | (377) | \nCash dividends paid |  | (3,284) |  |  | (2,908) |  |  | (376) | \nOther |  | (1,801) |  |  | (2,078) |  |  | 277 | \nTotal uses of cash |  | (21,409) |  |  | (21,714) |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | 106 |  |  | 57 |  |  | 49 | \nNet increase in cash and cash equivalents |  | $ | 18,448 |  |  | $ | 3,237 |  |  | $ | 15,211 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Moody\u2019s (a) |  | S&P Global |  | Fitch |  | A.M. Best\n | Ratings |  | Outlook |  | Ratings |  | Outlook |  | Ratings |  | Outlook |  | Ratings |  | Outlook\nSenior unsecured debt | A3 |  | Positive |  | A+ |  | Stable |  | A |  | Stable |  | A |  | Stable\nCommercial paper | P-2 |  | n/a |  | A-1 |  | n/a |  | F1 |  | n/a |  | AMB-1+ |  | n/a  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30, 2023\nIncrease (Decrease) in Market Interest Rate |  | InvestmentIncome\u00a0PerAnnum |  | InterestExpense\u00a0PerAnnum |  | Fair\u00a0Value\u00a0ofFinancial Assets |  | Fair\u00a0Value\u00a0ofFinancial Liabilities\n2 % |  | $ | 1,025 |  |  | $ | 469 |  |  | $ | (3,500) |  |  | $ | (8,164) | \n1 |  | 512 |  |  | 234 |  |  | (1,799) |  |  | (4,458) | \n(1) |  | (512) |  |  | (207) |  |  | 1,882 |  |  | 5,415 | \n(2) |  | (1,025) |  |  | (410) |  |  | 3,817 |  |  | 12,059 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFor the Month Ended |  | Total Number of Shares Purchased |  | Average Price Paid Per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number of Shares That May Yet Be Purchased Under The Plans or Programs\n |  | (in millions) |  |  |  | (in millions) |  | (in millions)\nApril 30, 2023 |  | 1.2 |  |  | $ | 499.99 |  |  | 1.2 |  |  | 25.8\nMay 31, 2023 |  | 1.5 |  |  | 486.68 |  |  | 1.5 |  |  | 24.3\nJune 30, 2023 |  | 3.5 |  |  | 475.99 |  |  | 3.5 |  |  | 20.8\nTotal |  | 6.2 |  |  | $ | 483.07 |  |  | 6.2 |  |  |   |  |  |  |  |  |  |  | \n3.1 |  | Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company\u2019s Registration Statement on Form 8-A/A filed on July 1, 2015)\n3.2 |  | Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by reference to Exhibit 3.2 to UnitedHealth Group Incorporated\u2019s Current Report on Form 8-K filed on February 26, 2021)\n4.1 |  | Amended and Restated Indenture, dated as of April 27,2023, between UnitedHealth Group Incorporated and Wilmington Trust Company, as successor trustee (incorporated by reference to Exhibit 4.1 to UnitedHealth Group Incorporated\u2019s Current Report on Form 8-K filed on April28, 2023)\n4.2 |  | Indenture, dated as of February\u00a04,\u00a02008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company\u2019s Registration Statement on Form S-3, SEC File Number 333-149031, filed on February\u00a04, 2008)\n4.3 |  | Supplemental Indenture, dated as of April 18, 2023, between UnitedHealth GroupIncorporated and U.S. BankTrust Company, National Association, as trustee, relating to the 6.875% Senior Notes due 2038 (incorporated by reference to Exhibit 4.1 to UnitedHealth Group Incorporated\u2019s Current Report on Form 8-K filed on April 24, 2023)\n31.1 |  | Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\n32.1 |  | Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\n101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n101.SCH |  | Inline XBRL Taxonomy Extension Schema Document.\n101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document.\n101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document.\n101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document.\n101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document.\n104 |  |  | Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).  |  |  |  |  |  |  |  | \n* |  | Pursuant to Item\u00a0601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n/s/    ANDREWWITTY |  | Chief Executive Officer(principal executive officer) | Dated: | August 2, 2023\nAndrew Witty |  |  | \n |  | \n/s/    JOHNREX |  | Executive Vice President andChief\u00a0Financial\u00a0Officer(principal financial officer) | Dated: | August 2, 2023\nJohn Rex |  |  | \n |  | \n/s/THOMASROOS |  | Senior Vice President andChief Accounting Officer(principal accounting officer) | Dated: | August 2, 2023\nThomas Roos |  |  | "}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For United Health Group, in 2023 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |   |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  |  |  |  |  |  |  | \nDelaware |  | 41-1321939\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)\nUnitedHealth Group Center |  | 55343\n9900 Bren Road East | \nMinnetonka, | Minnesota | \n(Address of principal executive offices) |  | (Zip Code)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered\nCommon Stock, $.01 par value |  | UNH |  | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 |  | Accelerated\u00a0filer | \u2610 |  | Non-accelerated filer | \u2610\nSmaller\u00a0reporting\u00a0company | \u2610 |  |  |  |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page\n |  |  |  | \nPart I. Financial\u00a0Information | \nItem\u00a01. | Financial Statements (unaudited) | 1\n |  | Condensed Consolidated Balance Sheets as ofSeptember30, 2023 and December 31, 2022 | 1\n |  | Condensed Consolidated Statements of Operations for theThreeandNineMonths EndedSeptember30, 2023 and 2022 | 2\n |  | Condensed Consolidated Statements of Comprehensive Income for the Three andNineMonths EndedSeptember30, 2023 and 2022 | 3\n |  | Condensed Consolidated Statements of Changes in Equity for the Three andNineMonths EndedSeptember30, 2023 and 2022 | 4\n |  | Condensed Consolidated Statements of Cash Flows for theNineMonths EndedSeptember30, 2023 and 2022 | 6\n |  | Notes to the Condensed Consolidated Financial Statements | 7\n |  | 1. | Basis of Presentation | 7\n |  | 2. | Investments | 8\n |  | 3. | Fair Value | 10\n |  | 4. | Medical Costs Payable | 11\n |  | 5. | Short-Term Borrowings and Long-Term Debt | 11\n |  | 6. | Dividends | 12\n |  | 7. | Commitments and Contingencies | 12\n |  | 8. | Business Combinations | 13\n |  | 9. | Segment Financial Information | 14\nItem\u00a02. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 16\nItem\u00a03. | Quantitative and Qualitative Disclosures About Market Risk | 23\nItem\u00a04. | Controls and Procedures | 24\nPart\u00a0II. Other Information | \nItem\u00a01. | Legal Proceedings | 24\nItem\u00a01A. | Risk Factors | 24\nItem\u00a02. | Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities | 24\nItem\u00a05. | Other Information | 25\nItem\u00a06. | Exhibits | 25\nSignatures | 26  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except per share data) |  | September 30,2023 |  | December 31,2022\nAssets |  |  |  | \nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 38,915 |  |  | $ | 23,365 | \nShort-term investments |  | 5,182 |  |  | 4,546 | \nAccounts receivable, net |  | 20,673 |  |  | 17,681 | \nOther current receivables, net |  | 17,752 |  |  | 12,769 | \nAssets under management |  | 3,616 |  |  | 4,087 | \nPrepaid expenses and other current assets |  | 5,767 |  |  | 6,621 | \nTotal current assets |  | 91,905 |  |  | 69,069 | \nLong-term investments |  | 45,474 |  |  | 43,728 | \nProperty, equipment and capitalized software, net |  | 11,070 |  |  | 10,128 | \nGoodwill |  | 101,703 |  |  | 93,352 | \nOther intangible assets, net |  | 15,200 |  |  | 14,401 | \nOther assets |  | 16,711 |  |  | 15,027 | \nTotal assets |  | $ | 282,063 |  |  | $ | 245,705 | \nLiabilities, redeemable noncontrolling interests and equity |  |  |  | \nCurrent liabilities: |  |  |  | \nMedical costs payable |  | $ | 32,792 |  |  | $ | 29,056 | \nAccounts payable and accrued liabilities |  | 31,164 |  |  | 27,715 | \nShort-term borrowings and current maturities of long-term debt |  | 5,290 |  |  | 3,110 | \nUnearned revenues |  | 15,311 |  |  | 3,075 | \nOther current liabilities |  | 29,622 |  |  | 26,281 | \nTotal current liabilities |  | 114,179 |  |  | 89,237 | \nLong-term debt, less current maturities |  | 58,079 |  |  | 54,513 | \nDeferred income taxes |  | 2,210 |  |  | 2,769 | \nOther liabilities |  | 13,615 |  |  | 12,839 | \nTotal liabilities |  | 188,083 |  |  | 159,358 | \nCommitments and contingencies (Note 7) |  |  |  | \nRedeemable noncontrolling interests |  | 4,416 |  |  | 4,897 | \nEquity: |  |  |  | \nPreferred stock, $0.001par value -10shares authorized;noshares issued or outstanding |  | \u2014 |  |  | \u2014 | \nCommon stock, $0.01par value -3,000shares authorized;925and934issued and outstanding |  | 9 |  |  | 9 | \nRetained earnings |  | 93,173 |  |  | 86,156 | \nAccumulated other comprehensive loss |  | (8,688) |  |  | (8,393) | \nNonredeemable noncontrolling interests |  | 5,070 |  |  | 3,678 | \nTotal equity |  | 89,564 |  |  | 81,450 | \nTotal liabilities, redeemable noncontrolling interests and equity |  | $ | 282,063 |  |  | $ | 245,705 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months EndedSeptember 30,\n(in millions, except per share data) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nRevenues: |  |  |  |  |  |  |  | \nPremiums |  | $ | 72,339 |  |  | $ | 64,491 |  |  | $ | 217,599 |  |  | $ | 192,457 | \nProducts |  | 10,354 |  |  | 9,190 |  |  | 31,272 |  |  | 28,026 | \nServices |  | 8,671 |  |  | 6,700 |  |  | 25,414 |  |  | 19,717 | \nInvestment and other income |  | 997 |  |  | 513 |  |  | 2,910 |  |  | 1,175 | \nTotal revenues |  | 92,361 |  |  | 80,894 |  |  | 277,195 |  |  | 241,375 | \nOperating costs: |  |  |  |  |  |  |  | \nMedical costs |  | 59,550 |  |  | 52,635 |  |  | 179,663 |  |  | 157,251 | \nOperating costs |  | 13,855 |  |  | 11,663 |  |  | 41,289 |  |  | 34,773 | \nCost of products sold |  | 9,423 |  |  | 8,306 |  |  | 28,576 |  |  | 25,389 | \nDepreciation and amortization |  | 1,007 |  |  | 828 |  |  | 2,998 |  |  | 2,418 | \nTotal operating costs |  | 83,835 |  |  | 73,432 |  |  | 252,526 |  |  | 219,831 | \nEarnings from operations |  | 8,526 |  |  | 7,462 |  |  | 24,669 |  |  | 21,544 | \nInterest expense |  | (834) |  |  | (516) |  |  | (2,416) |  |  | (1,416) | \nEarnings before income taxes |  | 7,692 |  |  | 6,946 |  |  | 22,253 |  |  | 20,128 | \nProvision for income taxes |  | (1,654) |  |  | (1,562) |  |  | (4,784) |  |  | (4,397) | \nNet earnings |  | 6,038 |  |  | 5,384 |  |  | 17,469 |  |  | 15,731 | \nEarnings attributable to noncontrolling interests |  | (197) |  |  | (122) |  |  | (543) |  |  | (372) | \nNet earnings attributable to UnitedHealth Group common shareholders |  | $ | 5,841 |  |  | $ | 5,262 |  |  | 16,926 |  |  | $ | 15,359 | \nEarnings per share attributable to UnitedHealth Group common shareholders: |  |  |  |  |  |  |  | \nBasic |  | $ | 6.31 |  |  | $ | 5.63 |  |  | $ | 18.20 |  |  | $ | 16.37 | \nDiluted |  | $ | 6.24 |  |  | $ | 5.55 |  |  | $ | 18.01 |  |  | $ | 16.15 | \nBasic weighted-average number of common shares outstanding |  | 926 |  |  | 935 |  |  | 930 |  |  | 938 | \nDilutive effect of common share equivalents |  | 10 |  |  | 13 |  |  | 10 |  |  | 13 | \nDiluted weighted-average number of common shares outstanding |  | 936 |  |  | 948 |  |  | 940 |  |  | 951 | \nAnti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents |  | 6 |  |  | 3 |  |  | 6 |  |  | 3 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months EndedSeptember 30,\n(in millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022\nNet earnings |  | $ | 6,038 |  |  | $ | 5,384 |  |  | $ | 17,469 |  |  | $ | 15,731 | \nOther comprehensive loss: |  |  |  |  |  |  |  | \nGross unrealized losses on investment securities during the period |  | (893) |  |  | (1,471) |  |  | (684) |  |  | (4,825) | \nIncome tax effect |  | 204 |  |  | 340 |  |  | 156 |  |  | 1,109 | \nTotal unrealized losses, net of tax |  | (689) |  |  | (1,131) |  |  | (528) |  |  | (3,716) | \nGross reclassification adjustment for net realized losses (gains) included in net earnings |  | 7 |  |  | 138 |  |  | (27) |  |  | 134 | \nIncome tax effect |  | (2) |  |  | (32) |  |  | 6 |  |  | (31) | \nTotal reclassification adjustment, net of tax |  | 5 |  |  | 106 |  |  | (21) |  |  | 103 | \nTotal foreign currency translation (losses) gains |  | (354) |  |  | (331) |  |  | 254 |  |  | (89) | \nOther comprehensive loss |  | (1,038) |  |  | (1,356) |  |  | (295) |  |  | (3,702) | \nComprehensive income |  | 5,000 |  |  | 4,028 |  |  | 17,174 |  |  | 12,029 | \nComprehensive income attributable to noncontrolling interests |  | (197) |  |  | (122) |  |  | (543) |  |  | (372) | \nComprehensive income attributable to UnitedHealth Group common shareholders |  | $ | 4,803 |  |  | $ | 3,906 |  |  | $ | 16,631 |  |  | $ | 11,657 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Common Stock |  | Additional Paid-In Capital |  | Retained Earnings |  | Accumulated Other Comprehensive Loss |  | Nonredeemable Noncontrolling Interests |  | TotalEquity\nThree months ended September 30,(in millions) |  | Shares |  | Amount |  |  |  | Net Unrealized Losses on Investments |  | Foreign Currency Translation Losses |  | \nBalance at June 30, 2023 |  | 927 |  |  | $ | 9 |  |  | $ | \u2014 |  |  | $ | 89,994 |  |  | $ | (2,643) |  |  | $ | (5,007) |  |  | $ | 5,015 |  |  | $ | 87,368 | \nNet earnings |  |  |  |  |  |  |  | 5,841 |  |  |  |  |  |  | 149 |  |  | 5,990 | \nOther comprehensive loss |  |  |  |  |  |  |  |  |  | (684) |  |  | (354) |  |  |  |  | (1,038) | \nIssuances of common stock, and related tax effects |  | 1 |  |  | \u2014 |  |  | 395 |  |  |  |  |  |  |  |  |  |  | 395 | \nShare-based compensation |  |  |  |  |  | 235 |  |  |  |  |  |  |  |  |  |  | 235 | \nCommon share repurchases |  | (3) |  |  | \u2014 |  |  | (588) |  |  | (923) |  |  |  |  |  |  |  |  | (1,511) | \nCash dividends paid on common shares ($1.88per share) |  |  |  |  |  |  |  | (1,739) |  |  |  |  |  |  |  |  | (1,739) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | (42) |  |  |  |  |  |  |  |  |  |  | (42) | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 42 |  |  | 42 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (136) |  |  | (136) | \nBalance at September 30, 2023 |  | 925 |  |  | $ | 9 |  |  | $ | \u2014 |  |  | $ | 93,173 |  |  | $ | (3,327) |  |  | $ | (5,361) |  |  | $ | 5,070 |  |  | $ | 89,564 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at June 30, 2022 |  | 935 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 80,540 |  |  | $ | (2,165) |  |  | $ | (5,565) |  |  | $ | 3,385 |  |  | $ | 76,205 | \nNet earnings |  |  |  |  |  |  |  | 5,262 |  |  |  |  |  |  | 99 |  |  | 5,361 | \nOther comprehensive loss |  |  |  |  |  |  |  |  |  | (1,025) |  |  | (331) |  |  |  |  | (1,356) | \nIssuances of common stock, and related tax effects |  | 2 |  |  | \u2014 |  |  | 294 |  |  |  |  |  |  |  |  |  |  | 294 | \nShare-based compensation |  |  |  |  |  | 163 |  |  |  |  |  |  |  |  |  |  | 163 | \nCommon share repurchases |  | (2) |  |  | \u2014 |  |  | (462) |  |  | (538) |  |  |  |  |  |  |  |  | (1,000) | \nCash dividends paid on common shares ($1.65per share) |  |  |  |  |  |  |  | (1,542) |  |  |  |  |  |  |  |  | (1,542) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  | 5 | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 32 |  |  | 32 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (98) |  |  | (98) | \nBalance at September 30, 2022 |  | 935 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 83,722 |  |  | $ | (3,190) |  |  | $ | (5,896) |  |  | $ | 3,418 |  |  | $ | 78,064 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Common Stock |  | Additional Paid-In Capital |  | Retained Earnings |  | Accumulated Other Comprehensive(Loss) Income |  | Nonredeemable Noncontrolling Interests |  | TotalEquity\nNine months ended September 30,(in millions) |  | Shares |  | Amount |  |  |  | Net Unrealized (Losses) Gains on Investments |  | Foreign Currency Translation (Losses) Gains |  | \nBalance at January 1, 2023 |  | 934 |  |  | $ | 9 |  |  | $ | \u2014 |  |  | $ | 86,156 |  |  | $ | (2,778) |  |  | $ | (5,615) |  |  | $ | 3,678 |  |  | $ | 81,450 | \nNet earnings |  |  |  |  |  |  |  | 16,926 |  |  |  |  |  |  | 401 |  |  | 17,327 | \nOther comprehensive (loss) income |  |  |  |  |  |  |  |  |  | (549) |  |  | 254 |  |  |  |  | (295) | \nIssuances of common stock, and related tax effects |  | 4 |  |  | \u2014 |  |  | 963 |  |  |  |  |  |  |  |  |  |  | 963 | \nShare-based compensation |  |  |  |  |  | 833 |  |  |  |  |  |  |  |  |  |  | 833 | \nCommon share repurchases |  | (13) |  |  | \u2014 |  |  | (1,663) |  |  | (4,886) |  |  |  |  |  |  |  |  | (6,549) | \nCash dividends paid on common shares ($5.41per share) |  |  |  |  |  |  |  | (5,023) |  |  |  |  |  |  |  |  | (5,023) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | (133) |  |  |  |  |  |  |  |  |  |  | (133) | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,339 |  |  | 1,339 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (348) |  |  | (348) | \nBalance at September 30, 2023 |  | 925 |  |  | $ | 9 |  |  | $ | \u2014 |  |  | $ | 93,173 |  |  | $ | (3,327) |  |  | $ | (5,361) |  |  | $ | 5,070 |  |  | $ | 89,564 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at January 1, 2022 |  | 941 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 77,134 |  |  | $ | 423 |  |  | $ | (5,807) |  |  | $ | 3,285 |  |  | $ | 75,045 | \nNet earnings |  |  |  |  |  |  |  | 15,359 |  |  |  |  |  |  | 281 |  |  | 15,640 | \nOther comprehensive loss |  |  |  |  |  |  |  |  |  | (3,613) |  |  | (89) |  |  |  |  | (3,702) | \nIssuances of common stock, and related tax effects |  | 6 |  |  | \u2014 |  |  | 801 |  |  |  |  |  |  |  |  |  |  | 801 | \nShare-based compensation |  |  |  |  |  | 639 |  |  |  |  |  |  |  |  |  |  | 639 | \nCommon share repurchases |  | (12) |  |  | \u2014 |  |  | (1,679) |  |  | (4,321) |  |  |  |  |  |  |  |  | (6,000) | \nCash dividends paid on common shares ($4.75per share) |  |  |  |  |  |  |  | (4,450) |  |  |  |  |  |  |  |  | (4,450) | \nRedeemable noncontrolling interests fair value and other adjustments |  |  |  |  |  | 239 |  |  |  |  |  |  |  |  |  |  | 239 | \nAcquisition and other adjustments of nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 135 |  |  | 135 | \nDistribution to nonredeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | (283) |  |  | (283) | \nBalance at September 30, 2022 |  | 935 |  |  | $ | 10 |  |  | $ | \u2014 |  |  | $ | 83,722 |  |  | $ | (3,190) |  |  | $ | (5,896) |  |  | $ | 3,418 |  |  | $ | 78,064 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months EndedSeptember 30,\n(in millions) |  | 2023 |  | 2022\nOperating activities |  |  |  | \nNet earnings |  | $ | 17,469 |  |  | $ | 15,731 | \nNoncash items: |  |  |  | \nDepreciation and amortization |  | 2,998 |  |  | 2,418 | \nDeferred income taxes |  | (494) |  |  | (590) | \nShare-based compensation |  | 851 |  |  | 675 | \nOther, net |  | (59) |  |  | \u2014 | \nNet change in other operating items, net of effects from acquisitions and changes in AARP balances: |  |  |  | \nAccounts receivable |  | (2,574) |  |  | (2,563) | \nOther assets |  | (2,358) |  |  | (741) | \nMedical costs payable |  | 3,837 |  |  | 4,192 | \nAccounts payable and other liabilities |  | 2,370 |  |  | 1,416 | \nUnearned revenues |  | 12,221 |  |  | 10,201 | \nCash flows from operating activities |  | 34,261 |  |  | 30,739 | \nInvesting activities |  |  |  | \nPurchases of investments |  | (12,998) |  |  | (14,183) | \nSales of investments |  | 3,674 |  |  | 5,376 | \nMaturities of investments |  | 6,474 |  |  | 4,740 | \nCash paid for acquisitions, net of cash assumed |  | (8,389) |  |  | (7,154) | \nPurchases of property, equipment and capitalized software |  | (2,427) |  |  | (1,936) | \nOther, net |  | (721) |  |  | 50 | \nCash flows used for investing activities |  | (14,387) |  |  | (13,107) | \nFinancing activities |  |  |  | \nCommon share repurchases |  | (6,500) |  |  | (6,000) | \nCash dividends paid |  | (5,023) |  |  | (4,450) | \nProceeds from common stock issuances |  | 1,039 |  |  | 1,084 | \nRepayments of long-term debt |  | (2,125) |  |  | (2,100) | \nProceeds from (repayments of) short-term borrowings, net |  | 1,579 |  |  | (16) | \nProceeds from issuance of long-term debt |  | 6,394 |  |  | 5,922 | \nCustomer funds administered |  | 2,037 |  |  | 7,028 | \nOther, net |  | (1,774) |  |  | (1,634) | \nCash flows used for financing activities |  | (4,373) |  |  | (166) | \nEffect of exchange rate changes on cash and cash equivalents |  | 49 |  |  | 4 | \nIncrease in cash and cash equivalents |  | 15,550 |  |  | 17,470 | \nCash and cash equivalents, beginning of period |  | 23,365 |  |  | 21,375 | \nCash and cash equivalents, end of period |  | $ | 38,915 |  |  | $ | 38,845 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | AmortizedCost |  | GrossUnrealizedGains |  | GrossUnrealizedLosses |  | FairValue\nSeptember 30, 2023 |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 5,739 |  |  | $ | \u2014 |  |  | $ | (340) |  |  | $ | 5,399 | \nState and municipal obligations |  | 7,695 |  |  | 1 |  |  | (643) |  |  | 7,053 | \nCorporate obligations |  | 23,511 |  |  | 5 |  |  | (1,857) |  |  | 21,659 | \nU.S. agency mortgage-backed securities |  | 8,632 |  |  | \u2014 |  |  | (1,158) |  |  | 7,474 | \nNon-U.S. agency mortgage-backed securities |  | 3,091 |  |  | \u2014 |  |  | (324) |  |  | 2,767 | \nTotal debt securities - available-for-sale |  | 48,668 |  |  | 6 |  |  | (4,322) |  |  | 44,352 | \nDebt securities - held-to-maturity: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 466 |  |  | \u2014 |  |  | (10) |  |  | 456 | \nState and municipal obligations |  | 28 |  |  | \u2014 |  |  | (5) |  |  | 23 | \nCorporate obligations |  | 188 |  |  | \u2014 |  |  | \u2014 |  |  | 188 | \nTotal debt securities - held-to-maturity |  | 682 |  |  | \u2014 |  |  | (15) |  |  | 667 | \nTotal debt securities |  | $ | 49,350 |  |  | $ | 6 |  |  | $ | (4,337) |  |  | $ | 45,019 | \nDecember 31, 2022 |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 4,093 |  |  | $ | 1 |  |  | $ | (285) |  |  | $ | 3,809 | \nState and municipal obligations |  | 7,702 |  |  | 25 |  |  | (479) |  |  | 7,248 | \nCorporate obligations |  | 23,675 |  |  | 17 |  |  | (1,798) |  |  | 21,894 | \nU.S. agency mortgage-backed securities |  | 7,379 |  |  | 15 |  |  | (808) |  |  | 6,586 | \nNon-U.S. agency mortgage-backed securities |  | 3,077 |  |  | 1 |  |  | (294) |  |  | 2,784 | \nTotal debt securities - available-for-sale |  | 45,926 |  |  | 59 |  |  | (3,664) |  |  | 42,321 | \nDebt securities - held-to-maturity: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 578 |  |  | \u2014 |  |  | (14) |  |  | 564 | \nState and municipal obligations |  | 29 |  |  | \u2014 |  |  | (3) |  |  | 26 | \nCorporate obligations |  | 89 |  |  | \u2014 |  |  | \u2014 |  |  | 89 | \nTotal debt securities - held-to-maturity |  | 696 |  |  | \u2014 |  |  | (17) |  |  | 679 | \nTotal debt securities |  | $ | 46,622 |  |  | $ | 59 |  |  | $ | (3,681) |  |  | $ | 43,000 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Available-for-Sale |  | Held-to-Maturity\n(in millions) |  | AmortizedCost |  | FairValue |  | AmortizedCost |  | FairValue\nDue in one year or less |  | $ | 5,372 |  |  | $ | 5,340 |  |  | $ | 375 |  |  | $ | 372 | \nDue after one year through five years |  | 15,098 |  |  | 14,183 |  |  | 262 |  |  | 255 | \nDue after five years through ten years |  | 11,256 |  |  | 9,898 |  |  | 25 |  |  | 24 | \nDue after ten years |  | 5,219 |  |  | 4,690 |  |  | 20 |  |  | 16 | \nU.S. agency mortgage-backed securities |  | 8,632 |  |  | 7,474 |  |  | \u2014 |  |  | \u2014 | \nNon-U.S. agency mortgage-backed securities |  | 3,091 |  |  | 2,767 |  |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 48,668 |  |  | $ | 44,352 |  |  | $ | 682 |  |  | $ | 667 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Less Than 12 Months |  | 12 Months or Greater |  | Total\n(in millions) |  | FairValue |  | GrossUnrealizedLosses |  | FairValue |  | GrossUnrealizedLosses |  | FairValue |  | GrossUnrealizedLosses\nSeptember 30, 2023 |  |  |  |  |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 2,023 |  |  | $ | (34) |  |  | $ | 2,081 |  |  | $ | (306) |  |  | $ | 4,104 |  |  | $ | (340) | \nState and municipal obligations |  | 2,872 |  |  | (124) |  |  | 4,042 |  |  | (519) |  |  | 6,914 |  |  | (643) | \nCorporate obligations |  | 5,563 |  |  | (149) |  |  | 14,821 |  |  | (1,708) |  |  | 20,384 |  |  | (1,857) | \nU.S. agency mortgage-backed securities |  | 2,562 |  |  | (140) |  |  | 4,867 |  |  | (1,018) |  |  | 7,429 |  |  | (1,158) | \nNon-U.S. agency mortgage-backed securities |  | 480 |  |  | (21) |  |  | 2,249 |  |  | (303) |  |  | 2,729 |  |  | (324) | \nTotal debt securities - available-for-sale |  | $ | 13,500 |  |  | $ | (468) |  |  | $ | 28,060 |  |  | $ | (3,854) |  |  | $ | 41,560 |  |  | $ | (4,322) | \nDecember 31, 2022 |  |  |  |  |  |  |  |  |  |  |  | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | $ | 2,007 |  |  | $ | (96) |  |  | $ | 1,290 |  |  | $ | (189) |  |  | $ | 3,297 |  |  | $ | (285) | \nState and municipal obligations |  | 4,630 |  |  | (288) |  |  | 1,178 |  |  | (191) |  |  | 5,808 |  |  | (479) | \nCorporate obligations |  | 13,003 |  |  | (893) |  |  | 6,637 |  |  | (905) |  |  | 19,640 |  |  | (1,798) | \nU.S. agency mortgage-backed securities |  | 3,561 |  |  | (345) |  |  | 2,239 |  |  | (463) |  |  | 5,800 |  |  | (808) | \nNon-U.S. agency mortgage-backed securities |  | 1,698 |  |  | (128) |  |  | 976 |  |  | (166) |  |  | 2,674 |  |  | (294) | \nTotal debt securities - available-for-sale |  | $ | 24,899 |  |  | $ | (1,750) |  |  | $ | 12,320 |  |  | $ | (1,914) |  |  | $ | 37,219 |  |  | $ | (3,664) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | OtherObservableInputs(Level 2) |  | UnobservableInputs(Level 3) |  | TotalFair and CarryingValue\nSeptember 30, 2023 |  |  |  |  |  |  |  | \nCash and cash equivalents |  | $ | 38,880 |  |  | $ | 35 |  |  | $ | \u2014 |  |  | $ | 38,915 | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 5,050 |  |  | 349 |  |  | \u2014 |  |  | 5,399 | \nState and municipal obligations |  | \u2014 |  |  | 7,053 |  |  | \u2014 |  |  | 7,053 | \nCorporate obligations |  | 15 |  |  | 21,462 |  |  | 182 |  |  | 21,659 | \nU.S. agency mortgage-backed securities |  | \u2014 |  |  | 7,474 |  |  | \u2014 |  |  | 7,474 | \nNon-U.S. agency mortgage-backed securities |  | \u2014 |  |  | 2,767 |  |  | \u2014 |  |  | 2,767 | \nTotal debt securities - available-for-sale |  | 5,065 |  |  | 39,105 |  |  | 182 |  |  | 44,352 | \nEquity securities |  | 2,231 |  |  | 31 |  |  | 70 |  |  | 2,332 | \nAssets under management |  | 1,420 |  |  | 2,094 |  |  | 102 |  |  | 3,616 | \nTotal assets at fair value |  | $ | 47,596 |  |  | $ | 41,265 |  |  | $ | 354 |  |  | $ | 89,215 | \nPercentage of total assets at fair value |  | 53 | % |  | 46 | % |  | 1 | % |  | 100 | %\nDecember 31, 2022 |  |  |  |  |  |  |  | \nCash and cash equivalents |  | $ | 23,202 |  |  | $ | 163 |  |  | $ | \u2014 |  |  | $ | 23,365 | \nDebt securities - available-for-sale: |  |  |  |  |  |  |  | \nU.S. government and agency obligations |  | 3,505 |  |  | 304 |  |  | \u2014 |  |  | 3,809 | \nState and municipal obligations |  | \u2014 |  |  | 7,248 |  |  | \u2014 |  |  | 7,248 | \nCorporate obligations |  | 7 |  |  | 21,695 |  |  | 192 |  |  | 21,894 | \nU.S. agency mortgage-backed securities |  | \u2014 |  |  | 6,586 |  |  | \u2014 |  |  | 6,586 | \nNon-U.S. agency mortgage-backed securities |  | \u2014 |  |  | 2,784 |  |  | \u2014 |  |  | 2,784 | \nTotal debt securities - available-for-sale |  | 3,512 |  |  | 38,617 |  |  | 192 |  |  | 42,321 | \nEquity securities |  | 2,043 |  |  | 35 |  |  | 70 |  |  | 2,148 | \nAssets under management |  | 1,788 |  |  | 2,203 |  |  | 96 |  |  | 4,087 | \nTotal assets at fair value |  | $ | 30,545 |  |  | $ | 41,018 |  |  | $ | 358 |  |  | $ | 71,921 | \nPercentage of total assets at fair value |  | 42 | % |  | 57 | % |  | 1 | % |  | 100 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | OtherObservableInputs(Level 2) |  | UnobservableInputs(Level 3) |  | TotalFairValue |  | Total Carrying Value\nSeptember 30, 2023 |  |  |  |  |  |  |  |  |  | \nDebt securities - held-to-maturity |  | $ | 593 |  |  | $ | 74 |  |  | $ | \u2014 |  |  | $ | 667 |  |  | $ | 682 | \nLong-term debt and other financing obligations |  | $ | \u2014 |  |  | $ | 55,137 |  |  | $ | \u2014 |  |  | $ | 55,137 |  |  | $ | 60,769 | \nDecember 31, 2022 |  |  |  |  |  |  |  |  |  | \nDebt securities - held-to-maturity |  | $ | 577 |  |  | $ | 102 |  |  | $ | \u2014 |  |  | $ | 679 |  |  | $ | 696 | \nLong-term debt and other financing obligations |  | $ | \u2014 |  |  | $ | 53,626 |  |  | $ | \u2014 |  |  | $ | 53,626 |  |  | $ | 56,823 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions) |  | 2023 |  | 2022\nMedical costs payable, beginning of period |  | $ | 29,056 |  |  | $ | 24,483 | \nAcquisitions |  | 1 |  |  | 177 | \nReported medical costs: |  |  |  | \nCurrent year |  | 180,423 |  |  | 157,601 | \nPrior years |  | (760) |  |  | (350) | \nTotal reported medical costs |  | 179,663 |  |  | 157,251 | \nMedical payments: |  |  |  | \nPayments for current year |  | (149,671) |  |  | (130,788) | \nPayments for prior years |  | (26,257) |  |  | (22,059) | \nTotal medical payments |  | (175,928) |  |  | (152,847) | \nMedical costs payable, end of period |  | $ | 32,792 |  |  | $ | 29,064 |   |  |  |  |  |  |  |  | \n(in millions, except percentages) |  | Par Value\n4.250% notes due January 2029 |  | $ | 1,250 | \n4.500% notes due April 2033 |  | 1,500 | \n5.050% notes due April 2053 |  | 2,000 | \n5.200% notes due April 2063 |  | 1,750 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPayment Date |  | Amount per Share |  | Total Amount Paid\n |  |  |  | (in millions)\nMarch 21 |  | $ | 1.65 |  |  | $ | 1,537 | \nJune 27 |  | 1.88 |  |  | 1,747 | \nSeptember 19 |  | 1.88 |  |  | 1,739 |   |  |  |  |  |  |  |  | \n(in millions) |  | \nCash and cash equivalents |  | $ | 104 | \nAccounts receivable and other current assets |  | 587 | \nProperty, equipment and other long-term assets |  | 573 | \nOther intangible assets |  | 1,800 | \nTotal identifiable assets acquired |  | 3,064 | \nMedical costs payable |  | (1) | \nAccounts payable and other current liabilities |  | (551) | \nOther long-term liabilities |  | (661) | \nTotal identifiable liabilities acquired |  | (1,213) | \nTotal net identifiable assets |  | 1,851 | \nGoodwill |  | 8,073 | \nRedeemable noncontrolling interests |  | (121) | \nNonredeemable noncontrolling interests |  | (1,339) | \nNet assets acquired |  | $ | 8,464 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except years) |  | Fair Value |  | Weighted-Average Useful Life\nAcquired finite-lived intangible assets: |  |  |  | \nCustomer-related |  | $ | 223 |  |  | 12years\nTrademarks and technology |  | 171 |  |  | 5years\nOther |  | 42 |  |  | 6years\nTotal acquired finite-lived intangible assets |  | 436 |  |  | 9years\nTotal acquired indefinite-lived intangible assets - operating licenses and certificates |  | 1,364 |  |  | \nTotal acquired intangible assets |  | $ | 1,800 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Optum |  |  |  | \n(in millions) |  | UnitedHealthcare |  | Optum Health |  | Optum Insight |  | Optum Rx |  | Optum Eliminations |  | Optum |  | Corporate\u00a0andEliminations |  | Consolidated\nThree Months Ended September 30, 2023 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 66,709 |  |  | $ | 5,630 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,630 |  |  | $ | \u2014 |  |  | $ | 72,339 | \nProducts |  | \u2014 |  |  | 61 |  |  | 40 |  |  | 10,253 |  |  | \u2014 |  |  | 10,354 |  |  | \u2014 |  |  | 10,354 | \nServices |  | 2,550 |  |  | 3,629 |  |  | 1,938 |  |  | 554 |  |  | \u2014 |  |  | 6,121 |  |  | \u2014 |  |  | 8,671 | \nTotal revenues - unaffiliated customers |  | 69,259 |  |  | 9,320 |  |  | 1,978 |  |  | 10,807 |  |  | \u2014 |  |  | 22,105 |  |  | \u2014 |  |  | 91,364 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 14,227 |  |  | 2,964 |  |  | 17,999 |  |  | (961) |  |  | 34,229 |  |  | (34,229) |  |  | \u2014 | \nInvestment and other income |  | 594 |  |  | 317 |  |  | 35 |  |  | 51 |  |  | \u2014 |  |  | 403 |  |  | \u2014 |  |  | 997 | \nTotal revenues |  | $ | 69,853 |  |  | $ | 23,864 |  |  | $ | 4,977 |  |  | $ | 28,857 |  |  | $ | (961) |  |  | $ | 56,737 |  |  | $ | (34,229) |  |  | $ | 92,361 | \nEarnings from operations |  | $ | 4,592 |  |  | $ | 1,568 |  |  | $ | 1,109 |  |  | $ | 1,257 |  |  | $ | \u2014 |  |  | $ | 3,934 |  |  | $ | \u2014 |  |  | $ | 8,526 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (834) |  |  | (834) | \nEarnings before income taxes |  | $ | 4,592 |  |  | $ | 1,568 |  |  | $ | 1,109 |  |  | $ | 1,257 |  |  | $ | \u2014 |  |  | $ | 3,934 |  |  | $ | (834) |  |  | $ | 7,692 | \nThree Months Ended September 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 59,375 |  |  | $ | 5,116 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,116 |  |  | $ | \u2014 |  |  | $ | 64,491 | \nProducts |  | \u2014 |  |  | 2 |  |  | 37 |  |  | 9,151 |  |  | \u2014 |  |  | 9,190 |  |  | \u2014 |  |  | 9,190 | \nServices |  | 2,435 |  |  | 2,756 |  |  | 1,067 |  |  | 442 |  |  | \u2014 |  |  | 4,265 |  |  | \u2014 |  |  | 6,700 | \nTotal revenues - unaffiliated customers |  | 61,810 |  |  | 7,874 |  |  | 1,104 |  |  | 9,593 |  |  | \u2014 |  |  | 18,571 |  |  | \u2014 |  |  | 80,381 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 10,302 |  |  | 2,566 |  |  | 15,592 |  |  | (800) |  |  | 27,660 |  |  | (27,660) |  |  | \u2014 | \nInvestment and other income |  | 185 |  |  | 287 |  |  | 23 |  |  | 18 |  |  | \u2014 |  |  | 328 |  |  | \u2014 |  |  | 513 | \nTotal revenues |  | $ | 61,995 |  |  | $ | 18,463 |  |  | $ | 3,693 |  |  | $ | 25,203 |  |  | $ | (800) |  |  | $ | 46,559 |  |  | $ | (27,660) |  |  | $ | 80,894 | \nEarnings from operations |  | $ | 3,799 |  |  | $ | 1,575 |  |  | $ | 1,007 |  |  | $ | 1,081 |  |  | $ | \u2014 |  |  | $ | 3,663 |  |  | $ | \u2014 |  |  | $ | 7,462 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (516) |  |  | (516) | \nEarnings before income taxes |  | $ | 3,799 |  |  | $ | 1,575 |  |  | $ | 1,007 |  |  | $ | 1,081 |  |  | $ | \u2014 |  |  | $ | 3,663 |  |  | $ | (516) |  |  | $ | 6,946 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Optum |  |  |  | \n(in millions) |  | UnitedHealthcare |  | Optum Health |  | Optum Insight |  | Optum Rx |  | Optum Eliminations |  | Optum |  | Corporate\u00a0andEliminations |  | Consolidated\nNine Months Ended September 30, 2023 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 201,214 |  |  | $ | 16,385 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 16,385 |  |  | $ | \u2014 |  |  | $ | 217,599 | \nProducts |  | \u2014 |  |  | 156 |  |  | 119 |  |  | 30,997 |  |  | \u2014 |  |  | 31,272 |  |  | \u2014 |  |  | 31,272 | \nServices |  | 7,689 |  |  | 10,259 |  |  | 5,859 |  |  | 1,607 |  |  | \u2014 |  |  | 17,725 |  |  | \u2014 |  |  | 25,414 | \nTotal revenues - unaffiliated customers |  | 208,903 |  |  | 26,800 |  |  | 5,978 |  |  | 32,604 |  |  | \u2014 |  |  | 65,382 |  |  | \u2014 |  |  | 274,285 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 42,947 |  |  | 8,089 |  |  | 52,174 |  |  | (2,713) |  |  | 100,497 |  |  | (100,497) |  |  | \u2014 | \nInvestment and other income |  | 1,649 |  |  | 1,038 |  |  | 80 |  |  | 143 |  |  | \u2014 |  |  | 1,261 |  |  | \u2014 |  |  | 2,910 | \nTotal revenues |  | $ | 210,552 |  |  | $ | 70,785 |  |  | $ | 14,147 |  |  | $ | 84,921 |  |  | $ | (2,713) |  |  | $ | 167,140 |  |  | $ | (100,497) |  |  | $ | 277,195 | \nEarnings from operations |  | $ | 13,293 |  |  | $ | 4,869 |  |  | $ | 2,984 |  |  | $ | 3,523 |  |  | $ | \u2014 |  |  | $ | 11,376 |  |  | $ | \u2014 |  |  | $ | 24,669 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,416) |  |  | (2,416) | \nEarnings before income taxes |  | $ | 13,293 |  |  | $ | 4,869 |  |  | $ | 2,984 |  |  | $ | 3,523 |  |  | $ | \u2014 |  |  | $ | 11,376 |  |  | $ | (2,416) |  |  | $ | 22,253 | \nNine Months Ended September 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRevenues - unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 178,680 |  |  | $ | 13,777 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 13,777 |  |  | $ | \u2014 |  |  | $ | 192,457 | \nProducts |  | \u2014 |  |  | 14 |  |  | 135 |  |  | 27,877 |  |  | \u2014 |  |  | 28,026 |  |  | \u2014 |  |  | 28,026 | \nServices |  | 7,492 |  |  | 8,054 |  |  | 3,075 |  |  | 1,096 |  |  | \u2014 |  |  | 12,225 |  |  | \u2014 |  |  | 19,717 | \nTotal revenues - unaffiliated customers |  | 186,172 |  |  | 21,845 |  |  | 3,210 |  |  | 28,973 |  |  | \u2014 |  |  | 54,028 |  |  | \u2014 |  |  | 240,200 | \nTotal revenues - affiliated customers |  | \u2014 |  |  | 30,355 |  |  | 6,885 |  |  | 44,921 |  |  | (1,941) |  |  | 80,220 |  |  | (80,220) |  |  | \u2014 | \nInvestment and other income |  | 523 |  |  | 528 |  |  | 99 |  |  | 25 |  |  | \u2014 |  |  | 652 |  |  | \u2014 |  |  | 1,175 | \nTotal revenues |  | $ | 186,695 |  |  | $ | 52,728 |  |  | $ | 10,194 |  |  | $ | 73,919 |  |  | $ | (1,941) |  |  | $ | 134,900 |  |  | $ | (80,220) |  |  | $ | 241,375 | \nEarnings from operations |  | $ | 11,447 |  |  | $ | 4,340 |  |  | $ | 2,693 |  |  | $ | 3,064 |  |  | $ | \u2014 |  |  | $ | 10,097 |  |  | $ | \u2014 |  |  | $ | 21,544 | \nInterest expense |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,416) |  |  | (1,416) | \nEarnings before income taxes |  | $ | 11,447 |  |  | $ | 4,340 |  |  | $ | 2,693 |  |  | $ | 3,064 |  |  | $ | \u2014 |  |  | $ | 10,097 |  |  | $ | (1,416) |  |  | $ | 20,128 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(in millions, except percentages and per share data) |  | Three Months EndedSeptember 30, |  | Increase/(Decrease) |  | Nine Months EndedSeptember 30, |  | Increase/(Decrease)\n | 2023 |  | 2022 |  | 2023 vs. 2022 |  | 2023 |  | 2022 |  | 2023 vs. 2022\nRevenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPremiums |  | $ | 72,339 |  |  | $ | 64,491 |  |  | $ | 7,848 |  |  | 12 | % |  | $ | 217,599 |  |  | $ | 192,457 |  |  | $ | 25,142 |  |  | 13 | %\nProducts |  | 10,354 |  |  | 9,190 |  |  | 1,164 |  |  | 13 |  |  | 31,272 |  |  | 28,026 |  |  | 3,246 |  |  | 12 | \nServices |  | 8,671 |  |  | 6,700 |  |  | 1,971 |  |  | 29 |  |  | 25,414 |  |  | 19,717 |  |  | 5,697 |  |  | 29 | \nInvestment and other income |  | 997 |  |  | 513 |  |  | 484 |  |  | 94 |  |  | 2,910 |  |  | 1,175 |  |  | 1,735 |  |  | 148 | \nTotal revenues |  | 92,361 |  |  | 80,894 |  |  | 11,467 |  |  | 14 |  |  | 277,195 |  |  | 241,375 |  |  | 35,820 |  |  | 15 | \nOperating costs: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMedical costs |  | 59,550 |  |  | 52,635 |  |  | 6,915 |  |  | 13 |  |  | 179,663 |  |  | 157,251 |  |  | 22,412 |  |  | 14 | \nOperating costs |  | 13,855 |  |  | 11,663 |  |  | 2,192 |  |  | 19 |  |  | 41,289 |  |  | 34,773 |  |  | 6,516 |  |  | 19 | \nCost of products sold |  | 9,423 |  |  | 8,306 |  |  | 1,117 |  |  | 13 |  |  | 28,576 |  |  | 25,389 |  |  | 3,187 |  |  | 13 | \nDepreciation and amortization |  | 1,007 |  |  | 828 |  |  | 179 |  |  | 22 |  |  | 2,998 |  |  | 2,418 |  |  | 580 |  |  | 24 | \nTotal operating costs |  | 83,835 |  |  | 73,432 |  |  | 10,403 |  |  | 14 |  |  | 252,526 |  |  | 219,831 |  |  | 32,695 |  |  | 15 | \nEarnings from operations |  | 8,526 |  |  | 7,462 |  |  | 1,064 |  |  | 14 |  |  | 24,669 |  |  | 21,544 |  |  | 3,125 |  |  | 15 | \nInterest expense |  | (834) |  |  | (516) |  |  | (318) |  |  | 62 |  |  | (2,416) |  |  | (1,416) |  |  | (1,000) |  |  | 71 | \nEarnings before income taxes |  | 7,692 |  |  | 6,946 |  |  | 746 |  |  | 11 |  |  | 22,253 |  |  | 20,128 |  |  | 2,125 |  |  | 11 | \nProvision for income taxes |  | (1,654) |  |  | (1,562) |  |  | (92) |  |  | 6 |  |  | (4,784) |  |  | (4,397) |  |  | (387) |  |  | 9 | \nNet earnings |  | 6,038 |  |  | 5,384 |  |  | 654 |  |  | 12 |  |  | 17,469 |  |  | 15,731 |  |  | 1,738 |  |  | 11 | \nEarnings attributable to noncontrolling interests |  | (197) |  |  | (122) |  |  | (75) |  |  | 61 |  |  | (543) |  |  | (372) |  |  | (171) |  |  | 46 | \nNet earnings attributable to UnitedHealth Group common shareholders |  | $ | 5,841 |  |  | $ | 5,262 |  |  | $ | 579 |  |  | 11 | % |  | $ | 16,926 |  |  | $ | 15,359 |  |  | $ | 1,567 |  |  | 10 | %\nDiluted earnings per share attributable to UnitedHealth Group common shareholders |  | $ | 6.24 |  |  | $ | 5.55 |  |  | $ | 0.69 |  |  |  |  | $ | 18.01 |  |  | $ | 16.15 |  |  | $ | 1.86 |  |  | \nMedical care ratio (a) |  | 82.3 | % |  | 81.6 | % |  | 0.7 | % |  |  |  | 82.6 | % |  | 81.7 | % |  | 0.9 | % |  | \nOperating cost ratio |  | 15.0 |  |  | 14.4 |  |  | 0.6 |  |  |  |  | 14.9 |  |  | 14.4 |  |  | 0.5 |  |  | \nOperating margin |  | 9.2 |  |  | 9.2 |  |  | \u2014 |  |  |  |  | 8.9 |  |  | 8.9 |  |  | \u2014 |  |  | \nTax rate |  | 21.5 |  |  | 22.5 |  |  | (1.0) |  |  |  |  | 21.5 |  |  | 21.8 |  |  | (0.3) |  |  | \nNet earnings margin (b) |  | 6.3 |  |  | 6.5 |  |  | (0.2) |  |  |  |  | 6.1 |  |  | 6.4 |  |  | (0.3) |  |  | \nReturn on equity (c) |  | 28.0 | % |  | 28.5 | % |  | (0.5) | % |  |  |  | 27.7 | % |  | 28.1 | % |  | (0.4) | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months EndedSeptember 30, |  | Increase/(Decrease) |  | Nine Months EndedSeptember 30, |  | Increase/(Decrease)\n(in millions, except percentages) |  | 2023 |  | 2022 |  | 2023 vs. 2022 |  | 2023 |  | 2022 |  | 2023 vs. 2022\nRevenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nUnitedHealthcare |  | $ | 69,853 |  |  | $ | 61,995 |  |  | $ | 7,858 |  |  | 13 | % |  | $ | 210,552 |  |  | $ | 186,695 |  |  | $ | 23,857 |  |  | 13 | %\nOptum Health |  | 23,864 |  |  | 18,463 |  |  | 5,401 |  |  | 29 |  |  | 70,785 |  |  | 52,728 |  |  | 18,057 |  |  | 34 | \nOptum Insight |  | 4,977 |  |  | 3,693 |  |  | 1,284 |  |  | 35 |  |  | 14,147 |  |  | 10,194 |  |  | 3,953 |  |  | 39 | \nOptum Rx |  | 28,857 |  |  | 25,203 |  |  | 3,654 |  |  | 14 |  |  | 84,921 |  |  | 73,919 |  |  | 11,002 |  |  | 15 | \nOptum eliminations |  | (961) |  |  | (800) |  |  | (161) |  |  | 20 |  |  | (2,713) |  |  | (1,941) |  |  | (772) |  |  | 40 | \nOptum |  | 56,737 |  |  | 46,559 |  |  | 10,178 |  |  | 22 |  |  | 167,140 |  |  | 134,900 |  |  | 32,240 |  |  | 24 | \nEliminations |  | (34,229) |  |  | (27,660) |  |  | (6,569) |  |  | 24 |  |  | (100,497) |  |  | (80,220) |  |  | (20,277) |  |  | 25 | \nConsolidated revenues |  | $ | 92,361 |  |  | $ | 80,894 |  |  | $ | 11,467 |  |  | 14 | % |  | $ | 277,195 |  |  | $ | 241,375 |  |  | $ | 35,820 |  |  | 15 | %\nEarnings from operations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nUnitedHealthcare |  | $ | 4,592 |  |  | $ | 3,799 |  |  | $ | 793 |  |  | 21 | % |  | $ | 13,293 |  |  | $ | 11,447 |  |  | $ | 1,846 |  |  | 16 | %\nOptum Health |  | 1,568 |  |  | 1,575 |  |  | (7) |  |  | \u2014 |  |  | 4,869 |  |  | 4,340 |  |  | 529 |  |  | 12 | \nOptum Insight |  | 1,109 |  |  | 1,007 |  |  | 102 |  |  | 10 |  |  | 2,984 |  |  | 2,693 |  |  | 291 |  |  | 11 | \nOptum Rx |  | 1,257 |  |  | 1,081 |  |  | 176 |  |  | 16 |  |  | 3,523 |  |  | 3,064 |  |  | 459 |  |  | 15 | \nOptum |  | 3,934 |  |  | 3,663 |  |  | 271 |  |  | 7 |  |  | 11,376 |  |  | 10,097 |  |  | 1,279 |  |  | 13 | \nConsolidated earnings from operations |  | $ | 8,526 |  |  | $ | 7,462 |  |  | $ | 1,064 |  |  | 14 | % |  | $ | 24,669 |  |  | $ | 21,544 |  |  | $ | 3,125 |  |  | 15 | %\nOperating margin |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nUnitedHealthcare |  | 6.6 | % |  | 6.1 | % |  | 0.5 | % |  |  |  | 6.3 | % |  | 6.1 | % |  | 0.2 | % |  | \nOptum Health |  | 6.6 |  |  | 8.5 |  |  | (1.9) |  |  |  |  | 6.9 |  |  | 8.2 |  |  | (1.3) |  |  | \nOptum Insight |  | 22.3 |  |  | 27.3 |  |  | (5.0) |  |  |  |  | 21.1 |  |  | 26.4 |  |  | (5.3) |  |  | \nOptum Rx |  | 4.4 |  |  | 4.3 |  |  | 0.1 |  |  |  |  | 4.1 |  |  | 4.1 |  |  | \u2014 |  |  | \nOptum |  | 6.9 |  |  | 7.9 |  |  | (1.0) |  |  |  |  | 6.8 |  |  | 7.5 |  |  | (0.7) |  |  | \nConsolidated operating margin |  | 9.2 | % |  | 9.2 | % |  | \u2014 | % |  |  |  | 8.9 | % |  | 8.9 | % |  | \u2014 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Increase/(Decrease) |  | Nine Months Ended September 30, |  | Increase/(Decrease)\n(in millions, except percentages) |  | 2023 |  | 2022 |  | 2023 vs. 2022 |  | 2023 |  | 2022 |  | 2023 vs. 2022\nUnitedHealthcare Employer & Individual - Domestic |  | $ | 16,854 |  |  | $ | 15,929 |  |  | $ | 925 |  |  | 6 | % |  | $ | 50,157 |  |  | $ | 47,318 |  |  | $ | 2,839 |  |  | 6 | %\nUnitedHealthcare Employer & Individual - Global |  | 2,417 |  |  | 2,120 |  |  | 297 |  |  | 14 |  |  | 6,905 |  |  | 6,500 |  |  | 405 |  |  | 6 | \nUnitedHealthcare Employer & Individual - Total |  | 19,271 |  |  | 18,049 |  |  | 1,222 |  |  | 7 |  |  | 57,062 |  |  | 53,818 |  |  | 3,244 |  |  | 6 | \nUnitedHealthcare Medicare & Retirement |  | 32,022 |  |  | 27,895 |  |  | 4,127 |  |  | 15 |  |  | 97,468 |  |  | 85,620 |  |  | 11,848 |  |  | 14 | \nUnitedHealthcare Community & State |  | 18,560 |  |  | 16,051 |  |  | 2,509 |  |  | 16 |  |  | 56,022 |  |  | 47,257 |  |  | 8,765 |  |  | 19 | \nTotal UnitedHealthcare revenues |  | $ | 69,853 |  |  | $ | 61,995 |  |  | $ | 7,858 |  |  | 13 | % |  | $ | 210,552 |  |  | $ | 186,695 |  |  | $ | 23,857 |  |  | 13 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30, |  | Increase/(Decrease)\n(in thousands, except percentages) |  | 2023 |  | 2022 |  | 2023 vs. 2022\nCommercial - Domestic: |  |  |  |  |  |  |  | \nRisk-based |  | 8,120 |  |  | 8,055 |  |  | 65 |  |  | 1 | %\nFee-based |  | 19,130 |  |  | 18,500 |  |  | 630 |  |  | 3 | \nTotal Commercial - Domestic |  | 27,250 |  |  | 26,555 |  |  | 695 |  |  | 3 | \nMedicare Advantage |  | 7,645 |  |  | 7,035 |  |  | 610 |  |  | 9 | \nMedicaid |  | 8,065 |  |  | 8,005 |  |  | 60 |  |  | 1 | \nMedicare Supplement (Standardized) |  | 4,345 |  |  | 4,370 |  |  | (25) |  |  | (1) | \nTotal Community and Senior |  | 20,055 |  |  | 19,410 |  |  | 645 |  |  | 3 | \nTotal UnitedHealthcare - Domestic Medical |  | 47,305 |  |  | 45,965 |  |  | 1,340 |  |  | 3 | \nCommercial - Global |  | 5,475 |  |  | 5,360 |  |  | 115 |  |  | 2 | \nTotal UnitedHealthcare - Medical |  | 52,780 |  |  | 51,325 |  |  | 1,455 |  |  | 3 | %\nSupplemental Data: |  |  |  |  |  |  |  | \nMedicare Part D stand-alone |  | 3,335 |  |  | 3,310 |  |  | 25 |  |  | 1 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30, |  | Increase/(Decrease)\n(in millions) |  | 2023 |  | 2022 |  | 2023 vs. 2022\nSources of cash: |  |  |  |  |  | \nCash provided by operating activities |  | $ | 34,261 |  |  | $ | 30,739 |  |  | $ | 3,522 | \nIssuances of short-term borrowings and long-term debt, net of repayments |  | 5,848 |  |  | 3,806 |  |  | 2,042 | \nProceeds from common stock issuances |  | 1,039 |  |  | 1,084 |  |  | (45) | \nCustomer funds administered |  | 2,037 |  |  | 7,028 |  |  | (4,991) | \nOther |  | \u2014 |  |  | 50 |  |  | (50) | \nTotal sources of cash |  | 43,185 |  |  | 42,707 |  |  | \nUses of cash: |  |  |  |  |  | \nCommon stock repurchases |  | (6,500) |  |  | (6,000) |  |  | (500) | \nCash paid for acquisitions, net of cash assumed |  | (8,389) |  |  | (7,154) |  |  | (1,235) | \nPurchases of investments, net of sales and maturities |  | (2,850) |  |  | (4,067) |  |  | 1,217 | \nPurchases of property, equipment and capitalized software |  | (2,427) |  |  | (1,936) |  |  | (491) | \nCash dividends paid |  | (5,023) |  |  | (4,450) |  |  | (573) | \nOther |  | (2,495) |  |  | (1,634) |  |  | (861) | \nTotal uses of cash |  | (27,684) |  |  | (25,241) |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | 49 |  |  | 4 |  |  | 45 | \nNet increase in cash and cash equivalents |  | $ | 15,550 |  |  | $ | 17,470 |  |  | $ | (1,920) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Moody\u2019s |  | S&P Global |  | Fitch |  | A.M. Best\n | Ratings |  | Outlook |  | Ratings |  | Outlook |  | Ratings |  | Outlook |  | Ratings |  | Outlook\nSenior unsecured debt | A2 |  | Stable |  | A+ |  | Stable |  | A |  | Stable |  | A |  | Stable\nCommercial paper | P-1 |  | n/a |  | A-1 |  | n/a |  | F1 |  | n/a |  | AMB-1+ |  | n/a  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30, 2023\nIncrease (Decrease) in Market Interest Rate |  | InvestmentIncome\u00a0PerAnnum |  | InterestExpense\u00a0PerAnnum |  | Fair\u00a0Value\u00a0ofFinancial Assets |  | Fair\u00a0Value\u00a0ofFinancial Liabilities\n2 % |  | $ | 971 |  |  | $ | 419 |  |  | $ | (3,408) |  |  | $ | (7,067) | \n1 |  | 486 |  |  | 209 |  |  | (1,758) |  |  | (3,846) | \n(1) |  | (486) |  |  | (193) |  |  | 1,858 |  |  | 4,635 | \n(2) |  | (971) |  |  | (386) |  |  | 3,800 |  |  | 10,274 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFor the Month Ended |  | Total Number of Shares Purchased |  | Average Price Paid Per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number of Shares That May Yet Be Purchased Under The Plans or Programs\n |  | (in millions) |  |  |  | (in millions) |  | (in millions)\nJuly 31, 2023 |  | 1.2 |  |  | $ | 481.19 |  |  | 1.2 |  |  | 19.6\nAugust 31, 2023 |  | 1.0 |  |  | 501.09 |  |  | 1.0 |  |  | 18.6\nSeptember 30, 2023 |  | 0.9 |  |  | 488.62 |  |  | 0.9 |  |  | 17.7\nTotal |  | 3.1 |  |  | $ | 489.56 |  |  | 3.1 |  |  |   |  |  |  |  |  |  |  | \n3.1 |  | Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company\u2019s Registration Statement on Form 8-A/A filed on July 1, 2015)\n3.2 |  | Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by reference to Exhibit 3.2 to UnitedHealth Group Incorporated\u2019s Current Report on Form 8-K filed on February 26, 2021)\n4.1 |  | Amended and Restated Indenture, dated as of April 27, 2023, between UnitedHealth Group Incorporated and Wilmington Trust Company, as successor trustee (incorporated by reference to Exhibit 4.1 to UnitedHealth Group Incorporated\u2019s Current Report on Form 8-K filed on April 28, 2023)\n4.2 |  | Indenture, dated as of February\u00a04,\u00a02008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company\u2019s Registration Statement on Form S-3, SEC File Number 333-149031, filed on February\u00a04, 2008)\n4.3 |  | Supplemental Indenture, dated as of April 18, 2023, between UnitedHealth Group Incorporated and U.S. Bank Trust Company, National Association, as trustee, relating to the 6.875% Senior Notes due 2038 (incorporated by reference to Exhibit 4.1 to UnitedHealth Group Incorporated\u2019s Current Report on Form 8-K filed on April 24, 2023)\n31.1 |  | Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\n32.1 |  | Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\n101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n101.SCH |  | Inline XBRL Taxonomy Extension Schema Document.\n101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document.\n101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document.\n101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document.\n101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document.\n104 |  |  | Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).  |  |  |  |  |  |  |  | \n* |  | Pursuant to Item\u00a0601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n/s/    ANDREWWITTY |  | Chief Executive Officer(principal executive officer) | Dated: | November 6, 2023\nAndrew Witty |  |  | \n |  | \n/s/    JOHNREX |  | Executive Vice President andChief\u00a0Financial\u00a0Officer(principal financial officer) | Dated: | November 6, 2023\nJohn Rex |  |  | \n |  | \n/s/THOMASROOS |  | Senior Vice President andChief Accounting Officer(principal accounting officer) | Dated: | November 6, 2023\nThomas Roos |  |  | "}]}
